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ABSTRACT 
 
Docosahexaenoic Acid and Butyrate Synergistically Modulate Intracellular 
Calcium Compartmentalization to Induce Colonocyte Apoptosis. (August 2007) 
Satya Sree N. Kolar, B.M.S., Bangalore University, India; 
M.S., University of Kentucky 
Chair of Advisory Committee: Dr. Robert S. Chapkin 
 
Docosahexaenoic acid (DHA, 22:6n-3) from fish oil, and butyrate, a short-chain 
fatty acid fiber-fermentation product, protect against colon tumorigenesis in part by 
coordinately inducing apoptosis.  We have demonstrated that the combination of these 
two bioactive compounds demonstrates an enhanced ability to induce colonocyte 
apoptosis by potentiating mitochondrial lipid oxidation.  In order to explore the potential 
involvement of intracellular Ca2+ in the pro-apoptotic effect of DHA and butyrate, young 
adult mouse colonocytes (YAMC) and human colonocytes (HCT-116: p53+/+ and p53-
/-) were treated with DHA or linoleic acid (LA) for 72 h ± butyrate for the final 6, 12 or 
24 h.  Cytosolic and mitochondrial Ca2+ levels were measured using Fluo-4 and Rhod-2.  
In addition, IP3 pool, store-operated channel (SOC)-mediated changes and apoptosis 
were measured.  DHA did not alter basal Ca2+ or apoptosis following 6 h butyrate co-
treatment.  In contrast, at 12 and 24 h, DHA and butyrate treated cultures exhibited a 
decrease in cytosolic Ca2+ and enhanced apoptosis compared to LA and butyrate.  DHA 
and butyrate also increased the mitochondrial-to-cytosolic Ca2+ ratio at 6, 12 and 24 h.  
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The accumulation of mitochondrial Ca2+ preceded the onset of apoptosis which increased 
only following 12 h of butyrate co-treatment.  RU-360, a mitochondrial uniporter 
inhibitor, abrogated mitochondrial Ca2+ accumulation and also partially blocked 
apoptosis in DHA and butyrate co-treated cells.  p53+/+ and p53-/- cells demonstrated 
similar data with respect to all parameters.    
Additionally, mitochondrial Ca2+ measurements were also made in rat primary-
colonocyte-culture.  Rats were fed semipurified diets containing either fish oil (a source 
of DHA) or corn oil (a source of LA), and colonic crypts were incubated in butyrate ex-
vivo and mitochondrial Ca2+ was quantified.  Crypts from rats fed fish oil incubated in 
butyrate exhibited an increase in the mitochondrial-to-cytosolic Ca2+ ratio compared to 
fish oil only.   
In summary, our results indicate for the first time that the combination of DHA 
and butyrate, compared to butyrate alone, further enhances apoptosis by additionally 
recruiting a p53-independent Ca2+-mediated intrinsic mitochondrial pathway.  These data 
explain in part why fermentable fiber when combined with fish oil exhibits an enhanced 
ability to induce apoptosis and protect against colon tumorigenesis.   
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CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW 
 
Intestinal physiology and pathogenesis of colon cancer  
Statistics of colon cancer.   The incidence and mortality rates of colon cancer are 
similar in both men and women below 50 yrs (1).  This is unlike the incidence of breast 
and prostate cancer which take precedence in women and men, respectively.  In the year 
2006 it is estimated that about 106,608 new cases of colorectal cancer were diagnosed 
and approximately 56,000 patients died from the disease.  The incidence of colon cancer 
varies geographically.  North America and Northern Europe have a higher incidence 
compared to Southern Europe.  Asia and Africa report the lowest incidence of colon 
cancer.  Nevertheless, the incidence of colon cancer is on the rise in developing 
countries with an increase in cases among people who migrate from low incidence to 
high incidence regions (2).  The variation in geographical incidence of colon cancer 
indicates that environmental factors, especially modifiable factors like diet and physical 
activity play a major role (2).  It is estimated that $8.1 billion is spent on treatment of 
colorectal cancer each year in the USA (3).   With health care costs on the rise, dietary 
intervention to curtail the incidence of colon cancer is the focus of this study.  
 
 
This dissertation follows the style of Cancer Research. 
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Anatomy and histology of the colon.  The human digestive tract is 28 feet long 
and the distal 5 feet constitute the colon (about 1.5 -2 m).  The colon constitutes ~22% of 
the length of the alimentary tract.  The colon is anatomically divided into 5 parts- the 
ceacum, the ascending, transverse, descending colon and rectum.  The large intestine, 
unlike the small intestine plays a very minimal role in digestion and absorption.   
Its main functions include water and salt reabsorption from the digested material 
which enters the colon from the small intestine.  In addition, the microflora of the colon 
is very important in the digestion and fermentation of vitamin K and short chain fatty 
acids like butyrate.  The metabolites that are not digested by the intestinal enzymes reach 
the colon (4).  Fiber, which is fermented by the bacterial microflora, yields short chain 
fatty acids like acetate, butyrate and propionate.  Unlike the rest of the organs, butyrate, 
synthesized in the colon by the bacterial fermentation serves as a major source of the 
energy for the colonocytes (5-7).   
Histologically, the walls of the intestine are made up of four different layers. The 
outermost serosal layer protects the intestine from its external environment and also 
lubricates the large intestine so as to aid its movement against the other organs. The 
muscularis mucosa is the mucosal layer of the large intestine which causes the 
contraction of the colon.  The muscle layer is made up of longitudinal muscle fibers that 
provide integrity to the colon and contraction, which permits the transit of food through 
the colon.  The submucosal layer consists of loose connective tissue submucosal glands, 
blood and lymphatic vessels responsible for nourishing the intestinal wall and the 
removal of metabolic waste.  The innermost layer of the intestine is the mucosal layer 
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which consists of different sub-layers.  This sub-layer consists of smooth muscle fibers 
and connective tissue layer called the lamina propria and a flexible lining of epithelial 
cells laid out over the flexible sublayers.  
The epithelial cells, (i.e. “colonocytes”) line the luminal surface of the colon.  
The luminal surface of the colon is folded into deep cavities lined by finger-like 
projections known as crypts that are embedded in connective tissue.  The crypt openings 
appear as pits on the luminal surface of the colon.  This architectural arrangement of 
colonocytes increases the surface area of the colon and therefore increases the efficiency 
of absorption of the salt and water (8, 9).  The colonocytes are responsible for secretory, 
absorptive and barrier function of the colon.  
The normal anatomy of the colon as seen in the anterior view of a male abdomen 
is demonstrated in Figure 1. 
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Figure 1.  Anatomy of the Colon.  This image reveals the normal anatomy of the large intestine (colon) 
as seen in the anterior view of a male abdomen.  The distal 5 feet of the digestive tract comprising of the 
ceacum, ascending, transverse, descending colon and rectum form the 5 parts of the colon.  The colon 
from the ceacum to the mid-transverse colon is known as the right colon while the reminder is known as 
the left colon.  Parts of the colon lie in the abdominal cavity while the other parts are retroperitoneal.  
Source: Doe Report, 2007 (10). 
 
Turn-over of the colonic epithelium.  Colonocytes lining the crypts of the colon 
are in a continuous process of self-renewal.  The cells undergo mitotic division at the 
base of the crypts and undergo differentiation during migration to the top crypt regions.  
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The colonocytes undergo apoptosis as they migrate from the base to the top of the crypts 
and are sloughed off into the lumen of the colon.  Colonic cells possess an intrinsic 
mechanism for their own self-destruction, which is activated following transformation of 
colonocytes to differentiated cells.  Death and sloughing off of the aged cells occurs 
continously, which is concurrent with replenishment by new colonocytes (8, 9, 11).  The 
colonic epithelium in humans is completely replaced every 4-8 days. An accurate 
balance between the rate of new cell production and cell death is tightly maintained as is 
the cell number along the crypt axis.  The molecular events responsible for the 
proliferation, maturation, differentiation, migration, apoptosis and renewal of 
colonocytes are very tightly regulated by a combination of events.  Accumulating 
evidence suggests that these processes depend on the position of the cell in the crypt and 
simultaneous expression of genes (12).  These findings indicate that the initiation and 
execution of colonocyte death depends on an apoptosis-permissive environment.  A 
prevailing view is that the apoptotic process is regulated by a complex interplay of local 
apoptosis-inducing and survival factors which are tightly regulated by complex 
molecular events (13).   
Carcinogenic transformation of colonocytes.  Colon cancer is the primary 
cancer of the digestive system and begins in the form of benign polyps.  These growths 
are usually non-cancerous and have the potential for malignant transformation and 
metastasis if they are not treated appropriately.  Mutations in specific DNA sequences, 
like APC, K-Ras and tumor suppressor gene- p53, lead to uncontrolled cell proliferation 
in conjunction to resistance to apoptosis resulting in malignant tumor formation. The 
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causes for these mutations range from non-modifiable factors like genetic aberrations to 
modifiable factors like diet.  Some diets are known to be pro-carcinogenic while diets 
rich in n-3 polyunsaturated fatty acids (n-3 PUFAs) and fiber appear to prevent against 
colon carcinogenesis (14-16).  The exact reason why and how diet might prevent 
colorectal cancer remains uncertain.  
Carcinogenesis is a multi-step process that involves genetic mutations resulting 
in transformation of normal colonocytes to malignant cells.  This transformation is due 
to 6 vital alterations in cell physiology.  These include: incessant potential for cell 
proliferation, ability of the cells to generate their own growth signals, capacity of cells to 
resist growth-inhibitory signals, evasion of programmed cell death (apoptosis), sustained 
angiogenesis, and tissue invasion and metastasis (17).  The proliferative-apoptotic 
anticancer defense mechanism is a tightly maintained balance.  Any or all of the events 
that alter cell physiology tip the balance in favor of developing cancer by malignant 
transformation.   
Genetic alterations that predispose tissue for carcinogenesis include mutations of 
oncogenes and malfunction or loss of function in the tumor suppressor genes (18).  
Accretion of sequential genetic modifications results in 4 definable stages - the initiation, 
promotion, progression and malignant transformation stages of colon carcinogenesis. 
The initiation stage, involves a change in the genetic makeup of a cell.  This change may 
occur randomly or when a carcinogen interacts with DNA causing damage.  Initiation 
stage changes may involve base pair modification which could result in mismatch during 
gene expression.  These mismatches if left unrepaired can lead to genetic mutations.  In 
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addition, alkylation of the single or double strand breaks can lead to an erroneous repair 
process predisposing the tissue for carcinogenesis.  This initial damage rarely results in 
cancer because the cell has many mechanisms to repair damaged DNA (19).  However, 
if repair does not occur and the damage to DNA is in the location of a gene that regulates 
cell growth and proliferation, DNA repair, or function of the immune system, then the 
cell is more prone to be coming cancerous.  Genetic alterations seen in the initiation 
stage predispose the colon to enhanced proliferation and resistance to cellular apoptosis 
leading to the promotion stage (20).   
During promotion, the mutated cell is stimulated to grow and divide faster 
becoming a population of cells.  At this stage there is microscopic evidence of alteration 
in crypt morphology and formation of aberrant crypts.  The aberrant crypts congregate 
together, the consequences of which are specific regions which form the focus for 
transformation.  These areas are known to be precursors of colon cancer lesions (21).  
During progression, there is growth and expansion of tumor cells relative to normal 
cells.  The genetic material of tumors is more fragile and prone to additional mutations.  
These mutations occur in genes that regulate growth and cell function such as 
oncogenes, tumor suppressor genes, and DNA mismatch-repair genes.  These changes 
contribute to tumor growth until malignant transformation occurs.  The tumor then starts 
invading the submucosal layer of the intestine upon which it is termed as carcinoma.  
Eventually, the tumor shows signs of malignancy which includes increased 
angiogenesis, sustained proliferation and resistance to apoptosis.  Mutations in at least 
four or five genes are required to produce a malignant tumor (22-24). 
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Colorectal tumors occur as a result of activation of oncogenes coupled with 
inactivation of the tumor suppressor genes. (18, 22).  A significant number of studies 
demonstrates that mutations or truncation of the tumor suppressor gene, adenomatous 
polyposis gene (APC) results in the development of colon tumors (25-27).  A mutation 
in the APC gene is seen in approximately 60% of patients with an early stage colon 
tumor (25).  Although genetic alterations occur in a specific sequence, the cumulative 
effect of these changes, rather than their chronology of appearance are responsible for 
the tumor’s properties.  In addition to APC gene mutation, Ras oncogene was found to 
be activated in about 50% of colon carcinomas (22).  In addition, cyclin D1, mismatch 
repair gene like (mismatch repair genes) MSH2, MSH6, MSH3, MLH1, PMS1, PMS2, 
and p53 are involved in colon tumorigenesis (18, 22, 28-31). 
 
Diet and colon cancer 
Epidemiological data related to colon cancer.  Despite evidence indicating a 
strong association between immodifiable genetic factors and colon cancer, clinical and 
epidemiological studies demonstrate that dietary factors play a significant role.   Dietary 
fat has been long known to have a significant influence in the development of colon 
cancer (9).  Differences in colon cancer incidence and mortality rates between native and 
migrant populations and the increased risk in populations migrating from low- to high-
risk areas suggest that modifiable factors, specifically dietary factors, play a critical role 
in colon carcinogenesis (2).  Epidemiological data in the late 1960’s performed in Japan 
by Wynder et al demonstrated that dietary fat had a major influence in colon cancer 
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incidence (32).  Burkitt et al reported in the early 1970’s that the incidence of colon 
cancer was much lower in African populations who consumed a high fiber and low fat 
diet compared to their white counter parts (33).  Data from these seminal studies resulted 
in considerable emphasis on the effect of dietary fat and fiber on colon carcinogenesis.  
Since then substantial progress has been made in acquiring knowledge to study the 
relationship between dietary components and colon cancer.  Currently epidemiological 
data from population studies indicate that diets high in fat increase the incidence of 
colon cancer (34-36).    
Effect of dietary fat on colon cancer.  Dietary fat is one of the key nutritional 
modulators of colon cancer development (9).  Several studies that examined the 
relationship between dietary saturated, animal fat and colon cancer found a strong 
positive association between higher intake of fat and an increase in the risk of colorectal 
cancer development (37-40).  Data from experimental animals also suggested that both 
the amount of fat and the composition modulate colon tumor development (41).  Studies 
have consistently shown that the consumption of a diet rich in omega-3 fatty acids (n-3 
PUFA’s) enriched in fish oil may decrease the risk of colon cancer (42-46).  For 
example, rats fed a fish oil diet produced a smaller number of experimentally induced 
colon tumors compared to those fed a diet high in corn oil (46, 47).  The major 
difference between fish and corn oil diets was the dietary lipid source.  There were 
significantly higher amounts of eicosapentaenoic acid (EPA, 20:5∆5,8,11,14,17) and 
docosahexaenoic acid (DHA, 22:6∆4,7,10,13,16,19) in fish oil diet compared to corn oil diet 
  
10
 
which had higher amounts of linoleic acid (LA, 18:2∆9,12), an important source of 
omega-6 PUFA in the western diet (48).   
Colon tumorigenesis, a multistep transformation process ensues due to a 
disruption in the balance between colonocyte apoptosis and proliferation.  Dysregulation 
in any of the homeostatic processes results in the clonal expansion and carcinogenic 
transformation.  Induction of colonocyte apoptosis is a way by which the cells with 
damaged DNA are deleted so as to prevent the initiation stage of colon cancer.  We have 
data demonstrating that fish oil enhances the targeted deletion of DNA-damaged cells, 
which may explain a mechanism by which it protects against colon cancer (45).  There is 
also substantial evidence to demonstrate that colonic epithelial transformation to 
carcinoma is associated with the progressive inhibition of apoptosis (49-51).  Therefore 
bioactive agents that enhance apoptosis demonstrate a potential for having a 
chemoprotective effect.  Along these lines, our data demonstrate that fish oil fed rats 
have a higher level of apoptosis with resistance to alkylation and oxidation induced 
DNA damage (45, 52-54).  These findings are consistent with clinical data which 
demonstrate that increasing intake of n-3 PUFA promoted colonocyte apoptosis in 
human colon (54).  Collectively, these human and rodent data indicate a strong potential 
for fish oil to be a chemotherapeutic agent against tumor growth.    
With respect to the mechanism by which n-3 PUFA acts as a chemoprotective 
agent, a plethora of studies indicate its ability to incorporate into membrane 
phospholipids thus altering membrane composition and function. (55-57).  Since 
membranes constituents including phospholipids are an integral part of various signaling 
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mechanisms, any alteration in phospholipid composition could result in modulation of 
mechanisms involved in cellular apoptosis, proliferation and differentiation (57, 58).  
We have demonstrated that n-3 PUFA from fish oil exerts a protective effect against 
colon tumorigenesis primarily by enhancing colonocyte apoptosis rather than decreasing 
proliferation (14, 16).  More recent investigations have demonstrated that highly 
unsaturated fatty acids present in fish oil are incorporated into the mitochondrial 
membrane and have effects on reactive oxygen species (ROS) production (57, 59), 
membrane lipid oxidation (58, 60), transcriptional or translational regulation (61, 62), 
mitochondrial Ca2+ level (63), eicosanoid biosynthesis (64) and intracellular signal 
transduction.   These cumulative effects are believed to mediate the n-3 PUFA-induced 
pro-apoptotic effect which could in part explain the protective effect of fish oil in colon 
tumorigenesis.  
Effect of dietary fiber and colon cancer.  Fiber is one of the most important 
nutritional factors considered to be protective against colon cancer, with well established 
biological mechanisms underlying this hypothesis.  Experimental and population based 
studies conducted since the early 1970’s have demonstrated that high fiber diet is 
protective against colon carcinogenesis (33, 65-67).  In contrast, large prospective 
studies from USA, Sweden and Finland showed no protective effects of fiber against 
colon carcinogenesis (68-70).  More recently, the European Prospective Investigation of 
Cancer and Nutrition Study (EPIC), one of the largest studies performed in 10 European 
countries, concluded that there was a 40% decrease in risk of colon cancer incidence 
associated with the increased intake of fiber from food (71).  The inconclusive evidence 
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from epidemiological studies on the chemoprotective effects of fiber challenged the 
recommendation to increase fiber intake to reduce the risk of colorectal cancer.  Some of 
the inconsistencies in the data could be as a result of the type of fiber investigated or the 
interaction of fiber with other dietary components like fat (37).   
Putative mechanisms by which fiber can be protective are well described (72).  
Fiber increases stool weight, shortens transit time, dilutes colonic contents, stimulates 
bacterial anaerobic fermentation, which reduces contact between the intestinal contents 
and mucosa, and leads to the production of short chain fatty acids (SCFA) like acetate, 
propionate and butyrate, thus reducing luminal pH and the conversion of primary bile 
acids to secondary bile acids (72-74).  Butyrate, a major source of energy for the 
coloncoytes is known to have chemoprotective properties (73).  Although the 
chemoprotective effect of butyrate in animal studies is inconclusive (75, 76) its effect in 
cell lines is well established (77, 78).  In cell lines, butyrate reduces cell proliferation 
and induces apoptosis, factors that are associated with inhibition of the transformation of 
the colonic epithelium to carcinoma (79-81).  With evidence of the chemoprotective 
effect of dietary fiber and butyrate, recent research has focused on its combined effect 
with other dietary factors of which fat is one of the most widely investigated. 
Fat-fiber interaction.  Fat and fiber are two of the most widely investigated 
dietary components in the prevention of colon carcinogenesis.  We have demonstrated 
that the bioactive compounds generated by dietary fish oil (DHA and EPA) and 
fermentable fiber (butyrate) work together to protect against colon carcinogenesis 
primarily by enhancing apoptosis (14, 16, 29, 47, 52).  In addition, our in-vivo 
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experiments have demonstrated that fish oil and fermentable (pectin) fed animals 
enhanced ROS generation compared to corn oil fed animals (52).  Although there is well 
documented evidence that butyrate alone inhibits histone deacetylases and activates the 
Fas mediated apoptotic pathway (29, 82, 83), these effects seem to occur as a 
consequence of its ability to promote cellular oxidation (82, 84).  These findings are 
important because DHA and EPA are highly susceptible to lipid oxidation and this could 
explain the synergistic effect seen when DHA is combined with butyrate (58, 63).  
Along the same lines, we have demonstrated that enhanced mitochondrial lipid 
hydroperioxides which can be blocked by mitochondrion-specific antioxidants play an 
important role in DHA and butyrate induced apoptosis (58).  All of these events 
culminated in creating an environment conducive for cellular apoptosis.  Despite all the 
scientific evidence indicating the protective effect of fish oil and fermentable fiber, we 
still lack information regarding the molecular mechanisms by which this combination 
exerts its protective effect against colon tumorigenesis.  
 
Ion transport across biological membranes 
Ion channels.  All eukaryotes are made of cell (plasma) membranes which are 
highly selective barriers separating the contents of the cytosol from the exterior.  The 
plasma membrane consists of lipids and proteins.  Membranes permit the development 
of concentration gradients crucial for the transport of solutes across the membrane. 
Structurally the plasma membrane is made of a phospholipid bilayer with membrane 
lipids having a hydrophilic and hydrophobic part.  The major kinds of lipids present in 
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the cell membranes are phospholipids, glycolipids and cholesterol. The phospholipid 
bilayer is impenetrable to water soluble molecules and ions. However, complex integral 
protein molecules present within the bilayer permit the flow of selected molecules and 
ions in and out of the cell.  Singer and Nicolson proposed the 'Fluid Mosaic Model' of 
the structure of cell membranes which is widely accepted today (85).  According to this 
model the integral membrane proteins are embedded in the phospholipid bilayer.  The 
model suggests that three major classes of membrane proteins exist.  They are the 
channels, pumps and receptors.  These proteins function to meet the transport needs of 
the cell.  They move ions and other small molecules through the otherwise impermeable 
phospholipid bilayer.  The ion pumps are active and require ATP to move ions against 
the concentration gradient.  In contrast, passive ion channels are transmembrane proteins 
that form a channel through the cell membrane.  Ion channels pass ions down a 
concentration gradient by facilitated diffusion without the expenditure of energy.  The 
channel can be opened or closed and therefore is referred to as a gated channel.  There 
are three types of gated ion channels:  Ligand gated, mechanically gated and voltage 
gated.  Ligand gated channels open or close in response to the binding of signaling-
ligand.  Voltage gated channels are found predominantly in excitable cells like neurons.  
They open or close in response to changes in membrane potential across the plasma 
membrane.  Ion channels are highly selective and allow only specific ions through the 
cell membrane.  Ca2+ selective channels are extremely important due to the role of the 
ion in various cellular functions.  The focus of this study is based on Ca2+ selective 
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channels present in various cellular membranes, non-excitable colonocyte cells in 
particular.   
Voltage dependent Ca2+ channels (VDCC), which are permeable to Ca2+ are 
found to play an important role in membrane potential, release of neurotransmitter, 
hormones, muscle contraction etc.  In excitable cells, VDCC are the preponderant type 
involved in the influx of Ca2+.  VDCC’s are classified into N-type (neuron) present in 
neurons, L-type (long lasting) or T-type (transient type) present in the cardiac muscle, P-
type (Purkinje) which are similar to the N-type but present in the heart, and the poorly 
understood Q-type and R-type which are present in the brain (85, 86).  In non-excitable 
cells, Ca2+ influx is essential for regulating distinct cellular processes involving enzyme 
control, gene regulation, cell growth, proliferation, and apoptosis.  In contrast to 
excitable cells, VDCC are generally absent in non-excitable cells like colonocytes.  The 
store-operated channels (SOC) or Ca2+ release–activated Ca2+ (CRAC) channels form the 
major Ca2+ entry pathways, in addition to some involvement from second messenger 
operated channels (87).  The SOC entry pathway involves entry of Ca2+ through the SOC 
channels situated on the plasma membrane following emptying of the intracellular Ca2+ 
stores (88).  An overview of intracellular Ca2+ homeostasis including membrane 
channels and pumps is demonstrated in Figure 2. 
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Figure 2.  Overview of intracellular Ca2+ homeostasis.  Ca2+ enters the cell through the plasma 
membrane channels and is processed by the ER and mitochondria via the pumps and channels situated on 
their membranes.  Ca2+ movement from the ER to mitochondria is a key process in the activation of 
apoptosis by some stimuli.  PM Ca2+ channel, plasma membrane calcium channel; PMCA, plasma 
membrane channel pump; RyR, ryanodine receptor; SERCA, sarcoplasmic-reticulum-Ca2+ -ATPase pump.  
Source: Rizzuto et al, 2004 (90). 
 
Intracellular Ca2+ and apoptosis.  Ca2+ is one of the most versatile and universal 
signaling mediators in cells and is required for the activation of many cellular processes 
(89).   Increasing evidence indicates that alterations in the finely tuned intracellular 
homeostasis and compartmentalization of Ca2+ can lead to cell death either through 
apoptosis or necrosis (89, 90).  Extracellular Ca2+ concentration is 1 – 2 mM while the 
intracellular cytosolic concentration of Ca2+ is 4 orders of magnitude lower at 
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approximately 0.1 mM.  Free cytosolic Ca2+ does not represent the total concentration of 
0.1 mM because much of the intracellular Ca2+ is sequestered in intracellular organelles 
such as the endoplasmic reticulum (ER) and mitochondria.   In response to a stimulus, 
the release of Ca2+ from these intracellular stores, or its entry into the cells through Ca2+ 
channels in the membrane, rapidly increases the intracellular concentration of Ca2+ some 
10 100 fold.  The transient increase in intracellular Ca2+ concentration is a signal for 
various cellular events like muscle contraction, secretion etc.  A consistent increase in 
Ca2+ overload within the cell can induce apoptosis and the activation of Ca2+ binding 
proteins, e.g., calmodulin (91).  
The Ca2+ concentration inside the cell is regulated by the simultaneous interplay 
of various counteracting mechanisms, which can turn cellular signals “on” and/ or “off” 
(92).  Eukaryotic cells can increase their cytosolic Ca2+ levels by 2 mechanisms: (1) 
release of Ca2+ from intracellular stores or influx via plasma membrane channels.  
Channels located in the plasma membrane, like SOC, receptor operated channels and 
voltage operated channels regulate the influx of Ca2+ into the cell.  Currently, there is a 
good understanding of the organelles that function as Ca2+ stores and how Ca2+ can be 
released from the stores into the cytosol.  Although the importance of the ER as the 
major storage organelle is indisputable, growing evidence indicates that functional 
compartmentalization of Ca2+ exists within the various cellular organelles.  More recent 
studies have identified the contributions of the nuclear envelope, golgi apparatus, 
lysosomes and most importantly, the mitochondria in maintaining intracellular Ca2+ 
homeostasis and cellular physiologic function (88).  Mitochondria play a key role in both 
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apoptosis and necrosis by affecting energy metabolism, participating in Ca2+ 
homeostasis, regulating activation of caspases and releasing ROS (93-95).  Mitochondria 
are localized in close proximity to inositol 1, 4, 5 – trisphosphate (IP3) gated channels 
situated on the ER.  Ca2+ uniporters, which are high affinity and low capacity active 
pumps situated on the mitochondrial outer membrane, rapidly take up Ca2+ that is 
released from the ER stores and re-circulate it back into the cytosol via exchangers such 
as the Na2+/ Ca2+ exchanger.  In summary, mitochondria can sequester cytosolic Ca2+ 
acting as a sink thereby preventing a rapid and sudden change in cytosolic Ca2+ level.   
Under normal conditions, mitochondrial Ca2+ uptake may serve as a signal to 
under certain conditions increase cellular metabolism (96).  However, a plethora of 
studies indicate that mitochondrial Ca2+ accumulation is a trigger for cytochrome-c 
release and therefore apoptosis (97).   In addition, studies addressing ER-mitochondria 
communication indicate that both pro-apoptotic and anti-apoptotic proteins modulate ER 
Ca2+ release by acting on the IP3Rs (98).    Interestingly, pro-apoptotic factors act on 
both the mitochondria and ER by enhancing mitochondrial Ca2+ signal propagation in 
conjunction with facilitating ER Ca2+ mobilization.  This results in Ca2+-dependent 
mitochondrial membrane permeabilization and apoptosis.  In addition, ER Ca2+ release 
causes more extensive changes in mitochondrial Ca2+ signaling as opposed to cytosolic 
Ca2+ signal (99).  Cytochrome c released from the mitochondria at the onset of apoptosis 
is known to bind with high affinity to IP3R. This blocks the Ca2+-dependent inhibition of 
IP3-induced Ca2+ efflux which increases mitochondrial Ca2+ loading (100).  ROS 
produced by the mitochondria also demonstrates a similar mechanism of increase in IP3- 
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induced Ca2+ release and mitochondrial Ca2+ loading to induce apoptosis (101).  
Therefore, ER and mitochondria form an intricate network to mediate Ca2+- dependent 
cellular apoptosis.   
 
Intracellular Ca2+ homeostasis 
Under normal circumstances there is a constant influx of Ca2+ from the 
extracellular environment into the ER.  Ca2+ influx from the extracellular medium into 
the cytosol is mediated by the SOC and second messenger operated channels and other 
transporters present on the plasma membrane.  Once Ca2+ enters the cytosol, sarco-
endoplasmic reticulum ATPase (SERCA) pumps situated on the ER membrane pump 
Ca2+ into the ER by expending ATP. The mobilization of intracellular Ca2+ stores in 
response to receptor-stimulated formation of IP3 depends on the IP3 receptor (IP3R) 
present on the ER membrane.  According to the capacitative model of Ca2+, mobilization 
of intracellular Ca2+ stores from the ER results in cells refilling their intracellular emptied 
pool by Ca2+ entry through the SOC (102).  Various theories have been put forth to 
explain the connection between intracellular emptying and cellular refilling by opening 
of the SOC.  Theories suggest a conformational coupling hypothesis according to which 
a physical connection between the ER stores and the plasma membrane via protein-
protein interaction (103, 104).  The release of a diffusible signal – the calcium influx 
factor (CIF), is discussed below.  However, most recently critical new information on 
the nature of the SOC has been revealed (105, 106).  By using interfering RNA 
technique, Roos et al studied genes encoding for various Ca2+ channel proteins and 
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transient receptor potential genes (105).  They demonstrated that knocking out of the 
gene encoding protein stromal interaction molecule (STIM) substantially decreased Ca2+ 
entry.  Two homologs of this protein were found in humans - STIM1 and STIM.  STIM1 
is found to be present in the plasma and ER membrane.  The sequence of STIM1 led to 
speculation that the protein present on the ER and plasma membrane could interact 
forming a bridge facilitating SOC entry (105).  However, Zhang et al demonstrated very 
elegantly that STIM1 acts as a Ca2+ sensor and upon intracellular Ca2+ depletion, 
migrates from the ER to the plasma membrane to activate the SOC (106).  To further 
strengthen the findings of Roos and Zhang, intracellular Ca2+ oscillations were studied.  
Wedel et al demonstrated that knocking out STIM1 and Orai1 (another component of 
SOC) abolished intracellular Ca2+ oscillations completely (107).  These data demonstrate 
the importance of these proteins in the SOC pathway.  Although the precise actions of 
these proteins are still unclear, their future study will be a critical step towards 
understanding the mechanism involved in SOC activation, function and signaling.  If ER 
store depletion activates SOC entry, then refilling of the stores should inactivate SOC 
entry.  Recent work has demonstrated that thapsigargin which prevents ER filling, 
reduces SOC entry (88).  There is also evidence that phospholipase-C and diacylglycerol 
lipase which liberate arachidonic acid from phosphotidyl-inositol (4,5)-bisphosphate, 
increase cytoplasmic Ca2+ due to SOC entry (95).  In addition, PLA2-dependent release 
of arachidonic acid from membrane phospholipids has been implicated.  Arachidonic 
acid has numerous effects on Ca2+ signaling, and there is growing evidence that 
arachidonic acid inhibits store-operated entry (108).  Other SOC inhibitory molecules 
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include nitric oxide (109) lipoxygenase, calmodulin, sphingomyelin, ceramide (110), 
protein kinase C (111), and cyclic GMP (112).  
The dynamic interaction between the ER and the mitochondria with respect to 
intracellular signaling and cell death is well established.  Recent work has shown that 
mitochondria are closely juxtaposed with the ER to facilitate efficient mitochondrial Ca2+ 
uptake during IP3-induced Ca2+ release (113, 114).  The precise molecular mechanism 
and regulation of the cross talk between these two storage organelles are still unknown.  
Nonetheless, there is evidence of clustering of IP3R’s on ER membranes facing the 
mitochondria (114-116).  Besides the close physical association of the ER and 
mitochondria, IP3R associated Ca2+ signals are found to be associated with an increase in 
mitochondrial Ca2+ levels (117).  More recently, PACS2, which is an ER-associated 
vesicular-sorting protein, was proposed to link the ER to mitochondria.  The knockdown 
of PACS2, led to uncoupling of the organelles and inhibition of Ca2+ signal transmission 
(118).   Mitochondria take up Ca2+ released from the ER and circulate it back into the 
cytosol. Therefore, it is obvious that mitochondria modulate cytosolic Ca2+ signaling, 
either by rapidly accumulating the Ca2+ released from the ER or by suppressing the 
positive feed-back of Ca2+ via IP3 receptors, thus acting as a buffer to increase cytosolic 
Ca2+ (119).  In addition to sequestering cytosolic Ca2+, mitochondria can trigger 
cytosolic Ca2+ signals via activation of permeability transition pore (120).  These 
findings demonstrate that the mitochondria and ER maintain a local communication 
pathway for effective transfer of Ca2+ between the 2 organelles.  During ER release, 
mitochondria sequester Ca2+ without an increase in cytosolic Ca2+ levels (120, 121).  
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Likewise in the case of permeability transition pore (PTP)-mediated mitochondrial Ca2+ 
release, the ER is known to rapidly accumulate Ca2+ before it is detected in the cytosol 
(122).    
Mitochondrial Ca2+ and apoptosis.  There is substantial evidence that 
intracellular Ca2+ fluxes occur during most forms of cell death including apoptosis (123).  
The role of these fluxes in the induction of mitochondrial apoptosis is still under debate.  
The transfer of Ca2+ from intracellular stores and mitochondria controls cellular 
respiratory events and activation of respiratory enzymes.  Mitochondria are known to 
function not only in the production of ATP but also in the regulation of cellular apoptotic 
signaling via maintenance of intracellular Ca2+ homeostasis.  Cell stimulation leading to 
increased cytosolic Ca2+ level activates the VDAC present on the outer mitochondrial 
membrane (124, 125).  This leads to Ca2+ entry into the mitochondrial matrix.  
Mitochondrial uniporters, proteins that are highly Ca2+ sensitive pass the ions across 
along the electrochemical gradient due the highly negative membrane potential (-180 
mV).  Additional mitochondrial uniporters like VDAC are also Ca2+ sensitive. Therefore, 
VDAC and the uniporters act in unison to buffer the increase in cytosolic Ca2+ levels 
(125, 126).   Ca2+ entering the mitochondria stimulate Ca2+ sensitive mitochondrial 
dehydrogenases (CSMDH) which induce the efflux of Ca2+ from the mitochondria into 
the cytosol.  This is important for maintaining Ca2+ uptake and energy generation (127).  
Ca2+ transfer back to the cytosol is mediated by the Ca2+ exchangers Na+/Ca2+ and/ or 
H+/Ca2+.  It is long known that mitochondrial sequestration of large amounts of Ca2+ 
contributes to cell death.  Sustained elevation of cytosolic Ca2+ from a concentration of 
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100 nM to 1 µM activates both VDAC and the uniporter to enhance mitochondrial Ca2+ 
uptake.  Accumulation of large amounts of Ca2+ in the mitochondria leads to the 
interaction of Ca2+ with cyclophilin D to induce PTP opening (128).  Further elevation of 
Ca2+ in the mitochondrial matrix generates ROS and free fatty acids which also promote 
formation of PTP (129, 130).  Finally, dissipation of the mitochondrial membrane 
potential, release of pro-apoptotic molecules, and impairment of mitochondrial function 
leads to apoptosis of the cell. 
The accumulation of intra-mitochondrial Ca2+ along with the production of 
mediators such as arachidonate or ceramide can trigger cells to undergo apoptosis.  Intra-
mitochondrial sequestration of Ca2+ alters the architecture of the mitochondria via the 
induction of swelling and rupture (131).  Release of contents from the mitochondrial 
intermembrane space requires that the outer mitochondrial membrane (OMM) be 
permeabilized.  The mechanism involved is controversial although there is evidence that 
rupture due to sequestration of Ca2+ leading to MPT, activation and translocation of pro-
apoptotic proteins like Bax, Bak and tBid to the OMM, and the opening of the PTP 
could play a significant role in this process (132, 117).  A critical event associated with 
MPT and translocation of pro-apoptotic proteins in mitochondrial apoptotic signaling is 
the release of normal mitochondrial constituents, i.e., cytochrome-c, mitochondrial 
activator of caspases (SMAC/ Diablo) and apoptosis inducing factor (AIF) into the 
cytosol.  The released cytochrome-c then binds to apoptotic protease activating factor-1 
(APAF-1), which in turn recruits and activates caspase-9 to form an apoptosome.  The 
apoptosome finally activates effector caspase-3 resulting in apoptosis (117, 131).   
  
24
 
Ca2+, ROS, mitochondria and apoptosis.  Over the past few years, extensive 
progress has been made in elucidating the role of mitochondrial Ca2+ and ROS with 
respect to PTP and apoptotic signaling.  Mitochondria, the respiratory organelle of the 
cell, are the major source of ROS production.  Superoxide (O2–·) is the primary form of 
ROS generated by mitochondria. O2–· is converted to H2O2 by the enzyme superoxide 
dismutase (SOD) or by spontaneous dismutation (133).  Although the precise 
mechanism by which mitochondrial Ca2+ stimulates ROS generation and apoptosis is 
unclear, Ca2+ can enhance cytochrome c dislocation from the mitochondrial inner 
membrane by inducing the PTP.  This results in an effective block of the respiratory 
chain (complex III) which would enhance ROS generation (134).  Along these lines Ng 
and collogues have demonstrated that the combination of DHA and butyrate potentiate 
mitochondrial lipid oxidation and the dissipation of mitochondrial membrane potential 
which could be blocked by the PTP inhibitor, cyclosporine (58).  Another pathway by 
which Ca2+ can induce ROS production may involve the perturbation mitochondrial 
antioxidant status.  Consistent with this finding, our laboratory has recently 
demonstrated that fish oil enhances ROS production, while the combination of fish oil 
and fermentable fiber suppressed antioxidant enzyme, i.e., superoxide dismutase (SOD) 
and catalase (CAT) activity and increased the ratio of SOD: CAT (47).  Brookes et al 
have demonstrated that Ca2+-induced PTP opening causes the release of mitochondrial 
glutathione (GSH) (133).  This finding suggests that mitochondria exposed to Ca2+ 
generate more ROS because of diminished GSH levels.   Taken together, all these 
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findings demonstrate that Ca2+ may exert direct effects on ROS generation thus 
contributing to a pro-apoptotic environment.   
Apoptosis occurs concurrent to enhanced generation of mitochondrial ROS (94).  
Studies have indicated a complex interplay between PTP opening and mitochondrial 
ROS generation in response to Ca2+ (93, 135, 136).  Along these lines, oxidative stress 
and Ca2+ activate PTP opening while mitochondrial ROS inhibits SERCA pump and 
activates SOC (137-139).  This demonstrates that mitochondrial ROS can modulate 
extramitochondrial Ca2+ pools.  Overall, it is clear that mitochondrial ROS and Ca2+ 
accumulation exist as networks which influence each other and eventually modulate 
cellular apoptosis.  In conclusion, experimental evidence associating Ca2+ homeostasis 
and ROS and lipid hydroperoxide (LOOH) with mitochondrial mediated induction of 
apoptosis forms a strong basis to study intracellular Ca2+ homeostasis in n-3 PUFA and 
butyrate-treated colonocyte cultures.  
 
Tumor suppressor gene- p53   
p53 is a tumor suppressor gene found to be mutated in more than 50% of all 
human cancers, making it the most frequent target for genetic alterations in cancer (140-
143).  p53-mediated regulation of cell cycle arrest and apoptosis are vital for its tumor 
suppressor activity (143-145).  p53 is latent and not essential for the normal performance 
of cells within the body as suggested by data that demonstrates p53 knock-out mice also 
undergo normal development and maturation (146).  However, p53 responds to a variety 
of intrinsic and extrinsic stress signals to trigger various cellular events, like cell-cycle 
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arrest, apoptosis, inhibition of angiogenesis which indirectly affects metastasis, and 
DNA repair (147, 148).  Furthermore, p53 is also known to contribute, directly or 
indirectly, to DNA repair processes (149, 150).  In response to DNA damage, wild type 
p53 protein transcriptionally activates downstream target genes that serve as mediators 
of p53 function (151-152).  For example, p21, Bax, and Puma are some of the direct 
transcriptional targets of p53 (153-155).  Activation of down stream signals result in 
growth control, DNA repair, and apoptosis (56).  The deletion of p53 or the presence of 
a mutated p53 protein enhances proliferation of cells with damaged DNA due to the 
absence of cell cycle arrest and resistance to apoptosis.  Therefore, genetic manipulation 
used to suppress or knock down the expression of p53 not only facilitates cell survival 
but also aids metastasis by enhancing angiogenesis.     
p53 and apoptosis.  The precise molecular pathways of p53-mediated apoptosis 
are not fully understood.  p53 induces several proapoptotic molecules like p53-
upregulated modulator of apoptosis (Puma) (153, 156) and Noxa (157) which belong to 
the BH-3 group of Bcl-2 proteins.  Puma, a protein localized to the mitochondria is an 
essential mediator of DNA-damage induced “intrinsic” form of apoptosis.  Puma is 
known to induce apoptosis by various mechanisms.  Yu et al have demonstrated that 
second mitochondria-derived activator of caspase (SMAC)/Diablo, a mitochondrial 
apoptogenic protein, mediates Puma induced apoptotic events (157, 158).  They 
demonstrated that SMAC deficient cells do not undergo apoptosis.  Puma is also known 
to bind pro-apoptotic Bax and Bak (159) to induce mitochondrial membrane 
permeabilization and the release of cytochrome-c (160).  In addition, another important 
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mechanism by which Puma induces apoptosis is by activating caspase-12, a proapoptoic 
molecule present on the ER.  Interestingly, PUFA induces Ca2+ release from the ER 
(161).  Activated caspase-12 contributes to mitochondrial membrane permeabilization 
and the induction of p53-meditated apoptosis.  
p53 and Ca2+ homeostasis.  Shibue et al demonstrated that Puma regulates p53-
mediated apoptosis by inducing Ca2+ release from the ER (161).  The mechanism by 
which Puma mediates ER Ca2+ release is unclear.  More recently, studies have also 
shown direct interaction between antiapoptotic Bcl-2 and IP3R’s (161, 162).  Puma 
decreases the interaction between IP3R’s and antiapoptoic Bcl-2 resulting in a release of 
Ca2+ from the ER (95).  Small amounts of cytochrome c released during early apoptosis 
binds to IP3R to enhance Ca2+ release from the ER (163).  Therefore, Puma can also act 
along the same lines releasing a small amount of caspase-12 which binds to the IP3R’s 
on the ER thus stimulating a release of ER Ca2+ (95).  Although the precise mechanism 
by which p53 affects Ca2+ homeostasis is unclear, Puma seems to be an important 
regulator of p53 induced apoptosis.  
 
Summary and purpose   
Colon cancer is one of the major causes of mortality in most developed countries.  
There is substantial epidemiological and experimental evidence to suggest that 
environmental factors like diet play a very important role in determining risk.  Among 
the various dietary factors, fat and fiber are the most widely investigated components in 
the chemoprevention of colon carcinogenesis.  Evidence emerging from many 
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experimental and epidemiological studies show that diets rich in n-3 PUFA’s  found in 
fish oil, (enriched in EPA and DHA) protect against colon carcinogenesis.  However, 
there is a debate with regard to the effect of dietary fiber on colon cancer.  Nonetheless, 
one of the largest population studies reported that dietary fiber is protective against colon 
cancer and butyrate a fiber fermentation product has chemoprotective properties (65).  
The combination of fat (DHA) and fiber (butyrate) is known to be chemoprotecive 
primarily by enhancing cellular apoptosis (14, 16, 58).   Experimental evidence also 
suggests that DHA primes colonocytes by enhancing butyrate-induced mitochondrial 
lipid oxidation and apoptosis (58).  Although there is evidence for the chemoprotective 
properties of DHA and butyrate, their precise molecular mechanism of action is still 
obscure.  The role of Ca2+ as a key modulator of cellular apoptosis is well established.  
Local transfer of Ca2+ signals between ER and mitochondria and its importance in 
igniting apoptosis is also well known.  Nonetheless, the importance of Ca2+ in DHA and 
butyrate-mediated apoptosis is unclear.  Therefore, this study further elucidated the 
chemoprotective properties of components of fish oil (DHA) and fermentable fiber 
(butyrate) with respect of alteration in intracellular Ca2+ homeostasis both in-vitro and in 
ex-vivo primary colonocyte cultures.   In an attempt to elucidate the molecular 
mechanisms of action the following hypotheses and specific aims were designed: 
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Hypotheses   
1.   DHA and butyrate-dependent induction of lipid hydroperoxides (LOOH) 
in colonocytes increases mitochondrial Ca2+ levels, thereby triggering 
apoptosis. 
2.   Changes in intracellular Ca2+ homeostasis are consistent in human 
colonocyte cell lines and primary colonocyte cultures. 
 
Specific aims 
1. Determine intracellular Ca2+ levels in fatty acid and butyrate treated 
colonocytes.  
2. Determine the source of changes in Ca2+ homeostasis using 
pharmacological agents, e.g., thapsigargin to examine the IP3 pool (Ca2+ 
released from the ER on stimulation); EGTA and SKF to examine 
membrane channels. 
3. Determine mitochondrial Ca2+ levels using pharmacological agents.  
4. Determine the role of mitochondrial Ca2+ accumulation with respect to 
fatty acid and butyrate-induced apoptosis by inhibiting the mitochondrial 
uniporter. 
5. Determine the effect of DHA and butyrate on mitochondrial Ca2+ 
accumulation in immortalized mouse (YAMC) human colorectal 
adenoma cell lines (HCT-116). 
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6. Determine the role of p53, a tumor suppressor gene in DHA and butyrate 
induced apoptosis.  
7. Determine the role of mitochondrial uniporter in mitochondrial Ca2+ 
accumulation and induction of apoptosis in both mouse and human 
colonocytes. 
8. Measure mitochondrial Ca2+ levels in primary cultures from animals fed 
diets rich in n-3 PUFA and n-6 PUFA following incubation of viable 
crypts with butyrate ex vivo.  
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CHAPTER II 
DOCOSAHEXAENOIC ACID AND BUTYRATE SYNERGISTICALLY 
INDUCE COLONOCYTE APOPTOSIS BY ENHANCING MITOCHONDRIAL 
CA2+ ACCUMULATION* 
 
There is substantial experimental, epidemiological and clinical evidence 
indicating that fish oil-containing diets rich in n-3 polyunsaturated fatty acids (PUFA), 
e.g. docosahexaenoic acid (DHA, 22:6∆4,7,10,13,16,19) and eicosapentaenoic acid (EPA, 
20:5∆5,8,11,14,17), are protective against colon tumorigenesis (42-46).  In addition, there is 
evidence from epidemiological and observational studies indicating that the consumption 
of fiber, which increases butyrate levels in the lumen of the colon, is chemoprotective 
against colorectal cancers (6, 65).  In contrast, several systematic reviews have 
challenged the premise that dietary fiber and fish oil reduce colon cancer risk, fueling a 
debate regarding the role of dietary fat and fermentable fiber as chemoprotective 
nutrients (164-166).  In order to address this apparent conundrum, our laboratory has 
focused on the question as to why a diet containing highly fermentable fiber is only 
protective when fish oil is the lipid source.   
 
 
* Reprinted with permission from Cancer Research, Journal of the American Association for Cancer 
Research. Satya Sree Kolar, Rola Barhoumi, Joanne R. Lupton, Robert S. Chapkin.  Docosahexaenoic acid 
and butyrate synergistically induce colonocyte apoptosis by enhancing mitochondrial Ca2+ accumulation. 
2007 (In Press). 
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We have demonstrated that the bioactive components generated by fermentable fiber 
(butyrate) and fish oil (DHA) work coordinately to protect against colon tumorigenesis, 
primarily by increasing apoptosis rather than decreasing cell proliferation (14, 16, 52).   
With regard to a molecular mechanism of action, we have shown that DHA alters 
colonocyte mitochondrial membrane composition and function, thereby creating a 
permissive environment for apoptosis induced by luminal metabolites, such as butyrate 
(56, 57).  More recently, we have shown that mitochondrial lipid oxidation products, 
membrane phospholipid-derived hydroperoxides (LOOH), play an important role in 
DHA and butyrate-induced apoptosis (58).  Despite the evidence indicating that the 
combination of dietary fish oil and fermentable fiber enhance apoptosis and suppress 
colon cancer, we still lack information regarding the precise molecular mechanisms by 
which the DHA and butyrate combination protect against colon tumorigenesis.  
With respect to molecular triggers for apoptosis, Ca2+ is one of the most versatile 
and universal signaling mediators in cells and is required for the activation of many 
cellular processes.  Increasing evidence indicates that alterations in the finely tuned 
intracellular homeostasis and compartmentalization of Ca2+ can lead to cell death either 
through apoptosis or necrosis (103).  The Ca2+ concentration inside the cell is regulated 
by the simultaneous interplay of various counteracting mechanisms, which can turn 
cellular signals “on” and/or “off” (92).  Eukaryotic cells can increase their cytosolic Ca2+ 
levels via 2 mechanisms: release of Ca2+ from intracellular stores or influx via plasma 
membrane channels.  Channels located in the plasma membrane, e.g., store operated 
Ca2+ channels (SOC), receptor operated channels, and voltage operated channels, 
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regulate the influx of Ca2+ into the cell.  Currently, there is a good understanding of the 
organelles that function as Ca2+ stores and how Ca2+ can be released from stores into the 
cytosol.  Although the importance of the endoplasmic reticulum (ER) as the major 
storage organelle is indisputable, growing evidence indicates that functional 
compartmentalization of Ca2+ exists within the various cellular organelles.  More recent 
studies have identified the contributions of the nuclear envelope, Golgi apparatus, 
lysosomes and mitochondria in maintaining intracellular Ca2+ homeostasis and cellular 
physiologic function (96, 103, 120).  In fact, it is now recognized that mitochondria play 
a key role in both apoptosis and necrosis by regulating energy metabolism, intracellular 
Ca2+ homeostasis, activation of caspases and the release of reactive oxygen species 
(ROS) (96, 131).  
Mitochondria are localized in close proximity to inositol 1,4,5 – trisphosphate 
(IP3) gated channels situated on the ER.  Ca2+ uniporters, which are low affinity and high 
capacity active pumps located in the mitochondrial outer membrane, rapidly take up 
Ca2+ that is released from the ER stores and re-circulate it back into the cytosol via 
exchangers such as the Na2+/ Ca2+ exchanger (88,97).  Therefore, mitochondria can be 
regarded as critical check-points in Ca2+ signaling, acting as membrane-bound Ca2+ 
buffers.  Under normal conditions, mitochondrial Ca2+ uptake serves as a signal to 
increase cellular metabolism (24). However, in certain situations, mitochondrial Ca2+ 
accumulation is a trigger for cytochrome-C release and the induction of apoptosis (97).   
Given the central role of mitochondria in the commitment to apoptosis, we 
hypothesized that n-3 PUFA and butyrate can promote apoptosis by triggering changes 
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in mitochondrial Ca2+ levels that contribute to caspase activation and colonocyte cell 
death.  We used an immortalized mouse colonocyte (YAMC) cell line to determine 
whether or not chemoprotective nutrients modulate intracellular calcium 
compartmentalization and store-operated channel entry to induce colonocyte apoptosis.  
The results confirm and extend our previous observations and demonstrate that DHA 
and butyrate combination synergistically alter intracellular Ca2+ compartmentalization by 
enhancing mitochondrial Ca2+ accumulation through an SOC-mediated mechanism.  
These outcomes provide clear evidence that an increase in mitochondrial Ca2+ stores 
contributes to the induction of apoptosis by DHA and butyrate co-treatment.   
 
Experimental procedures 
Materials. RPMI 1640 and Hanks' balanced salt solution (HBSS) were purchased 
from Mediatech (Herndon, VA).  Fetal bovine serum (FBS) was from Hyclone (Logan, 
UT). Insulin, transferrin, selenium without linoleic acid were purchased from 
Collaborative Biomedical Products (Bedford, MA).  Glutamax, recombinant mouse 
interferon-γ (IFN-γ) and Leibovitz media were from GIBCO BRL (Grand Island, NY).  
Fatty acids were obtained from NuChek (Elysian, MN). Fluo-4 AM, Rhod-2 AM and 
Calcium Calibration buffer kit # 2 were purchased from Molecular Probes (Eugene, 
OR).  RU-360 and SKF-96365 were purchased from Calbiochem (San Deigo, CA).   
Cell death detection ELISA kit was obtained from Roche Applied Science (Indianapolis, 
IN).  2-well Lab-Tek Chambered Coverglass slides were purchased from Nunc, Inc. 
(Naperville, IL).  Thapsigargin, staurosporine, EGTA, sodium butyrate and all other 
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reagents were obtained from Sigma (St. Louis, MO).  Stock solutions of 1.0 mM Fluo-4, 
AM and 4.0 mM Rhod-2 were prepared in DMSO and diluted with medium to 3.0 µM 
and 2.0 µM, respectively (final concentration of the vehicle DMSO was maintained at 
0.1-0.3% in culture).  Thapsigargin stock (5.0 mM) was prepared in DMSO and used at a 
concentration of 5.0 µM (  0.1% DMSO).  RU-360 (1 mM) stock was prepared in 
degassed water and diluted to a final concentration of 10 µM for cell treatment.  A (1 
mM) stock solution of staurosporine (STS) was prepared in DMSO and diluted to a final 
concentration of 1 µM for cell treatment.  
Cell culture.  Conditionally immortalized YAMC cells were originally obtained 
from R. H. Whitehead, Ludwig Cancer Institute (Melbourne, Australia).  Cells were 
cultured under permissive (33°C with interferon-γ) or non-permissive conditions (39°C) 
as previously described (58, 83).  For all fluorescence measurements, cells (passages 12-
18) were seeded onto borosilicate 2-chambered cover glass slides at a density of 5-7 x 
103 to achieve a 50-70% confluence.  For apoptosis assays, cells were seeded onto 35 
mm cell culture dishes or 6 well plates at a density of 35 x103.  Bovine serum albumin 
(BSA) complexed fatty acids were added to cultures 24 h after cell plating as previously 
described (83).  Select cultures were treated with BSA-complexed DHA (22:6, n-3) or 
LA (18:2, n-6) (0- 200 µM) for 72 h.  Cells were co-incubated with sodium butyrate (0- 
10 mM) in RPMI 1640 media for the final 6, 12, 24 or 48 h of fatty acid pre-treatment.  
Quantification of cytosolic Ca2+ in mouse colonocytes.  Following fatty acid and 
butyrate treatment, cells were washed with Leibovitz media, free of serum and phenol 
red.  Cells were loaded with 3 µM Fluo-4, AM, at 33°C to determine the levels of 
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cytosolic Ca2+.  Fluo-4 is a visible wavelength non-ratiometric cytosolic Ca2+ indicator 
that exhibits a 40-fold increase in fluorescence intensity with Ca2+ binding (167, 168).  
Following a 1 h incubation with the probe, cells were washed with Leibovitz media and 
imaged.  Images were acquired from groups of 10 – 20 cells, 10-12 areas per well, 4-8 
wells per treatment using a Stallion Digital Imaging workstation equipped with 300W 
xenon fluorescent light source.  Fluorescent light was rapidly (<2 msec) switched 
between excitation wavelengths.  Images were captured using a 20X objective 0.75 N.A. 
and a ROPER CoolSnap HQ camera.  For image acquisition, imaging parameters were 
adjusted for maximum detection of fluorescence with minimal cellular photo bleaching.  
Cells were excited at 488 nm and fluorescence emission from individual cells was 
collected at 530 nm.  Image acquisition frequency was set to 1 image every 10 sec.  
Fluorescence intensities were recorded for 300 sec.  A minimum of 2 experiments 
performed on different days were analyzed.  Basal intracellular Ca2+ was measured prior 
to the addition of thapsigargin.  Thapsigargin, is an irreversible SERCA pump inhibitor 
which was used to empty the intracellular Ca2+ store from the ER (168).  Fluorescence 
intensities following thapsigargin stimulation were normalized to basal Ca2+ levels. 
 To determine the contribution of IP3 Ca2+ pools, extracellular Ca2+ was chelated 
using 2 mM EGTA followed by cell stimulation with thapsigargin.  Chelation of 
extracellular Ca2+ facilitates quantification of IP3 Ca2+ released from the ER following 
thapsigargin addition (169, 170).  Ca2+ was then added back into the media and the 
contribution of the SOC pool was evaluated (168).  In order to further evaluate the 
association between PUFA and butyrate co-treatment and SOC, cultures were pre-
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incubated with 10 µM SKF-96365, a pharmacological inhibitor of SOC, for 5 min prior 
to image acquisition.  Calibration of intracellular Ca2+ was performed using the Calcium 
Calibration Buffer kit #2 from Molecular Probes as previously described (171).  
Analysis of mitochondrial Ca2+.  Cells treated with fatty acid and butyrate were 
washed with Leibovitz media and co-loaded with 3 µM Fluo-4 and 2 µM Rhod-2 for 1 h 
at 33°C.  Cells were then washed twice with Leibovitz media and the mitochondrial-to-
cytosolic Ca2+ ratio was measured. For quantification of Fluo-4 and Rhod-2 
fluorescence, excitation light was provided at 488 nm and 550 nm and fluorescence 
emissions were collected at 530 nm and 580 nm, respectively.  The ratio of the cytosolic-
to-mitochondrial Ca2+ level was subsequently calculated.  Although accumulation of 
Rhod-2 dye in the nucleoli was noticed, MitoTracker was used to confirm that dye 
loading was predominantly localized within the mitochondria as previously described 
(172).  In other experiments, cells were incubated with RU-360 (10 µM), an inhibitor of 
the mitochondrial uniporter for 30 min prior to butyrate co-treatment (173).  Cells were 
then washed and co-loaded with fatty acid and butyrate for the final 6, 12 or 24 h 
following which the mitochondrial-to-cytosolic Ca2+ ratio was determined.  Nucleoli 
were not included in the analysis of mitochondrial Ca2+. 
Apoptosis assays.  Apoptosis was measured using cellular fragmentation enzyme 
linked immuno-sorbent (ELISA) (Roche) and caspase-3 activity (Molecular probes) 
assays as previously described (83,174).  To determine the association between 
mitochondrial Ca2+ and apoptosis, select cultures were pre-incubated with RU-360 (10 
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µM) for 30 min prior to butyrate exposure.  Cells were washed and treated with 5 mM 
butyrate and apoptosis was measured following a 6, 12 or 24 h incubation period.  
Statistical analysis.  The effect of independent variables (treatment effects) was 
assessed using SuperAnova.  Differences among means were determined using t/F type 
tests of contrast.   P-values less than 0.05 were considered to be statistically significant. 
 
Results 
DHA and butyrate combination decreases cytosolic Ca2+.  Cytosolic Ca2+ levels 
were initially examined following stimulation with thapsigargin, an irreversible SERCA 
(sarcoplasmic/endoplasmic reticulum Ca2+ ATPase) pump inhibitor used to empty ER 
Ca2+ stores.  Figure 3A shows representative traces of thapsigargin-induced Ca2+ 
response measured over 300 secs.  The arrow indicates the time point of thapsigargin 
addition.  Butyrate treatment (5 mM) over a period of 6 - 24 h increased (p<0.05) 
cytosolic Ca2+ in cells preincubated with LA (50 µM, a control n-6 fatty acid) by up to 
45% compared to untreated control (Figures 3B, C and D).  In contrast, cells pre-
incubated with DHA and butyrate consistently exhibited a lower cytosolic Ca2+ level 
compared to LA and butyrate co-treatment.   
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Control cultures containing either DHA or LA alone, in the absence of butyrate, 
exhibited a modest increase in cytosolic Ca2+ levels, 8 - 12%, compared to untreated 
control (Inset Figures 3C and D).  In comparison, cultures treated with LA and butyrate 
exhibited a 45% increase compared to untreated control at both time points.  Changes in 
Ca2+ levels were detected as early as 6 h following butyrate and fatty acid co-treatment.  
Store operated Ca2+ channel (SOC) involvement in maintaining intracellular 
Ca2+ homeostasis.  To examine the role of store-operated Ca2+ entry, the increase in 
plasma membrane influx associated with ER Ca2+ emptying was characterized using a 
Ca2+ add-back protocol.  This standard procedure utilizes extracellular Ca2+ chelation 
with EGTA followed by utilization of thapsigargin to induce an initial emptying of the 
ER Ca2+ pool, followed by repletion of the bathing solution with Ca2+ (30, 31).  
Consistent with previous experiments (Figure 3) following incubation with 5 µM 
thapsigargin, butyrate (24 h) treated cells preincubated with DHA in the presence of 
extracellular Ca2+ exhibited a 40% decrease in cytosolic Ca2+ compared to LA primed 
cells (p<0.05) (Figure 4).   
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Figure 3.  Effect of fatty acid and butyrate on thapsigargin-induced Ca2+ response. YAMC cells were 
treated with fatty acid alone (50 µM) for 72 h with butyrate (5 mM) for the final 6 (panel B); 12 (panel C); 
or 24 h (panel D).  Cells were subsequently incubated with Fluo-4 (3 µM), a fluorescent cytosolic Ca2+ 
indicator for 1 h at 33°C and basal Ca2+ was measured. Representative traces (15-20 cells/trace) are shown 
in panel A.  Arrow indicates point of thapsigargin (5 µM) addition.  Normalized intensity is the average 
intensity at any point in time, t divided by intensity at time 0.  Cytosolic Ca2+ was quantified at the single 
cell level by choosing at random 3-4 fields with 10-12 cells per field.  Representative data are from a 
single experiment, average of 80-120 cells per treatment, n = 4-6 independent experiments.  Mean values 
± S.E. not sharing common letters are significantly different, p < 0.05.  C, control- no fatty acid or 
butyrate; B, butyrate only; L, LA only; D, DHA only; LB, LA and butyrate; DB, DHA and butyrate.  DHA 
compared to LA pretreated cells demonstrated a significant decrease in cytosolic Ca2+ levels with 12 and 
24 h of butyrate co-treatment.  Inset: Cytosolic Ca2+ levels measured in untreated, butyrate only, fatty acid 
only and LB combination cells at 12 and 24 h are shown in the inset of panels C and D, respectively.  
Representative data are from a single experiment, average of 80-120 cells per treatment, n = 2-4 
independent experiments.  Mean values ± S.E. not sharing common letters are significantly different, 
p < 0.05.  DHA treated cells exhibited no significant difference in cytosolic Ca2+ levels when compared to 
LA treated cells.  
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Figure 4.  Effect of fatty acid on thapsigargin-induced Ca2+ response in the presence or absence of 
EGTA. YAMC cells were treated with fatty acid (50 µM) for 72 h with or without butyrate (5 mM) for the 
final 24 h. Panel A, Cells were incubated with Fluo-4 (3 µM) for 1 h at 33°C and basal Ca2+ was 
measured.  Panel B, Extracellular Ca2+ was chelated using 2 mM EGTA and cells were stimulated with 
thapsigargin (5 µM). Panel C, CaCl2 (10 mM) was added back to the extracellular media and cytosolic 
Ca2+ was quantified. Mean values ± S.E. not sharing common letters are significantly different, p<0.05.  
Representative data are from a single experiment, n = 2 independent experiments.   LB, LA and butyrate; 
DB, DHA and butyrate.  In colonocytes with the combination of DHA and butyrate, chelation of 
extracellular Ca2+ abolished the difference in cytosolic Ca2+ levels and replenishing extracellular media 
with Ca2+ reestablished the difference.  Taken together, these data demonstrate that plasma membrane 
channel entry contributed to the difference seen in cytosolic Ca2+ level.    
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Subsequently, extracellular Ca2+ was chelated by addition of 2 mM EGTA, which allows 
for indirect quantification of the ER Ca2+ pool.  In these experiments, butyrate treated 
cells primed with DHA or LA showed no difference in cytosolic Ca2+ levels (p>0.05) 
(Figure 4).  Following replacement of the medium with CaCl2 (10 mM), the phenotype 
was reestablished, implicating the involvement of plasma membrane channels in the 
propagation of fatty acid-induced Ca2+ signaling.  
To identify the plasma membrane channels involved in eliciting a rise in calcium 
influx following ER Ca2+ depletion in colonocytes, cultures were incubated with SKF-
96365, an inhibitor of non-voltage gated, SOC channels (175, 176).  Typically, butyrate 
treated cells primed with DHA or LA were pre- incubated with 10 µM SKF for 5 min 
prior to basal recording.  SKF abrogated the fatty acid-induced effect on cytosolic Ca2+ 
levels following 12 h butyrate co-treatment (Figure 5A).  Similar effects were observed 
following prolonged butyrate treatment (24 h) (Figure 5B).  Thus, the activation of 
store-operated channels, leading to rapid entry of Ca2+ through the plasma membrane, is 
likely to contribute to the observed fatty acid and butyrate-induced perturbation in 
colonocyte Ca2+ homeostasis. 
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Figure 5.  Thapsigargin-induced Ca2+ response in the presence or absence of SOC inhibitor, SKF-
96365.  YAMC cells were treated with 50 µM fatty acid for 72 h with or without 5 mM butyrate for the 
final 12 h (Panel A) and 24 h (Panel B), followed by Fluo-4 (3 µM) incubation for 1 h.  Select cultures 
were pre-incubated with SKF 96365 (10 µM) for 5 min prior to measuring basal Ca2+ levels.  Cells were 
stimulated with thapsigargin (5 µM) after 15 sec of basal Ca2+ quantification.  C, control- no fatty acid or 
butyrate; B, butyrate only; LB, LA and butyrate; DB, DHA and butyrate. Data are means ± S.E. from a 
representative experiment, n = 2 independent experiments.  SKF-96365 significantly blocked SOC entry 
indicating that SOC are major contributory plasma membrane channels. 
 
 Effect of DHA and butyrate co-treatment on mitochondrial Ca2+ levels.  Since 
the efflux of Ca2+ from the ER can lead to coupled increases in mitochondrial Ca2+ 
levels, we assessed the effects of fatty acid and butyrate co-treatment on mitochondrial 
Ca2+ uptake.  Butyrate co-treatment for 6 h increased (p<0.0001) the mitochondrial-to-
cytosolic Ca2+ ratio in cells treated with DHA by 73% in comparison with untreated cells 
(Figure 6A).  In addition, at 12 and 24 h, DHA and butyrate selectively increased 
(p<0.0001) mitochondrial Ca2+ by 18 and 37%, respectively (Figures 6B and C).  In 
contrast to DHA treated cultures, cells incubated in the presence of LA showed a small 
response or no change in the mitochondrial-to-cytosolic Ca2+ ratio compared to untreated 
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cells.  With respect to the fatty acid only controls, LA treatment had no effect on the 
mitochondrial to cytosolic Ca2+ ratio.   DHA treatment tended to increase the 
mitochondrial to cytosolic Ca2+ ratio at all time points (Inset, Figures 6B and C).  
However, in all cases, cultures pre-treated with DHA and co-incubated with butyrate 
demonstrated the largest increase in mitochondrial Ca2+ levels (Figure 6).  
Representative photomicrographs of untreated cells and cultures co-incubated with 
butyrate (5 mM for 24 h) and DHA or LA (50 µM) are shown in Figure 6, panels D-F.  
Effects of a mitochondrial uniporter inhibitor on mitochondrial Ca2+ uptake 
following DHA and butyrate co-treatment-- To investigate the role of the mitochondrial 
uniporter in Ca2+ uptake, cells were treated with RU-360, a mitochondrial Ca2+ uniporter 
inhibitor (131).  RU-360 (10 µM) partially inhibited (p<0.001) the butyrate-induced 
increase in mitochondrial Ca2+ in DHA primed cells upon addition 30 min prior to 
butyrate co-treatment at 6 or 12 h (Figure 7).  In comparison, RU-360 had no effect on 
mitochondrial Ca2+ levels in LA treated cells.   
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Figure 6.  Effect of fatty acid and butyrate co-treatment on mitochondrial Ca2+ levels inYAMC cells. 
YAMC cells were exposed to 50 µM fatty acid for 72 h in the absence or presence of 5 mM butyrate for 
the final 6 (panel A), 12 (panel B) or 24 h (panel C).  Cells were co-loaded with Fluo-4 (3 µM) and Rhod-
2 AM (2 µM), and the ratio of mitochondrial-to-cytosolic Ca2+ was evaluated as described in the Materials 
and Methods.  Data are means ± S.E. from a representative experiment, n = 3 independent experiments.  
Panels D, E and F are representative images from no-treatment (control), LA and butyrate, and DHA and 
butyrate 24 h cultures. A significant (p<0.0001) difference between the combination of LA with butyrate 
and DHA with butyrate existed starting from 6 h.  C, control- no fatty acid or butyrate; B, butyrate only; L, 
LA only; D, DHA only; LB, LA and butyrate; DB, DHA and butyrate.  Inset: Represents the effects of 
fatty acid treatment with or without butyrate on mitochondrial Ca2+ levels at 12 (Panel B) and 24 h (Panel 
C), respectively.  Data are means ± S.E. from a representative experiment, n = 2-3 independent 
experiments.  Bars not sharing common letters are significantly different, p < 0.05.  C, control- no fatty 
acid or butyrate; L, LA only; D, DHA only; LB, LA and butyrate; DB, DHA and butyrate co-treatment.   
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Figure 7.  Effect of RU-360 on mitochondrial Ca2+ uptake following fatty acid and butyrate co-
treatment. Cells were pretreated with fatty acid for a total of 72 h and RU-360 (10 µM) for 30 min prior 
to butyrate co-treatment for the last 6 h (Panel A) and 12 h (Panel B), respectively. Cells were co-
incubated with Fluo-4 (3 µM) and Rhod-2 (2 µM) for 1 h and the mitochondrial-to-cytosolic Ca2+ ratio 
was measured.  Data are means ± S.E. from a representative experiment, n = 2 independent experiments.  
C, control- no fatty acid or butyrate; B, butyrate only; L, LA only; D, DHA only; LB, LA and butyrate; 
DB, DHA and butyrate.  Data obtained demonstrate that in DHA and butyrate treated cells, RU-360 
partially blocked mitochondrial Ca2+ accumulation.  
 
Induction of colonocyte apoptosis by fatty acid and butyrate combination.  
Using the nucleosomal fragmentation assay, DHA significantly (p<0.0001) enhanced 
butyrate-induced apoptosis compared to cells treated with LA plus butyrate or butyrate 
alone (control) at 12 and 24 h (Figure 8).  In contrast, fatty acid treatment alone had no 
effect on apoptosis (Figure 8C, inset, (Figure 9A and B).  To further corroborate these 
observations, complimentary methodology (caspase-3 activity) was also used.  Similar 
results were obtained (Figure 8D).  For comparative purposes, staurosporine, a broad 
spectrum protein kinase inhibitor, which induces apoptosis in normal and malignant 
cells, was used as a positive control (177).  As expected, cultures pre-incubated with 1 
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µM staurosporine for 4 h exhibited an 8-fold increase in apoptotic cells as compared to 
untreated or fatty acid treated cells (p<0.0001) (Figure 8C, inset).    
 
 
 
 
Figure 8.  Effect of fatty acid and butyrate treatment on apoptotic index and caspase-3 activity in 
YAMC cells.  YAMC cells were treated with fatty acid (50 µM) for a total of 72 h and 0 or 5 mM  
butyrate for the final 6 (Panel A), 12 (Panel B) or 24 h (Panels C and D).  Nonadherent cells were 
harvested, and apoptosis was measured by the nucleosomal fragmentation release assay (Panels A, B and 
C) or both adherent and floating cells were processed and caspase-3 activity was measured as a marker of 
apoptosis (Panel D).  Inset: Control cultures containing no treatment (C), LA only (L), DHA only (D) and 
1 µM staurosporine (STS) 4 h prior to the addition of butyrate.  Data are means ± S.E. from 2 separate 
experiments, n = 6 wells per treatment.  Refer to figure 6 for legend details.  Data show that the 
combination of DHA and butyrate significantly enhanced apoptosis as compared to LA and butyrate or no 
treatment control. 
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Figure 9.   Effect of fatty acid controls on apoptosis in YAMC cells.  YAMC cells were treated with 
fatty acid (50 µM) for a total of 72 h or 0 or 5 mM  butyrate for 12 (Panel A), or 24 h (Panel B).  
Nonadherent cells were harvested, and apoptosis was measured by the nucleosomal fragmentation assay.  
Data are means ± S.E. from 2-4 separate experiments, n = 10 wells per treatment.  C, control- no fatty acid 
or butyrate; B, butyrate only; L, LA only; D, DHA only.   
 
 
The mitochondrial Ca2+ uniporter inhibitor, RU-360, suppresses induction of 
apoptosis following DHA and butyrate co-treatment.  To investigate the relationship 
between mitochondrial Ca2+ uptake and cellular apoptosis, we compared the levels of 
apoptosis observed in DHA plus butyrate treated cells in the absence or presence of the 
mitochondrial Ca2+ uniporter inhibitor, RU-360.  Results obtained in experiments with 
butyrate at 12 and 24 h following DHA or LA co-treatment are shown in Figure 10.  
RU-360 significantly (p<0.05) reduced apoptosis by ~ 45% following 12 h butyrate co-
treatment.  Similar results were observed in DHA primed cells following 24 h butyrate 
co-treatment.  In contrast, inhibition of the uniporter had no effect on cells treated with 
LA plus butyrate or butyrate alone at 12 and 24 h.  Collectively, these results 
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demonstrate that mitochondrial Ca2+ uptake is required for the enhanced apoptosis 
associated with DHA and butyrate co-treatment.  
 
 
 
Figure 10.  Effect of RU-360 on apoptotic index in YAMC cells.  YAMC cells were treated with DHA 
or LA (50 µM) for 48 h and subsequently pre-incubated with 10 µM RU-360 for 30 min.  Treated cells 
were then co-incubated with fatty acid with or without 5 mM butyrate for the final 12 h (Panel A) and 24 h 
(Panel B).  Nonadherent cells were harvested, and nucleosomal fragmentation was used to quantify 
apoptosis. Data are means ± S.E. from 2 separate experiments, n = 6 wells per treatment.  C, control- no 
fatty acid or butyrate; LB, LA and butyrate; DB, DHA and butyrate.  Data demonstrate that RU-360 
significantly blocked apoptosis with cells pretreated with the combination of DHA and butyrate. 
 
Kinetics of DHA and butyrate induction of mitochondrial Ca2+ and apoptosis.  
To probe the functional proximity of mitochondrial Ca2+ uptake in relation to the 
induction of apoptosis, we analyzed the effects of treatment over time (6, 12 and 24 h).  
As shown in Figure 11, cells treated with butyrate and DHA exhibited a significantly 
(p<0.0001) higher level of mitochondrial Ca2+ compared to all other treatments as early 
as 6 h.  In contrast, the induction of apoptosis was not observed until 12 h.  These results 
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indicate that the increase in mitochondrial Ca2+ preceded the onset of apoptosis and 
therefore plays an important role in triggering programmed cell death in colonic mucosal 
cells.  
 
Discussion 
Dietary DHA (22:6n-3) has been extensively studied over the last decade in relation to 
its role as a bioactive chemopreventive agent.  Past results from our laboratory have 
demonstrated that DHA, when combined with either a fermentable fiber source or 
butyrate, enhances ROS and LOOH production, and causes a change in mitochondrial 
permeability transition (MPT) in colonocytes (56-58, 47).  Herein, we report that DHA 
and butyrate co-treatment also synergistically enhance apoptosis by up to 43% in 
colonocyte cultures compared to butyrate alone (Figure 8).  In contrast, colonocytes 
treated with either DHA or LA alone, demonstrated no significant increase in the level of 
apoptosis compared to untreated cells (Figure 9).  From a biological relevance 
perspective, these data are consonant with animal carcinogen studies demonstrating that 
the bioactive components of fermentable fiber (butyrate) and fish oil (DHA) 
coordinately protect against colon tumorigenesis, primarily by increasing apoptosis (14, 
16, 45, 52).   Further, our studies reveal that the combination of DHA and butyrate, 
compared to butyrate alone, further enhances apoptosis by additionally recruiting a Ca2+ 
-mediated intrinsic mitochondrial pathway.  Based on our findings, we propose a 
pathway for the induction of apoptosis in colonic epithelium that involves the synergistic 
action of DHA and butyrate on enhanced mitochondrial Ca2+ accumulation (Figure 12). 
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Figure 11.  Effect of DHA and butyrate treatment on induction of mitochondrial Ca2+ and apoptosis 
in YAMC cells.  The time-dependent effect of fatty acid (72 h) and butyrate co-treatment (6, 12, 24 h) 
were compared.  Induction of mitochondrial Ca2+ and apoptosis were measured as described in the 
Materials and Methods.  Data are expressed as a percentage of control (no treatment), mean ± S.E. from n 
= 3 separate experiments; (*, Apoptotic index, control vs treatment at each time point p < 0.05; **, 
Mitochondrial Ca2+, control vs treatment at each time point, p < 0.0001).                                                                                        
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Figure 12. Proposed molecular model of DHA and butyrate-induced apoptosis.  Butyrate induces 
colonocyte apoptosis via a non-mitochondrial, Fas-mediated, extrinsic pathway.  DHA and butyrate, in 
combination, synergistically perturb intracellular Ca2+, stimulating mitochondrial Ca2+ uptake.  This 
directly or indirectly decreases cytosolic Ca2+ and promotes SOC-mediated entry via plasma membrane 
channels.  Mitochondrial Ca2+ accumulation subsequently triggers the opening of the permeability 
transition pore (PTP) and release of pro-apoptotic molecules like cytochrome C and other factors such as 
apoptosis-inducing factor (AIF), and second mitochondrial activator of caspases (smac/DIABLO).  
Together, these effects culminate in the induction of pro-caspases and downstream caspases that execute 
cellular apoptosis. 
 
 
  
Over the last decade extensive progress has been made in establishing the effects 
of long chain PUFA on various ions and ion channels, including Ca2+ (66, 103, 177-179).  
With respect to a molecular mechanism of action, agents which increase mitochondrial 
ROS/LOOH generation have been linked to a pro-apoptotic cycle involving Ca2+ release 
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from intracellular stores and mitochondrial loading (180).  These data suggest that a 
change in mitochondrial Ca2+ homeostasis may mediate the pro-apoptotic effect of 
butyrate and DHA in colonocytes.  The current experiments support this hypothesis, 
because the combination of DHA and butyrate produced the highest mitochondrial Ca2+ 
accumulation (Figure 6) while simultaneously decreasing free cytosolic Ca2+ levels 
(Figures 3C and D).  These data are consistent with our previous finding that DHA 
primes the cell for butyrate induced lipid oxidation (58).       
The role of mitochondria in the regulation of intracellular Ca2+ homeostasis and 
apoptotic signaling is well established (87, 96, 120).  Recent work has shown that 
mitochondria are closely juxtaposed with the ER to effectively take up Ca2+ that is 
released from the ER.  There is also evidence of clustering of IP3 receptors on the ER 
membrane facing the mitochondria (116, 181).  Besides close physical association of the 
ER and mitochondria, IP3 receptor-dependent Ca2+ signals are associated with an 
increase in mitochondrial Ca2+ which is capable of triggering apoptosis (97, 117).  
Consistent with these observations, DHA treated cultures exhibited a significant 
accumulation of mitochondrial Ca2+ within 6 h of butyrate co-treatment (Figures 6A), 
preceding the onset of apoptosis which was not increased until 12 h following butyrate 
co-treatment (Figure 8B and Figure 11).   
To explore the connection between the accumulation of mitochondrial Ca2+ and 
apoptosis, we examined the effect of a mitochondrial Ca2+ uniporter inhibitor (RU-360).  
RU-360 significantly blocked mitochondrial Ca2+ uptake following DHA and butyrate 
co-treatment (Figure 7) and partially blocked the induction of apoptosis (Figure 10).  
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These outcomes provide evidence that an increase in mitochondrial Ca2+ levels 
contribute directly to the induction of apoptosis by DHA and butyrate co-treatment and 
the change in intracellular Ca2+ homeostasis is not an epiphenomenon.    
Despite the difficulties inherent to measuring mitochondrial Ca2+ levels, both 
imaging and uniporter inhibitor data indicate that Rhod-2 loads primarily into the 
mitochondria.  With respect to how mitochondria translate/interpret Ca2+ signals that 
ultimately trigger apoptosis, it has been demonstrated that multi-factorial cross-talk 
among Ca2+, ATP and oxidative stress enhance cytochrome-C dislocation from the inner 
mitochondrial membrane and  activate Ca2+-dependent endonucleases, which are 
responsible for the induction of the DNA fragmentation and apoptosis (133, 182).  There 
is also evidence that mitochondrial Ca2+ sequestration (via the mitochondrial uniporter) 
results in the opening of the mitochondrial permeability transition (MPT) pore which can 
induce the release of pro-apoptotic molecules, i.e., Bax, Bak, cytochrome-C, resulting in 
mitochondrial-mediated (intrinsic) apoptosis (181, 132).  This scenario correlates well 
with our finding of a decrease in colonic mitochondrial membrane potential in fish oil 
but not corn oil fed rats (56, 57).  
To elucidate the relative contribution of ER Ca2+ store emptying versus SOC 
Ca2+ entry in maintaining intracellular Ca2+ homeostasis, thapsigargin-evoked Ca2+ 
responses were measured in a Ca2+ free environment using EGTA.  The removal of 
extracellular Ca2+ effectively abolished the DHA and butyrate-induced decrease in 
cytosolic Ca2+ levels (Figure 4).  Following replenishment of extracellular Ca2+, the 
difference in cytosolic Ca2+ between DHA and butyrate versus control (LA and butyrate) 
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treatment groups was re-established.  These data suggest that Ca2+ influx through SOC 
partly mediates the DHA and butyrate perturbation of intracellular Ca2+.  To corroborate 
the involvement of plasma membrane non-voltage gated Ca2+ channels, SOC-dependent 
influx was also antagonized using SKF-96365.  SKF pre-treatment eliminated the 
difference in thapsigargin-evoked cytosolic Ca2+ levels between LA plus butyrate and 
DHA plus butyrate treatment groups.  These data are consistent with previous 
observations where DHA was found to regulate intracellular signaling by modulating 
plasma membrane Ca2+ entry (183), suggesting that the combination of DHA and 
butyrate alters colonocyte free cytosolic Ca2+ levels in part by modulating SOC entry.  
Along these lines, growing evidence suggests that the MPT pore is activated by both 
oxidative stress and Ca2+, while mitochondrial ROS inhibit SERCA pumps (138) and 
activate SOC (137, 139).  In accordance with these findings, we have recently 
demonstrated in HCT-116 cells that a mitochondrion-specific antioxidant blocks the 
DHA and butyrate-induced induction of apoptosis (manuscript in preparation).  Further 
studies are needed in order to determine if these effects extend to other members of the 
n-3 PUFA family, since a number of studies have shown that EPA and DHA have 
similar effects on biological membranes (43, 56, 57). 
We have previously demonstrated that butyrate induces colonocyte apoptosis via 
a Fas receptor-mediated extrinsic pathway (83).  In an extension of our findings, we 
demonstrate for the first time that the combination of DHA and butyrate, compared to 
butyrate alone, further enhances apoptosis by additionally recruiting a Ca2+ -dependent 
mitochondrial-intrinsic pathway.  Notably, DHA-enriched mitochondria were sensitized 
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to rapidly sequester Ca2+, which served to trigger apoptosis in the presence of butyrate.  
This could in part explain why the combination of dietary fish oil (containing DHA) and 
pectin (which generates butyrate in the lumen of the colon) appears to reduce tumor 
formation in the colon by promoting apoptosis (16, 14, 57, and 47).  Although previous 
studies have examined the effects of PUFA to mobilize intracellular Ca2+ (183, 184, 
185), it is apparent that DHA and butyrate work coordinately in the colon to initiate a 
pro-apoptotic cycle involving the activation of SOC, leading to rapid entry of Ca2+ 
through the plasma membrane and mitochondrial Ca2+ loading (Figure12).  With regard 
to putative upstream mediators, we have shown that a DHA - butyrate combination 
dissipates mitochondrial membrane potential, an effect which was reversed by 
coincubation with permeability transition pore (PTP) inhibitors (58).  This is consistent 
with the fact that mitochondrial Ca2+ interacts with cyclophilin D which can trigger 
opening of the permeability pore (128).  Although the precise chronology of these events 
have not been elucidated, it is likely that PTP opening, mitochondrial lipid oxidation, 
mitochondrial Ca2+ accumulation and the induction of apoptosis are all intimately linked.   
In summary, recent data indicate that chemotherapeutic agents which restore 
normal apoptotic pathways have the potential for effectively treating cancers that depend 
on aberrations of the apoptotic pathway to develop.  Hence, it is of interest that DHA 
and butyrate work coordinately in the colon to trigger a previously unrecognized pro-
apoptotic cycle involving mitochondrial Ca2+ loading.   This may explain why a diet 
containing highly fermentable fiber is only protective when fish oil is the lipid source.  
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CHAPTER III 
SYNERGY BETWEEN DOCOSAHEXAENOIC ACID AND BUTYRATE 
ELICITS p53-INDEPENDENT APOPTOSIS VIA MITOCHONDRIAL CA2+ 
ACCUMULATION IN HUMAN COLON CANCER CELLS AND IN RAT 
PRIMARY COLONOCYTE CULTURE 
 
The incidence of colon cancer is increasing among people who migrate from low 
incidence to high incidence regions (2).  This variation in geographical incidence of 
colon cancer indicates that environmental factors, especially modifiable factors like diet 
and physical activity play a major role in disease onset (1, 2).  Fat and fiber are two of 
the most widely investigated dietary components in the prevention of colon 
carcinogenesis. Currently, there is a plethora of experimental, epidemiological and 
clinical evidence indicating that diets rich in n-3 polyunsaturated fatty acids (PUFAs), 
e.g. docosahexaenoic acid (DHA, 22:6∆4,7,10,13,16,19) and eicosapentaenoic acid (EPA, 
20:5∆5,8,11,14,17) enriched in fish oil are protective against colon tumorigenesis (16, 38, 39, 
44, 46, 50, 54, 55, 66, 186, 36 Fernandez, 1999;Reddy, 1991; ).  In contrast, dietary 
lipids rich in n-6 PUFA (found primarily in vegetable oils), e.g., linoleic acid (LA, 
18:2∆9,12) and arachidonic acid (AA, 20:4∆5,8,11,14), enhance the development of colon 
tumors (50, 76, 187, 188,  Reddy, 1991).  Importantly, the typical Western diet contains 
10 to 20 times more n-6 than n-3 PUFA (189).  There is also evidence that the 
consumption of fiber, a luminal source of butyrate, is chemoprotective against colorectal 
cancers (65, 73).  Although there is still debate challenging the premise that dietary fiber 
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reduces colon cancer risk (36, 164, 166), we have demonstrated that the 
chemoprotective/proapoptotic effect of n-3 PUFA is enhanced when a highly 
fermentable fiber, pectin (or its fermentation product-butyrate) is added to the diet (29, 
47, 58, 50, 181).  This is significant because the transformation of colonic epithelium to 
carcinoma is in part associated with a progressive inhibition of apoptosis (49, 50, 51, 
161).  Hence, chemotherapeutic agents which restore the normal apoptotic pathways 
have the potential for effectively treating cancers that depend on aberrations of the 
apoptotic pathway to stay alive (190).  Along these lines, we have demonstrated that 
measurements of apoptosis have greater prognostic value to detect dietary effects on 
colon tumor incidence than do measurements of cell proliferation (50, 52).    
With regard to mechanisms of action, we have recently demonstrated that dietary 
DHA is incorporated into mitochondrial membrane phospholipids, thereby enhancing 
oxidative stress induced by butyrate metabolism (47, 56, 57).  We subsequently 
identified a pathway for the induction of apoptosis in colonic epithelium involving the 
synergistic enhancement of mitochondrial phospholipid hydroperoxides (PLOOH) by 
these two bioactive molecules (58).  Our results indicate that the effects of individual 
chemoprotective nutrients (n-3 PUFA and butyrate) may not be as important as the 
nutritional combination.  Indeed, this may explain why a diet containing highly 
fermentable fiber is only protective when fish oil is the lipid source (29, 50).   
Ca2+ is one of the most versatile universal signaling mediators of cellular 
apoptosis.  Cumulative evidence indicates a central role for mitochondrial Ca2+ 
accumulation in intrinsically-mediated apoptosis (113, 130, 131, 120).  Although the 
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importance of the endoplasmic reticulum (ER) as the major storage organelle is 
indisputable, it has been known for some time that mitochondrial sequestration of large 
amounts of Ca2+ contributes to cell death via apoptosis or necrosis (87, 90, 96, 113, 120).  
Several lines of recent evidence suggest that apoptosis is induced in response to 
alterations in intracellular Ca2+ compartmentalization and enhanced mitochondrial Ca2+ 
accumulation (120, 130, 131, 159).  The mitochondrial uniporter, a Ca2+ selective ion 
channel present on the outer mitochondrial membrane, mediates rapid mitochondrial 
Ca2+ uptake of the Ca2+ following release from ER stores (125, 126).  Furthermore, 
activation of the uniporter associated with a rise in mitochondrial Ca2+ stimulates the 
generation of reactive oxygen species (ROS) and free fatty acids, which promote the 
opening of the permeability transition pore (PTP) (129, 120).  Opening of the PTP 
causes dissipation of the mitochondrial membrane potential and eventually the release of 
Ca2+.  However, under certain circumstances, mitochondrial Ca2+ accumulation acts as a 
trigger for release of pro-apoptotic molecules from the mitochondria that leads to 
execution of the cells (98, 119).    
With accumulating evidence favoring a central role for mitochondrial Ca2+ 
accumulation in cellular apoptosis, we recently determined the effect of DHA and 
butyrate on mitochondrial Ca2+ levels.  Specifically, we demonstrated using young adult 
mouse colonocytes (YAMC), that DHA and butyrate combination synergistically alters 
intracellular Ca2+ compartmentalization by enhancing mitochondrial Ca2+ accumulation 
through a store-operated channel (SOC) -mediated mechanism (63).  In this study, our 
primary objective was to corroborate these novel findings utilizing human colonocyte 
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cell lines.   In addition, since mitochondria and the p53 tumor suppressor gene play a 
critical role in damage-induced apoptosis (161, 191), we postulated that the combination 
of DHA and butyrate significantly enhances mitochondrial Ca2+ accumulation and 
apoptosis in a p53-dependent fashion.  To address this hypothesis, we used isogenic p53 
wild type and deficient human colon tumor (HCT 116) cell lines to determine the effect 
of DHA and butyrate on mitochondrial Ca2+ levels.  Findings from this study 
demonstrate that an increase in mitochondrial Ca2+ accumulation directly contributes to a 
p53-independent induction of apoptosis by DHA and butyrate.  In order to address the in 
vivo relevance of these observations, parallel experiments were also conducted using 
intact crypts isolated from rats fed fish oil (contains DHA) or corn oil (contains no DHA, 
control).  Data from these experiments recapitulated observations in the human cell 
lines, providing conclusive evidence that DHA and butyrate enhance mitochondrial Ca2+ 
accumulation, culminating in the induction of apoptosis.   
 
Experimental procedures 
Materials.  McCoy’s 5A media, GlutaMAX and Leibovitz media were purchased 
from GIBCO BRL (Grand Island, NY).  Hanks' balanced salt solution (HBSS) was from 
Mediatech (Herndon, VA).  Fetal bovine serum (FBS) was purchased from Hyclone 
(Logan, UT).  Fatty acids were obtained from NuChek Prep (Elysian, MN).  Fluo-4 AM, 
Rhod-2 AM, Mitotracker green FM and LIVE/DEAD Viability/Cytotoxicity Kit were 
purchased from Molecular Probes (Eugene, OR).  RU-360 was purchased from 
Calbiochem (San Deigo, CA).  MitoQ, a mitochondrion targeted antioxidant was a 
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generous gift from Dr. Michael Murphy, Medical Research Council Dunn Human 
Nutrition Unit, Cambridge, UK.  Cell death detection ELISA kit was obtained from 
Roche Applied Science (Indianapolis, IN).  2-well Lab-Tek Chambered Coverglass 
slides were purchased from Nunc, Inc. (Naperville, IL).  Pre-cast 4-20% Tris-glycine 
gels were from Invitrogen (Carlsbad, CA).  Electroblotting poly-vinyldiene-difluoride 
(PVDF) membranes were obtained from Millipore (Burlington, MA).  Super Signal West 
Femto Maximum Sensitivity Substrate was from Pierce (Rockford, IL).  Primary rabbit 
anti-p53 antibody was obtained from Calbiochem (San Deigo, CA) and peroxidase-
conjugated goat anti-rabbit IgG secondary antibody was purchased from Kirkegaard 
& Perry (Gaithersburg, MD).  Sodium butyrate, EDTA and all other reagents were 
obtained from Sigma (St. Louis, MO).   
Stock solutions of 1.0 mM Fluo-4, AM and 4.0 mM Rhod-2 were prepared in 
DMSO and diluted with medium to 3.0 µM and 2.0 µM, respectively (final concentration 
of the vehicle DMSO was maintained at 0.1-0.3% in culture).  1 mM stock RU-360 was 
prepared in degassed water and diluted to a final concentration of 10 µM for cell 
treatment.  50 mM MitoQ stock was prepared in sterile water and a final concentration 
of 5 µM was used for cell culture.   
Cell culture.  Isogenic cell lines p53 wild type (p53+/+) and p53 deficient  
(p53-/-) were obtained from Dr. Bert Vogelstein, Johns Hopkins University, MD.  HCT 
116 cells were cultured in McCoy’s 5A media supplemented with 10% FBS and 1% -
200 mM GlutaMAX.  Cells were cultured at 37°C in 5% CO2.  For all fluorescence 
measurements, p53+/+ (passages 3-8) and p53-/- (passages 15-19) cells were seeded 
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onto borosilicate 2-chambered cover glass slides at a density of 1.2-1.5 x 105 for 72 h to 
achieve a 50-70% confluence.  For apoptosis assays, cells were seeded onto 35 mm cell 
culture dishes or 6 well plates at a density of 3.5 x104.  Bovine serum albumin (BSA) 
complexed fatty acids were added to cultures 24 h after cell plating as previously 
described (83).  Select cultures were treated with BSA-complexed DHA (22:6, n-3) or 
LA (18:2, n-6) (50 µM) for 72 h.  Cells were co-incubated with sodium butyrate (0 - 5 
mM) in McCoy’s 5A media for the final 6, 12 or 24 h of fatty acid pre-treatment.  
Analysis of mitochondrial Ca2+.  Cells treated with fatty acid and butyrate were 
washed with Leibovitz media and co-loaded with 3 µM Fluo-4 and 2 µM Rhod-2 for 1 h 
at 37°C. For quantification of Fluo-4 and Rhod-2 fluorescence, excitation light was 
provided at 488 nm and 550 nm and fluorescence emissions were collected at 530 nm 
and 580 nm, respectively.   10- 15 areas with 20-25 cells per area were imaged and the 
ratio of mitochondrial-to- cytosolic Ca2+ level was calculated.  Cells or crypts were 
analyzed with a Stallion Digital Imaging workstation equipped with 300W xenon 
fluorescent light source with rapid switching (<2msec) between excitation wavelengths.  
Images were collected using a 20X objective 0.75 N.A. and a ROPER CoolSnap HQ 
camera.  In select experiments, MitoTracker Green FM was used to confirm the 
subcellular localization of Rhod-2 fluorescence (172).  MitoTracker Green is a green-
fluorescent mitochondrial stain which localizes in the mitochondria regardless of 
mitochondrial membrane potential. This dye has an added advantage in that it is 
essentially non-fluorescent in aqueous solution, only becoming fluorescent when it 
accumulates in the lipid environment of the mitochondria.  In addition, to reconfirm that 
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Rhod-2 fluorescence corresponded to mitochondrial Ca2+ accumulation, experiments 
were performed in cultures incubated with RU-360 (10 µM), an inhibitor of the 
mitochondrial uniporter, for 30 min prior to butyrate co-treatment (173).  Cells were 
subsequently washed and treated with fatty acid and butyrate for the final 6, 12 or 24 h 
following which the mitochondrial-to-cytosolic Ca2+ ratio was determined. 
Apoptosis assay.  Apoptosis was measured using cellular fragmentation enzyme 
linked immuno-sorbent (ELISA) (Roche).  Floating cells were harvested, washed, lysed 
and centrifuged to sediment nuclei.  Supernatant containing mono and oligonucleosomes 
were incubated with substrate and subsequently analyzed by ELISA.  Absorbance values 
were measured at 405 nm and subsequently normalized to the number of adherent cells 
per dish as previously described (83).  To determine the association between 
mitochondrial Ca2+ and apoptosis, select cultures were pre-incubated with RU-360 (10 
µM) for 30 min prior to butyrate exposure.  Cells were washed and treated with 5 mM 
butyrate and apoptosis was measured following a 6, 12 or 24 h incubation period.  To 
determine the involvement of oxidative stress in fatty acid and butyrate-induced 
apoptosis, select cultures were pre-incubated with 5 µM MitoQ for 1 h prior to butyrate 
treatment (58).  Cells were then treated with fatty acid and 5 mM butyrate for an 
additional 12 h and apoptosis quantified.  
Western blotting.  Cell lysates from p53+/+ or p53 -/- cells were immunoblotted 
with p53 antibody using the method of Davidson et al. (192).  Briefly, samples were 
treated with SDS sample buffer and subjected to electrophoresis in 4-20% pre-cast Tris-
glycine mini-gels.  After electrophoresis, proteins were electroblotted onto a PVDF 
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membrane using a Hoefer Mighty Small Transphor unit (Pharmacia, Piscataway, NJ) at 
400 mA for 75 min.  Following transfer, the membrane was incubated with rabbit anti-
p53 antibody overnight at 4°C, followed by peroxidase labeled goat anti-rabbit IgG 
incubation for 1 h at room temperature.  Bands were developed using Super Signal West 
Femto Maximum Sensitivity Substrate, and blots were scanned using a Bio-Rad Fluor-S 
Max MultiImager system (Hercules, CA). 
Animals and diets.  Animal use was approved by the University Animal Care 
Committee of Texas A&M University and conformed to NIH guidelines.  Male weanling 
(28-d old) Sprague-Dawley rats (n = 60; Harlan Sprague Dawley) were housed 
individually in raised wire cages.  The animals were maintained in a temperature- and 
humidity-controlled animal facility with a daily 12 h light and 12 h dark photocycle as 
described by Sanders et al (47).  Rats were acclimated for 1 week prior to receiving 
semi-purified experimental diets.  The animals were weighed before the start of the diet 
and were randomly assigned into 1 of 2 experimental diets (n=15 rats/diet) so that the 
mean initial body weights did not differ between the two diet groups.  Rats were placed 
on experimental diets for 3 weeks ± 3 days.  The experimental diet composition is 
described in Tables 1 and 2.  The experimental diets differed only in the type of fat (corn 
oil or fish oil).   The major differences among the fatty acid composition of the dietary 
lipid sources were significantly higher amounts of EPA (20:5n-3) and DHA (22:6n-3) in 
the fish oil compared to corn oil diet, and higher amounts of linoleic acid (LA, 18:2n-6) 
in the corn oil diet (48).  Each diet contained 15% dietary fat by weight and 6% dietary 
fiber by weight.  Cellulose, a poorly fermentable fiber, was chosen as the source of fiber.  
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The percentage of fat and fiber corresponded to 30% energy from fat and 30 g of fiber 
per day as in a human diet.  The fish oil diet contained 3.5 g of corn oil/100 g diet to 
prevent essential fatty acid deficiency.  Food and water were freely available to the 
animals at all times.  To minimize fatty acid oxidation, diets were stored at –80°C and 
fresh food was provided every 24 h.  
Isolation of colonic crypts.  Following the feeding period, rats were killed by 
CO2 asphyxiation and cervical dislocation.  The colon was removed and the colonic 
crypts were isolated as described previously (193) with slight modification.  Briefly, the 
colon was flushed with phosphate-buffered saline (PBS) to remove feces and incubated 
at 37° C in calcium and magnesium-free Hank’s balanced salt solution (HBSS) 
containing 25 mM dithiothreitol, 0.1% fatty acid-free BSA, 1 mM glutamine and 30 mM 
EDTA in order to dislodge crypts from the colonic extracellular matrix.  The incubation 
buffer was developed to minimize the generation of crypt fragments and to reduce mucin 
levels, thereby improving image background.  Following a 15 min incubation period 
with gentle shaking, the mucosa was gently scraped with a rubber policeman and intact 
crypts were isolated.  Subsequently, the crypt suspension was centrifuged at 100 g for 3 
min, the supernatant discarded and the pellet gently resuspended in HBSS.  The 
centrifugation step was repeated three times.   Crypts were then resuspended in Leibovitz 
media and immediately analyzed. The time elapsed from animal termination to image 
capture did not exceed 70 min.  The isolation time period was optimized based on 
preliminary experiments which demonstrated that crypt viability decreased after 70 min.   
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Table 1.  Composition of Experimental Diets 
 
 
Ingredient  Corn Oil Fish Oil 
 
Sucrose 32.0 32.0 
Casein 20.0 20.0 
Corn Starch 22.0  22.0 
DL- Methionine 0.3 0.3 
AIN-76 Salt Mix 3.5 3.5 
AIN-76 Vitamin Mix 1.0 1.0 
Choline Chloride 0.2 0.2 
Cellulose 6.0 6.0 
Corn Oil 15.0 3.5 
Fish Oil 0.0 11.5 
Total 100 100 
 
     Values are listed as weight percentages. 
 
 
 
 
Table 2.  Dietary fatty acid composition1, 2 
 
 
Fatty acid Corn Oil 
 
Fish Oil 
14:0 0.1 6.9 
16:0 10.5 13.8 
16:1 (n-7) 0.2 9.3 
18:0 1.8 2.5 
18:1 (n-9) 27.2 11.6 
18:2 (n-6) 57.7 15.5 
18:3 (n-3) 1.0 1.3 
20:5 (n-3) Trace3 8.4 
22:5 (n-3) Trace 1.3 
22:6 (n-3) Trace 8.2 
 
1 Values are listed as g/100 g fatty acid.  Only the major fatty acids (>1 g/100 g) 
are listed.  
2 CO, diets contain 15% corn oil by weight; FO, 11.5% fish oil + 3.5% corn oil. 
3 Trace, amount (<0.1 g/100 g). 
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Measurement of mitochondrial to cytosolic Ca2+ ratio in primary culture.  
Isolated colonic crypts were incubated with or without 5 mM butyrate in Leibovitz 
media for 30 min at 37°C. Crypts were co-loaded with Fluo-4 and Rhod-2 for 30 min.  
Crypts were subsequently imaged and the ratio of mitochondrial to cytosolic Ca2+ was 
determined as described above.  A total of 10-15 areas with intact crypts were imaged 
for each sample.  This technique is well suited for studying significant differences 
between treatments because it minimizes the variability in dye loading and changes in 
the size or shape of the crypts.   
Crypt cell viability was evaluated in each sample following Ca2+ measurement.  
For this purpose, crypt pellets were co-loaded with Ethidium homodimer-1 and calcein 
AM (Molecular Probes, OR).  Live cells have ubiquitous intracellular esterase activity 
and convert non-fluorescent calcein AM to a highly fluorescent calcein which is retained 
inside the live cell to emit a uniform green signal.  Ethidium homodimer-1 enters cells 
with a damaged plasma membrane and is excluded by the intact plasma membrane of 
viable cells (194).  Therefore, Ethidium homodimer enters dead cells with a 
compromised plasma membrane and undergoes a 40-fold enhancement in fluorescence 
to produce a bright red fluorescence differentiating it from viable green cells.   
Statistical analysis.  The effect of independent variables (treatment effects) was 
assessed using SuperAnova.  Differences among means were determined using t/F type 
tests of contrast.   P-values less than 0.05 were considered to be statistically significant.  
In primary culture experiments, to understand how the ratios of the 
mitochondrial-to-cytosolic Ca2+ level vary with diet treatments, linear mixed effect 
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model (195) were carried out using a procedure “nlme” within the statistical software R 
(196).  A subject-level random effect was modeled to account for similarity of 
measurements collected from the same rat. The main fixed treatment effects considered 
in the model include oil (corn vs fish oil), fiber (w/ and w/o butyrate) and fat-fiber 
interactions.  Further, ratios of the mitochondrial-to-cytosolic Ca2+ level were considered 
at the log-scale to reduce potential effects of outlying observations at the right tail of the 
data distribution.  Several inferential statistical analyses within the mixed effects 
modeling framework were utilized to examine the effect of diet on the mitochondria-
cytosol Ca2+ ratio.  
 
Results 
Effect of fatty acid and butyrate co-treatment on induction of apoptosis in p53 
wild type and p53 null colonocytes.  The role of fatty acid and butyrate co-treatment on 
cellular apoptosis was initially investigated.  For this purpose, p53+/+ and p53-/- cells 
(Figure 13) were harvested following fatty acid and butyrate co-treatment and analyzed 
using TUNEL assay.  Butyrate co-incubation with DHA in p53+/+ cells induced an 
800% and 45% increase in apoptotic index compared to untreated control and to LA and 
butyrate treated cells, respectively (Figure 14).  Similarly, isogenic p53-/- cells 
exhibited a 700% increase in apoptosis compared to untreated control, and a 55% 
increase relative to LA + butyrate treated cells.   
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Figure 13.  Representative immunoblot of p53 wild type and knock out cell extracts.  HCT-116 cells 
(p53 wild type and knock out cells) were separately harvested and total cell lysates containing equivalent 
amount (10 µg) of protein were probed for p53 expression. Lane 1, molecular marker; lane 2, empty lane; 
lane 3, lysate from p53+/+ cells; and lane 4, lysate from p53-/- cells.  
 
 
Effect of DHA and butyrate co-treatment on intracellular Ca2+ levels.  Since 
mitochondria are key organelles involved in the regulation of cell death and intracellular 
Ca2+ homeostasis, we measured the ratio of mitochondrial to cytosolic Ca2+ ratio in 
individual cells.  Butyrate co-treatment for 6 h increased (p<0.0001) the mitochondrial-
to-cytosolic Ca2+ ratio in cells incubated with DHA by 43% and 57% in comparison with 
untreated or LA and butyrate co-treated p53+/+ cells, respectively (Figure 15A, closed 
bars).  Similarly, p53-/- cells treated with DHA + butyrate exhibited a 44% and 22% 
increase in mitochondrial Ca2+ levels as compared LA + butyrate and untreated cells, 
respectively (Figure 15A, open bars).  In addition, following a 12 h incubation with 
butyrate, DHA enhanced (p<0.0001) mitochondrial Ca2+ by 31% compared to untreated 
control in p53+/+ cells (Figures 15B, closed bars).  In contrast to DHA treated cultures, 
cells incubated in the presence of LA showed no change (Figure 15B, closed bars) in 
the mitochondrial-to-cytosolic Ca2+ ratio compared to untreated cells.  p53-/- exhibited a 
similar pattern of response (Figures 15B, open bars).  For comparative purposes, 24 h 
butyrate co-treatment was also examined. 
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Figure 14. Effect of fatty acid and butyrate co-treatment on apoptosis in HCT-116 cells.  p53 wild 
type (p53+/+) and p53 knock out (p53-/-) cells were treated with fatty acid (50 µM) for a total of 72 h and 
0 or 5 mM  butyrate for the final 12 h.  Nonadherent cells were harvested, and apoptosis was measured by 
the nucleosomal fragmentation release assay. Data are means ± S.E. from 3 separate experiments, n = 6 
wells per treatment.  Solid bars represent data from p53+/+ cells and open bars represent data from p53-/- 
cells.  Control cultures containing no treatment (C), LA and butyrate (LB), DHA and butyrate (DB).  Bars 
not sharing a common letter are significantly different at p<0.05.  
 
Consistent with observations made at earlier time points, DHA enhanced the 
mitochondrial to cytosolic ratio by 30 and 75% compared to LA and butyrate treatment 
in p53+/+ and p53-/- cells, respectively (Figure 15C).   
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Figure 15. Effect of fatty acid and butyrate co-treatment on mitochondrial Ca2+in HCT-116 cells. 
p53+/+ and p53-/-  cells were exposed to 50 µM fatty acid for 72 h in the absence (panel D) or presence of 
5 mM butyrate for the final 6 (panel A), 12 (panel B) or 24 h (panel C).  Cells were co-loaded with Fluo-4 
(3 µM) and Rhod-2 AM (2 µM) and the ratio of mitochondria-to-cytosolic Ca2+ was evaluated as 
described in the Materials and Methods.  Data represent means ± S.E. from a representative experiment, 
n = 3 independent experiments.  A significant (p<0.001) difference between the combination of LA with 
butyrate and DHA with butyrate was observed for both cell lines starting from 6 h.  In p53+/+ cells, 
butyrate only treatment did not show any difference compared to untreated cells.  DHA or LA in the 
absence of butyrate did not show any significant difference in the ratio of mitochondrial to cytosolic Ca2+ 
ratio.  Control data for p53-/- cells were similar (data not shown).  C, control- no fatty acid or butyrate; B, 
butyrate only; L, LA only; D, DHA only; LB, LA and butyrate; DB, DHA and butyrate.   
 
In addition, control experiments demonstrated that cells treated with butyrate in the 
absence of fatty acid did not exhibit a significant difference in mitochondrial Ca2+ 
compared to untreated p53+/+ cells.  p53+/+ cells treated with DHA in the absence of 
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butyrate did not demonstrate any significant difference in mitochondrial-to cytosolic- 
Ca2+ ratio compared to LA pre-treated cells (Figure 15D).  In contrast, butyrate treated 
cells pre-incubated with DHA demonstrated a significantly higher (p<0.0001) level of 
mitochondrial-to-cytosolic Ca2+ ratio.    
 
 
 
 
Figure 16.  Effect of a mitochondrial uniporter inhibitor (RU-360) on mitochondrial Ca2+ levels 
following fatty acid and butyrate co-treatment in HCT-116 cells.  p53+/+ cells (panel A) and p53-/- 
(panel B) were pretreated with fatty acid for a total of 72 h and RU-360 (10 µM) for 30 min prior to 
butyrate co-treatment for the last 12 h. Cells were co-incubated with Fluo-4 (3 µM) and Rhod-2 (2 µM) for 
1 h and the mitochondria to cytosolic Ca2+ ratio was measured.  Data represent means ± S.E. from a 
representative experiment, n = 2 independent experiments.  Note that RU-360 partially reversed the effects 
of the combination treatment (DHA and butyrate) on the intracellular ratio in both cell lines.  C, control- 
no fatty acid or butyrate; LB, LA and butyrate; DB, DHA and butyrate. 
 
 
 
 
Effect of a mitochondrial uniporter inhibitor (RU-360) on intracellular Ca2+ 
levels.  To investigate the role of the mitochondrial uniporter in Ca2+ uptake, cells were 
treated with RU-360, a mitochondrial Ca2+ uniporter inhibitor.  As expected, RU-360 (10 
µM) partially inhibited (p<0.001) the butyrate-induced increase in mitochondrial Ca2+ in 
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DHA primed cells by 20% in p53+/+ cells (Figure 16A) and 21% (p<0.01) in p53-/- 
cells at 12 h (Figure 16B).  In comparison, RU-360 had no effect on mitochondrial Ca2+ 
levels in LA and butyrate and untreated p53+/+ or p53-/- cells.   
Inhibition of the Ca2+ uniporter partially suppresses the induction of apoptosis 
following DHA and butyrate co-treatment.  The relationship between mitochondrial 
Ca2+ homeostasis and cellular apoptosis was examined by quantifying apoptosis 
following the blockade of mitochondrial Ca2+ uptake.  For this purpose, select p53+/+ 
and p53-/- cultures were treated with RU-360.  Results obtained in experiments with 
butyrate (12 h) following DHA or LA co-treatment are shown in Figure 17.  RU-360 
significantly (p<0.0001) reduced apoptosis by 88% following butyrate co-treatment in 
p53+/+ cells (Figure 17A).   Similarly, p53-/- cells exhibited a 75% decrease (p<0.0001) 
in apoptosis in the presence of RU-360 (Figure 17B).  In contrast, inhibition of the 
uniporter had no effect on cells treated with LA + butyrate or untreated cultures in both 
cell types.  Taken together, these results demonstrate that mitochondrial Ca2+ uptake is 
required for the enhanced apoptosis associated with DHA and butyrate co-treatment. 
The mitochondrion specific antioxidant, MitoQ, inhibits apoptosis induced by 
DHA and butyrate co-treatment.  To probe the association of mitochondrial oxidative 
stress with the induction of apoptosis, select p53+/+ and p53-/- cultures were treated 
with 5 µM MitoQ for 12 h in the presence of butyrate and fatty acid.  MitoQ 
significantly decreased apoptosis (p<0.0001) in DHA and butyrate co-treated cultures by 
40% in p53+/+ cells and 26% in p53-/- cells (Figure 18A and B). MitoQ also inhibited 
apoptosis in LA and butyrate treated cultures by 32% and 39% in p53+/+ and p53-/- 
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cultures, respectively (Figure 18A and B).  In contrast, MitoQ had no effect on 
untreated cell cultures. Collectively, these results demonstrate that mitochondrial 
ROS/PLOOH production is essential for DHA + butyrate-induced colonocyte apoptosis.  
 
 
Figure 17. Effect of RU-360 on the induction of apoptosis in HCT-116 cells.  p53+/+ cells (panel A), 
and p53-/- cells (panel B) were treated with DHA or LA (50 µM) for 48 h and subsequently co-incubated 
with 10 µM RU-360 for 30 min.   Cultures were subsequently co-incubated with fatty acid and butyrate 
following which nucleosomal fragmentation assay was used to quantify apoptosis.  Data are means ± S.E., 
n = 6 wells per treatment.  C, control- no fatty acid or butyrate; LB, LA and butyrate; DB, DHA and 
butyrate.   
 
Mitochondrial to cytosolic Ca2+ ratio increased in rats fed fish oil followed by 
butyrate incubation ex-vivo.  Intact colonic crypts isolated from rats fed experimental 
diets containing either LA (corn oil) or DHA (fish oil) were incubated with fluo-4 and 
Rhod-2 (Figure 19A) for the purpose of imaging mitochondrial to cytosolic Ca2+ 
responses following incubation with butyrate (5 mM) ex vivo.   Only crypts that 
exhibited higher than 85% cell viability were included in the analysis (Figure 19B). 
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Dietary fat composition did not significantly (p = 0.527) influence the basal 
mitochondrial-to-cytosolic Ca2+ ratio 
 
 
Figure 18.  Effect of a mitochondrial-targeted antioxidant (Mito-Q) on cellular apoptosis following 
fatty acid and butyrate co-treatment in HCT-116 cells.  p53+/+ and p53-/- cultures were treated with 
50 µM DHA or LA for 72 h and butyrate for the final 12 h.  Select cultures were pre-treated with 5 µM 
Mito-Q for 24 h prior to butyrate co-treatment.  Nonadherent cells were harvested, and apoptosis was 
measured by the nucleosomal fragmentation release assay. Data are means ± S.E., n = 6 wells per 
treatment.  Panel A represents p53+/+ cells ± Mito-Q incubation. Panel B represents p53-/- cells ± Mito-Q 
incubation.  C, control- no fatty acid or butyrate; LB, LA and butyrate; DB, DHA and butyrate. 
 
(Figure 19C).  In contrast, butyrate treatment and dietary lipid-butyrate interactions in 
the main model were significant; both p-values < 0.0001.  The colonic crypts from fish 
oil fed animals incubated in the presence of 5 mM butyrate for 30 min demonstrated a 
260% increase (p<0.001) in the mitochondrial to cytosolic Ca2+ ratio compared to crypts 
isolated from corn oil fed animals (Figure 7D).  Collectively, these outcomes 
demonstrate that DHA + butyrate combination enhance mitochondrial Ca2+ stores both 
in human tumor cell lines and primary rat crypt cultures.   
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Figure 19.  Measurement of intracellular Ca2+ in colonic crypt primary cultures. Rats fed either fish 
oil (FO, n-3 PUFA) or corn oil (CO, n-6 PUFA)-enriched diets and colonic crypts were isolated and 
subsequently incubated with or without 5 mM butyrate (B) for 30 min.  Crypts were co-incubated with 
Fluo-4 (3 µM) and Rhod-2 (2 µM) for 30 min and the mitochondrial to cytosolic Ca2+ ratio was 
determined.  Panel A, a representative fluorescence image of crypts co-loaded with Fluo-4 and Rhod-2.  
Panel B, an example of select cultures incubated with calcein (green) and ethidium homodimer (orange) 
to assess cell viability.  Panel C, relative mitochondria to cytosol Ca2+ ratios in isolated crypts under basal 
conditions, no butyrate added to the culture media.  Panel D, effect of exogenous butyrate on 
mitochondrial Ca2+ levels.  Data are means ± SE from 15 rats per treatment group with at least 15 images 
per rat.  Bars not sharing a common letter are significantly different, p<0.001. 
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Discussion 
The in vivo molecular mechanisms underlying n-3 PUFA-induced apoptosis in 
the colon are just emerging (43).  Furthermore, it is unclear whether observations 
derived from specialized cell lines accurately reflect endogenous cellular mechanisms.  
In the current study, we compared the effects of dietary fish vs corn oil, enriched in 
DHA (22:6n-3) and LA (18:2n-6 ) respectively, in combination with butyrate, a fiber 
fermentation product, on mitochondrial Ca2+ accumulation in primary colon crypt 
cultures and in human colonocyte tumor cell lines.  Further, our studies examined the 
relationship between the p53 tumor suppressor gene and mitochondrial Ca2+ signals with 
regard to the induction of colonocyte apoptosis in HCT-116 cells.  The present data 
reveal that: 1) The combination of DHA and butyrate enhance apoptosis by stimulating 
mitochondrial Ca2+ accumulation in a p53-independent manner; 2) blockade of  the 
mitochondrial uniporter inhibits mitochondrial Ca2+-induced colonocyte apoptosis; 3) 
suppression of mitochondrial oxidative stress with a mitochondrion-targeted antioxidant 
partially inhibits apoptosis; and 4) butyrate incubation with primary colonic crypts 
isolated from fish oil fed animals increases mitochondrial Ca2+ stores compared to 
cultures from corn oil fed animals.  
We initially investigated whether p53 plays an essential role in DHA and 
butyrate-induced apoptosis.  This is significant because inactivating mutations in this 
tumor suppressor gene occur in approximately 50% of all colon tumors (197, 198, 199).  
Existing data suggest that apoptosis can be mediated by the induction of the p53-
regulated modulator PUMA (95, 143, 145), a mitochondrial protein (153, 154).  Given 
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the central role of mitochondria in the commitment to apoptosis, we hypothesized that 
DHA and butyrate interactively promote p53-dependent apoptosis by triggering changes 
in mitochondrial Ca2+ levels that contribute to caspase activation and colonocyte cell 
death.  We used isogenic p53 wild type and deficient human colon tumor (HCT 116) cell 
lines to determine whether or not chemoprotective nutrients modulate intracellular Ca2+ 
compartmentalization to induce colonocyte apoptosis.  The results confirm and extend 
our previous observations (58) and demonstrate that DHA and butyrate synergistically 
enhance mitochondrial Ca2+ accumulation which serves as a trigger for apoptosis in a 
p53-independent manner. 
Consistent with previous observations (14, 16, 47, 52), our data demonstrate that 
pleiotropic bioactive components generated by fermentable fiber (butyrate) and fish oil 
(DHA) act synergistically to enhance apoptosis.  This is noteworthy, because it has now 
been clearly established that the transformation of colonic epithelium to carcinoma is in 
part associated with a progressive inhibition of apoptosis (49, 50, 51, 161).  Hence, 
chemotherapeutic agents in combination which restore the normal apoptotic pathways 
have the potential for effectively reducing cancer risk (195, 200).  Although it has been 
well documented that butyrate is an inhibitor of histone deacetylases and can activate the 
Fas receptor mediated extrinsic death pathway (201, 83), the role of these mechanisms in 
the induction of colonocyte apoptosis may be a secondary consequence of its ability to 
promote cellular oxidation (202, 203).  For example, serving as the primary energy 
source for colonic epithelial cells, butyrate induces cellular ROS generation (201, 204, 
205).  This is relevant because DHA relative to LA is oxidatively susceptible due 
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primarily to its high degree of unsaturation (56, 57). Consistent with previous 
observations (58), both LA/DHA and butyrate-induced apoptosis was partially blocked 
by coincubation with a mitochondrially targeted antioxidant, Mito-Q (206).  These data 
are further supported by the fact that enhanced mitochondrial lipid peroxidation can 
directly trigger the release of proapoptotic factors from mitochondria into the cytosol 
(207, 208, 209).  
The overloading of mitochondrial Ca2+ can activate the mitochondrial transition 
(MPT) pore and trigger a series of events culminating in cellular apoptosis (92, 98, 173, 
135, 120, 180, 182).  Since we have previously observed that butyrate and DHA 
treatment dissipated the MPT (58), we determined the effect of co-treatment on 
mitochondrial Ca2+ homeostasis.  Interestingly, only the combination of DHA and 
butyrate increased intra-mitochondrial Ca2+ levels at 6, 12 and 24 h in p53+/+ and p53-/- 
cells.  Butyrate co-treatment (12 h) in DHA vs LA incubated cells also increased 
apoptosis by 44 and 35% in p53+/+ and p53-/- cells, respectively.  RU360, a 
mitochondrial Ca2+ uniporter inhibitor (173) attenuated (p<0.05) DHA and butyrate-
induced mitochondrial Ca2+ accumulation and apoptosis by ~40% in all cell lines.  Based 
on these data, we propose that the combination of DHA and butyrate, compared to LA 
and butyrate, enhances apoptosis by additionally recruiting a p53-independent, oxidation 
sensitive, mitochondrial Ca2+-dependent (intrinsic) apoptotic pathway in the colonic 
epithelium.   This could in part explain why the combination of dietary fish oil 
(containing DHA) and pectin (fermented to butyrate in the colonic lumen) reduces tumor 
formation in the colon (14, 16 29, 47, 57). 
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In order to address the physiological relevance of our observations, a series of 
technically challenging proof-of-principle experiments were conducted.  For this 
purpose, intact viable colonic crypts were isolated from rats fed diets containing either 
DHA or LA and labeled with with appropriate fluorescent probes to simultaneously 
measure cytosolic and mitochondrial Ca2+ pools.  We hypothesized that only animals fed 
DHA would exhibit an increase in mitochondrial Ca2+ following incubation with 
butyrate.  Although no significant difference in the basal mitochondrial to cytosolic Ca2+ 
ratio in colonic crypts from fish oil or corn oil-fed animals was noted, the addition of 
butyrate to primary cultures induced mitochondrial Ca2+ accumulation exclusively in 
animals fed DHA.  These novel data corroborate our cell line observations indicating 
that DHA and butyrate synergistically trigger colonocyte mitochondrial Ca2+ 
accumulation.  
In summary, our results indicate that DHA and butyrate work coordinately in the 
colon to trigger a previously unrecognized pro-apoptotic cycle involving mitochondrial 
Ca2+ loading.   This is noteworthy, in view of the search for toxicologically innocuous 
cancer chemoprevention approaches which are free of safety problems intrinsic to drugs 
administered over long periods of time.  
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CHAPTER IV 
SUMMARY AND CONCLUSIONS  
 
n-3 polyunsaturated fatty acids have been promoted for their broad health 
benefits by virtue of their ability to prevent and treat a wide variety of diseases (183, 
187, 210, 211).  A growing body of clinical, epidemiological and experimental evidence 
has emphasized the role of fish oil enriched in n-3 PUFA, like DHA (22:6, n-3) and EPA 
(20:5, n-3), in a variety of diseases like cancer, heart disease, autoimmune and 
inflammatory disorders (43, 210, 211).  In addition, fiber is one of the most important, 
although controversial, factors thought to prevent colorectal cancer (71).  The rapidly 
growing incidence of colorectal cancer in the developed countries has intrigued scientists 
and prompted some to investigate the underlying mechanism involved in the 
chemoprotective effects of these 2 dietary factors.  The favorable effects of the 
combination of these two dietary components have been demonstrated to be due to 
enhanced colonocyte apoptosis (14, 16, 52, 53, 58).  Nonetheless, a comprehensive 
understanding of the underlying mechanism has yet to be elucidated.  Our previous in-
vivo and in-vitro model systems have demonstrated that the combination of DHA and 
butyrate, the bioactive products of fish oil and fermentable fiber, significantly enhance 
colonocyte apoptosis, which could in part explain the chemoprotective effect of this 
dietary combination (47, 58). 
Free fatty acids are known to trigger an alteration in intracellular Ca2+ 
homeostasis in various cell types (212, 213).  Experimental evidence also indicates that 
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Ca2+ activates calcium-binding non-lysosomal cysteine proteases like calpain (214) and 
calcium-dependent endonucleases that mediate DNA fragmentation and apoptosis (215, 
216).  ER-Ca2+ depletion in conjunction with enhanced mitochondrial uptake rather than 
an increase in cytosolic Ca2+ have also been identified as a trigger to initiate apoptosis 
(217).  In this investigation we hypothesized that the combination of DHA and butyrate 
altered intracellular Ca2+ homeostasis to induce colonocyte apoptosis.  The findings from 
this investigation may help develop a new model to better understand the fundamental 
mechanism involved in the pro-apoptotic effect of these bioactive compounds.   
The first portion of this study demonstrated that DHA and butyrate increased 
mitochondrial Ca2+ levels while concomitantly decreasing free cytosolic Ca2+ levels.  
This did not come as a surprise considering the well established role of intracellular Ca2+ 
in regulating apoptosis.  There is compelling evidence linking the release of Ca2+ from 
intracellular stores and the opening of influx channels on the plasma membrane (87, 
102).  Therefore, our findings raised an interesting question as to the pool that is 
involved in the alteration in intracellular Ca2+ levels.  To determine this we measured 
intracellular Ca2+ release from the ER under basal conditions, followed by chelation of 
extracellular Ca2+ using EGTA, and re-addition of Ca2+ back into the extracellular media.  
To further substantiate the importance of plasma membrane channels we also blocked 
the SOC using SKF-96365.  Data obtained indicated that extracellular Ca2+ was 
primarily responsible for the DHA and butyrate-induced perturbation in intracellular 
Ca2+.  Further studies are needed to examine if SOC are key players in the involvement 
of DHA and butyrate induced apoptosis. 
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This study also shed light on the channel involved in mitochondrial Ca2+ 
accumulation.  Considering the important role of mitochondrial Ca2+ accumulation in 
cellular apoptosis, RU-360, an inhibitor of the mitochondrial uniporter, was used to 
determine the association of apoptosis with mitochondrial Ca2+.  RU-360 inhibited both 
mitochondrial Ca2+ uptake and apoptosis.  These findings demonstrate the role of 
mitochondrial Ca2+ accumulation in the onset of apoptosis induced by DHA and 
butyrate.    
Another objective of this study was to determine if mitochondrial Ca2+ 
accumulation preceded the onset of apoptosis.  One potential mechanism by which DHA 
and butyrate enhances apoptosis could be via enhancing mitochondrial accumulation of 
Ca2+.  To examine this possibility, we measured mitochondrial accumulation of Ca2+ and 
apoptosis at 6, 12 and 24 h of fatty acid and butyrate co-treatment.  Indeed, this study 
demonstrated that mitochondrial Ca2+ elevations were seen as early as 6 h of butyrate co-
treatment while the onset of apoptosis did not occur until 12 h of butyrate co-treatment.  
This would not be unexpected as Ca2+ accumulation is considered to be important trigger 
for cytochrome-c release (88, 132) via opening of the permeability transition pore, 
culminating in apoptosis.   
In our previous experiments we demonstrated that butyrate acts via a Fas-
mediated pathway (83) and that DHA and butyrate combination enhances mitochondrial 
lipid hydroperoxide production, and mitochondrial membrane permeability transition 
(58) to induce colonocyte apoptosis.  Results from this investigation have generated 
additional mechanistic evidence suggesting that DHA and butyrate recruits a Ca2+ 
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dependent mitochondrion-mediated intrinsic pathway to induce colonocyte apoptosis 
(Figure 20).   
We next examined if human colonocytes exhibited effects analogous to mouse 
colonocytes.  In addition, we also wanted to elucidate the involvement of p53 in DHA 
and butyrate-induced apoptosis.  p53, a tumor suppressor gene plays a fundamental role 
in promoting apoptosis in response to cellular stress including DNA damage (145, 218).  
Previous animal experiments from our lab demonstrate that fish oil-fed animals target 
DNA damaged cells for deletion by apoptosis (52).  In an effort to examine if enhanced 
apoptosis due to mitochondrial Ca2+ accumulation was p53-dependent, experiments were 
conducted using isogenic (p53 wild type and p53 null human colonic tumor cells) - HCT 
116 cell.  Results from these experiments demonstrated that DHA and butyrate enhanced 
both apoptosis and mitochondrial Ca2+, which could be partially inhibited by RU-360 in 
both p53 wild type and null cells in a comparable manner.  These findings indicate that 
DHA and butyrate induce colonocyte apoptosis and enhance mitochondrial Ca2+ uptake 
via the mitochondrial uniporter in a p53-independent fashion.   
In the final phase of this investigation we examined the ability of dietary fish oil 
to alter mitochondrial Ca2+ levels in primary crypt cultures.  Rats were fed semi-purified 
diets containing n-3 PUFA (fish oil) or n-6 PUFA (corn oil) as the lipid source.  Colonic 
crypts were isolated and subsequently incubated with butyrate ex-vivo and the 
mitochondrial-to-cytosolic Ca2+ ratio was measured.  Colonic crypts from animals fed 
fish oil exhibited an enhanced accumulation of Ca2+ within the mitochondria compared 
to cultures not incubated in butyrate.  This enhanced accumulation in part explains the 
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mechanism responsible for the increase in colonoctye apoptosis seen in animals fed a 
combination of fish oil and fermentable fiber.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Proposed intrinsic-apoptosis model in DHA and butyrate co-treated cells.  DHA and 
butyrate enhances extracellular Ca2+ entry through the SOC.  This combination concomitantly decreases 
the cytosolic Ca2+ level and enhances mitochondrial Ca2+ accumulation.  These events result in opening of 
the permeability transition pore stimulating the release of pro-apoptoic molecules like cytochrome C 
resulting in enhanced cellular apoptosis. 
 
Collectively, these data indicate for the first time that the combination of DHA 
and butyrate, compared to butyrate alone, exhibits a further increase in apoptosis by 
additionally recruiting a p53-independent, Ca2+-mediated intrinsic mitochondrial 
pathway.  While the recruitment of the intrinsic apoptotic pathway may explain, in part, 
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the reason for the difference in cancer susceptibility between population consuming diets 
rich in n-3 PUFA versus n-6 PUFA and fiber, it is most likely not the only determining 
factor.  Nonetheless, investigations like these continue to provide insight into the 
mechanism/s involved in the chemoprotective effects of fish oil and fermentable fiber. 
The findings of this study are unique in that they examine the mechanism involved when 
two important dietary factors interact as seen physiological (in-vivo) environment.  
However, further studies are required to explain the downstream effects of mitochondrial 
Ca2+ accumulation.  Subsequent mechanistic studies may cede compelling evidence 
regarding the role of intracellular Ca2+ compartmentalization in colonocyte apoptosis 
thus providing a link to the consumption of dietary intake of fish oil and fermentable 
fiber in the prevention of colon carcinogenesis. 
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APPENDIX A 
 
EXPERIMENTAL PROTOCOLS 
 
Protocol # A-1, Preparation of Complete RPMI media for YAMC culture 
Ref: Fan et al. Am J Physiol. 1999 Aug;277(2 Pt 1):C310-9; Ng et al. Carcinogenesis. 2005 
Nov;26(11):1914-21. 
 
Hood sterility 
Purpose: To prepare the hood for all sterile techniques including cell culture 
- Turn UV light on in the hood for atleast 15 min prior to use 
- Use 95% Ethanol and spray the inside and outside of the hood 
- Wipe with a clean paper towel and repeat to ensure sterility 
-  Spray and clean the outside of media bottles, pipettes etc with ethanol before taking it 
under the hood 
 
Preparation of Media 
Purpose: To prepare complete RPMI media for YAMC cell culture 
Reagents (supplier, catalog number) 
 -500 ml RPMI without glutamine (Mediatech # 15- 040 CV) 
 -26.6 ml Fetal Bovine Serum (Hyclone AK 12434) 
 -5.3 ml Glutamax (Gibco, 35050-061) 
-0.532 ml ITS “-” minus (Insulin, Transferrin, Selenious acid without Linoleic acid) 
(Collaborative Biomed products, # 4351) 
- Reconstitution of ITS “-”: add 5 ml of sterile distilled water into 
lysophylized powder. 1 ml of ITS is sufficient for 1 L of media (0.1% 
dilution) 
Procedure  
-Thaw Glutamax and FBS at 4°C overnight 
- Add Glutamax, FBS and ITS “-” into 1 bottle of RPMI 1640 media. 
-Gently tilt the bottle to mix 
-Label as sterile, complete and store at 4°C  
 
Final volume: 531.9 ml 
Final concentration: 5% FBS, 1 % Glutamax, 0.1% ITS 
Linoleic acid 0 
Insulin  5 µg/ ml 
Transferin   5 µg/ ml 
Selenious acid  5 ng/ ml 
 
The following reagent is to be added fresh into the media before use: 
5 units γ-IFN (Gibco BRL, #13284-021) per 1 ml complete RPMI 1640 
media.  
Add 1µl γ-IFN per 10 ml of complete RPMI 1640 medium just prior to use. 
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Protocol # A-2, Preparation of Complete McCoy’s 5A modified media for HCT116 cells 
Ref: Fan et al. Am J Physiol. 1999 Aug; 277(2 Pt 1):C310-9; Ng et al. Carcinogenesis. 2005 
Nov;26(11):1914-21. 
 
Preparation of Media  
Purpose: To prepare complete McCoy’s 5A media for HCT116 cell culture p53+/+ and p53-/- 
cells 
Reagents (supplier, catalog number) 
  McCoy’s 5A (Gibco 16600-082) w/o HEPES 
10% FBS (Hyclone AJA9530) 
1% Glutamax (Gibco 3505-061) 
Procedure  
-Thaw 5.5 ml of Glutamax and 56 ml FBS at 4°C overnight. 
- Add Glutamax, FBS into 500 ml of McCoy’s 5A modified medium without HEPES. 
-Gently tilt the bottle to mix. 
-Label as sterile, complete, inital and store at 4°C.  
- Use separate bottles for p53+/+ and p53-/- cells and have the bottles labeled accordingly. 
- Take caution and don’t culture p53+/+ and p53-/- under the hood at the same time. 
 
Final concentration: 10% FBS, 1 % Glutamax 
 
 
Protocol # A-3, Preparation of YAMC Cell Culture 
Ref: Fan et al. Am J Physiol. 1999 Aug;277(2 Pt 1):C310-9; Ng et al. Carcinogenesis. 2005 
Nov;26(11):1914-21. 
 
Purpose: To start YAMC culture by growing cells in a T-75 flask. 
 
Preparation 
-Turn on the UV in the hood for atleast15 min prior to keep it sterile for culture 
 
Procedure 
1. Warm complete RPMI 1640 media to room temperature 
2. Aliquot 10 ml media in a 15 ml conical tube (to spin down frozen cells) and make up 30 
ml complete media with 3 µl γ-IFN (to resuspend and grow cells) 
3. Take a vial of YAMC cells from the liquid nitrogen storage system 
4. Thaw it in the water-bath immediately  
5. Add thawed cells into the media in the conical tube 
6. Centrifuge at 200 x g (1096 rpm: tabletop centrifuge, for 5 min) at 6 Acc./Dcc. 
7. Using sterile technique Open a T-75 flask and add 12 ml complete media (with γ-IFN) 
8. Following completion of spin, aspirate the supernatant to remove the freezing media  
9. Resuspend the pellet in 5 ml complete RPMI 1640 (with γ-IFN) 
10. Add resuspended cells into the T-75 flask with media, label the flask - specify the cell 
type,  passage number, date and initials  
11. Gently rotate the flask to distribute the cells evenly 
12. Incubate the flask at 33˚C under 5% CO2 atmospheric pressure 
 
 
  
109
Feeding cells 
Check of cell confluence every day 
Feed cells every 48 h (maximum 72 h) 
 
Procedure 
1. Aspirate old media from the flask using sterile techniques and replenish with 
fresh RPMI 1640 media (with γ-IFN) 
2. When culture reaches 70-90% confluence, trypsinize the cells and pass them 
(refer to Appendix A: Protocol # A-5 YAMC Cell Culture) 
 
 
Protocol # A-4, Preparation of HCT-116 Cell Culture 
Ref: Bunz, F et al.  Science, Vol.282, Nov, 1998  
Purpose: To start HCT 116 (both p53+/+ and p53-/- cells) culture by growing cells in separate 
T-75 flasks. 
 
Preparation 
-Turn on the UV in the hood for atleast15 min prior to keep it sterile for culture. 
 
Procedure 
1. Warm complete McCoy’s 5A media (both p53+/+ and p53-/- bottles) to room. 
temperature. 
2. Aliquot 10 ml PBS (w/o Ca2+ and Mg2+) in a 15 ml conical tube (to spin down frozen 
cells). 
3. Take a vial of p53+/+ cells from the liquid nitrogen storage system thaw rapidly at 37oC 
with gentle agitation. 
4. Add thawed cells into the media in the conical tube. 
5. Wash cells in 10 mL PBS (w/o Ca2+ and Mg2+).  
6. Slowly introduce cells to new environment by adding a few drops of PBS to cryovial before 
transferring to tube of PBS.   
7. Centrifuge at 150 x g for 5 min at room temperature. 
8. Resuspend the cell pellet in 1 ml McCoy’s 5A growth medium. 
9. Add resuspended cells into a T-75 flask with 14 ml McCoy’s  
10. Gently rotate the flask to distribute the cells evenly 
11. label the flask - specify the cell type,  passage number, date and initials  
12. Incubate at 37oC; under 5% CO2 atmospheric pressure 
13. Check daily until 70-90% confluent, usually 3 days. 
14. If cells are not passaged, re-feed cells. 
15. Repeat the same procedure for p53-/- cells. Take care not to culture both wild type and 
knock out cells at the same time.  
 
Feeding cells 
Check of cell confluence every day. 
Feed cells every 48 h (maximum 72 h). 
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Procedure 
1. Aspirate old media from the flask using sterile techniques and replenish with fresh 
complete McCoy’s 5A media. 
2. When culture reaches 70-90% confluence, trypsinize the cells and pass them (refer to 
Appendix A: Protocol # A-6 HCT-116 Cell Culture). 
3. Repeat the procedure for p53-/- cells. 
 
 
Protocol # A-5, YAMC Cell Culture: Seeding, Passing or Freezing 
 
Purpose: To pass and to seed or freeze YAMC cell culture. 
 
Preparation 
- Use sterile hood conditions for the procedure 
-Warm complete RPMI 1640 and trypsin-EDTA (Gibco, #25300-054) to room temperature 
 
Procedure  
For any 70% confluent cell culture in a T-75 flask: 
1. Aspirate old media, rinse monolayer of cells with ~10ml HBSS (Sigma, H-6648) add 
and aspirate gently without disturbing the cell monolayer 
2. Aspirate HBSS. Add 5 ml Trypsin-EDTA and incubate cells at 33 ˚C for 2-3 minutes or 
until > 90% cells are lifted 
3. Add 15 ml complete media in a 50 ml conical (to spin cells) and add 5 µl γ-IFN to 50 ml 
media (to grow cells)  
4. Check cells under microscope. Gently tap the bottom of the flask to release the adherent 
cells 
5. Add cells in suspension into a 50 ml conical tube containing ~15 ml complete RPMI 
1640 medium. 
6. Centrifuge cells at 200 x g (1096 rpm, countertop centrifuge for 5 min) 
7. Vaccum aspirate supernatant (media with trypsin), taking care not to disturb the pellet 
8. Add required volume (5 ml) of complete RPMI 1640 (with γ-IFN) and resuspend the 
pellet by gently pipetting up and down to make a homogenous supsension. 
 
A.  Procedure to count cells and seed  
-Once pellet is resuspended in media, cells are counted to seed at a known density 
-Transfer 5 µl of the cell suspension into a 500 µl micro-centrifuge tube with 40 µl PBS 
-Add 5 µl trypan blue to the tube, and mix well by gently pipetting up and down to get a 
homogenous suspension (10% suspension) 
-Transfer 20 µl of the cell suspension onto a hemacytometer.  
-Count cell:  Cell density (cells count per ml) = Living cells count x 10,000 
# Squares counted  
-Seed cell according to desired density.  
 
B. Procedure to continue cell growth and expansion in a T-75 flask 
-Take 1 ml of the homogenous cell suspension and add to 1 T-75 with ~ 15 ml complete 
media (with γ-IFN) 
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- Seed cells into as many flasks as needed 
 
C.  Procedure for cell freezing (to store) cells in liquid nitrogen 
-At step 8 in the cell passage protocol, resuspend cells in 4 ml of freezing media 
(EmbryoMax, # S-002-D) 
-Add 1 – 1.5 ml of cell suspension (~ 1.5 million per vial)  
-Label the vials with the cell type, passage number, date and initials 
-Keep vials in Mr. Frosty (Nalgene, #5100-0001) at –80˚C for a day (not more than 48 
h) and then transfer vials into liquid nitrogen for storage 
-Enter the rack, box # and vial position into cell culture log book 
 
 
Protocol # A-6, HCT-116 Cell Culture: Seeding, Passing or Freezing 
 
Purpose: To pass and to seed or freeze p53+/+ and p53-/- cell culture. 
 
Preparation 
- Use sterile hood conditions for the procedure. 
-Warm complete McCoy’s 5A media (both p53+/+ and p53-/- bottles) and trypsin-EDTA 
(Gibco, #25300-054) to room temperature. 
 
Procedure  
For any 70% confluent cell culture in a T-75 flask: 
1. When cells are 80-90% confluent, remove all medium. 
2. Wash cells once with PBS ((w/o Ca2+ and Mg2+), aspirate gently without disturbing the 
cell monolayer. 
3. Add Trypsin/EDTA, incubate 3 min at 37oC until > 90% cells detach. 
4. Add 5ml medium to Trypsinized cells, pipet cells into tube of medium. 
5. Spin cells down at 150 x g, 5 min.   
6. Vaccum aspirate supernatant (media with trypsin), taking care not to disturb the pellet. 
7. Resuspend pellet in complete McCoy’s 5A media. 
8. Incubate flasks in a humidified, 37oC, 5% CO2 incubator. 
9. Repeat the same for p53-/- cells. 
 
A. Procedure to count cells and seed cells is similar to YAMC cells  
  
-Count cell:  Cell density (cells count per ml) = Living cells count x 10,000 
# Squares counted  
-Seed cell according to desired density.  
 
B. Procedure for cell freezing (to store) cells in liquid nitrogen 
Freezing Medium:  Cell Culture Freezing Medium with DMSO (Specialty Media S-002-D). 
1. Label cryovials with cell type, passage number, date and initials. 
2. Defrost freezing medium, place both on ice 
3. To collect cells, follow Steps 1 - 6 of Procedure: Passage Cells  
4. Resuspend pellet from T-175 flask in freezing medium to give 5 x 106 cells / mL 
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5. Keep vials in Mr. Frosty (Nalgene, #5100-0001) at –80˚C for a day (not 
more than 48 h).  
6. Transfer vials into liquid nitrogen for storage 
7. Enter the rack, box # and vial position into cell culture log book 
 
 
Protocol # A-7: Fatty acid-BSA complex 
Ref: Fan et al. Am J Physiol. 1999 Aug;277(2 Pt 1):C310-9 
 
Purpose: To prepare 2.5 mM fatty acid and bovine serum albumin (BSA) complex. 
 
Materials 
a. Spatula (1), 100 ml beaker (1), vials (2). Glassware should be baked at 
180°C for 4hr 
b. Filter (0.2 µm) and 25 ml syringes (1 for each fatty acid) 
c. FA-free BSA (BM, #100069), MW: 68,000 
d. Sodium carbonate- Na2CO3 (J T Baker, #3604-01), MW: 105.99 
e. RPMI medium (Mediatech, #150400LV) 
f. Sterile distilled water (Baxter, 2F7115) 
g. DHA [21.14 µg/µL in EtOH], MW: 328.5 (2004) 
h. LA    [22.03 µg/µL in EtOH], MW: 280.48 (20041) 
Preparation  
Day before preparation: Bake 2 sets (1 stand-by) 
On prep day- Ice bucket, vial screw caps, and baked glassware 
Turn on the hood U.V light 
 
Procedure 
1. Vortex stock tubes of fatty acid (DHA, LA in ethanol) vigorously  
2. Add 10 mg (volumes recorded below) of FA-Ethanol into labeled 2 ml glass vials, 
respectively. 
 
Calculations to make up 10 mg for fatty acid stocks (dated) 10.22.03 
LA in EtOH – 11.68 µg/µl 
DHA in EtOH – 11.55 µg/µl 
 
LA = 10,000 µg   = 856.16 µL 
11.68 µg/µL 
 
DHA  = 10,000 µg   = 865.80 µL  
11.55 µg/µL 
 
1. Clean Nitrogen tank needles with organic solvent (methanol or ethanol).  
2. Dry down the FA with low stream of N2  (30 psi). Set timer for 1 hour and check every 
5- 10 min. 
3. Aliquot 10 ml of sterile water and  two - 20 ml of RPMI media under the hood 
4. Weigh 53 mg (0.053 gm) of sodium carbonate and 3 gm of fatty acid free BSA. 
5. Make 0.05M Na2CO3 
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53 mg of Na2CO3 in 10 ml sterile H2O (need 2mL per FA-BSA) 
 
Make 15% BSA solution 
Add 20 ml of RPMI medium into 100mL beaker  
Gently layer 3 g of BSA onto the medium   
Do not stir but let the BSA powder slowly dissolve down to the medium 
 
6. After drying down the fatty acid completely. Close the N2 tank.  
Add 2 ml of 0.05 M Na2CO3 to each FA vial.   
Flush the vial and lid with N2 and close the vial.  
Set timer for 1 hour and vortex the vials extensively.   
Sit the vials at room temperature for 1 hr (every 10 mins for the first 30 mins and then 
reduce the frequency to reduce the air bubbles).  
 
7. Calculate the materials needed to make 2.5 mM FA-BSA complex at the FA/BSA 
 3/1 mole ratio. 
Example   DHA (MW: 328.5): 10 mg in 2 mL 0.05M Na2CO3;  
  BSA(MW: 68000):15% Solution 
(i)   Calculate the volume of 15% BSA solution needed for 10 mg DHA to obtain FA/BSA 
3/1 mole ratio. 
   
      0.01 g DHA     x  _1  x 68000 (BSA MW) x  100  = 4.6 (ml) 
       328.5 (DHA mol wt)         3                 15 
  
(ii)Calculate the total volume of solution needed for 10 mg DHA to make  
 2.5 mM DHA-BSA complex. 
   
10 (mg of DHA)/ 328.5 (DHA mol. wt)/ 2.5 (mM) = 0.012177 (L) = 12.177 ml 
 
(iii) Calculate the volume of plain RPMI medium needed for making the 2.5 mM DHA-BSA 
complex.   
12.177 (total volume) - 2 (FA in 0.05M Na2CO3) - 4.6 (15% BSA) = 5.577  
 
 ====>> DHA  15% BSA RPMI  2.5mM DHA-BSA  
   2 ml  4.6 ml              5.577 ml---> 12.177 ml 
 
It is difficult to completely retrieve the 2 ml FA-Na2CO3 from the glass vial. Therefore, take only 95% 
of everything to make the DHA-BSA complex. 
   1.9 ml DHA +  4.37 ml 15% BSA + 5.298 ml RPMI. 
Apply similar calculation to LA. 
 
8. Add the following ml of FA-Na2CO3, 15% BSA, and RPMI to 50 ml conical tube for 
 individual FA. 
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     DHA TUBE     LA TUBE 
    10 mg                    10 mg                 
15 % BSA (ml)   4.37 ml      5.12 ml   
RPMI (ml)   5.3 ml      6.53 ml   
Fatty acid – Na2 Co3  1.9 ml      1.9 ml   
 
 
9. Flush the tubes and lids with N2. Shake the tubes on belly dancer for 1/2 hr at room 
temperature. 
10. Turn the UV light on for filter sterilization, filter-sterilize the FA- BSA complex using a 10 ml 
syringe and 0.2 µm Tufryn filter under sterile hood   
11. Aliquot 500 µl of each into 1.7 ml eppy’s and label the box. Store at -20°C 
 
 
Protocol #A-8 Cell Culture: Fatty acids, Butyrate and other Treatments 
Ref: Fan et al. Am J Physiol (1999) 
 
Purpose: To treat YAMC and p53 cells with polyunsaturated fatty acids (DHA and LA) and 
butyrate 
 
Preparation 
- Grow YAMC cells in a T-75 flask in complete RPMI 1640 medium with γ-IFN and/ or 
p53 isogenic cell lines in McCoy’s A media   
- Allow >24 h for cells to adhere and to recover from trypsinization. 
Pre-treatment of cover glass slides (Refer to media preparation for calculations) 
- Treat 2 wells chambered cover glasses (Nalge Nunc Intl, # 155380) with 25% filter sterilized 
FBS in serum free media. 1 ml media per well 
- Filter sterilize FBS with 0.2 µm tuffryn filter (Acrodisc, #4192) 
- Prepare 25 % FBS in serum free RPMI 1640 (for YAMC cells) or McCoys’s A (p53 isogenic 
cell lines) media  
- Load 1 ml media/FBS per well and incubate overnight (> 4 h) at 33 ˚C (YAMC) or 37°C (p53 
cells) at 5% CO2 
 
Cell plating- Day 0   
Trypsinize cells and seed 2 chambered cover glass slides with 1 ml per well 
YAMC required plating density = 5,000 cells/chamber i.e / 1ml  
p53 required plating density = 20,000 cells/chamber i.e / 1ml  
Dispense 1 ml of the cell suspension into each well/chamber. 
Rotate gently and incubate at 33°C (YAMC), 37°C (p53 cells) at 5% CO2.  
 
Seeding density for Apoptosis experiments 
YAMC required plating density in a 100 mm dish = 150,000 cells/ 8 ml/ dish (18750/ ml)  
p53 required plating density = 25,000 cells/ 1ml (1.5 ml per well in a 6 well plate) 
YAMC required plating density in a 35 mm dish= 30,000 cells / 1.5 ml / dish (20,000 cells/ ml)  
 
Fatty acid treatment- Day’s 1 and 2 
1. Record cell confluence every day prior to media change or treatment 
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2. Treat cells with a final concentration of 50 µM fatty acids (DHA or LA) in complete 
media  
3. Defrost FA-BSA stock 2.5 mM, prepared and stored at –20˚C (use before 30 days).  
4. Do not to re-use any reconstituted media or fatty acid aliquot  
5. Incubate cells in respective incubators at 5%CO2 O/N 
 
Fatty acid and butyrate co-treament – Day 3  
1. Make fresh Butyrate (500 mM) stock for treatments 
2. Weigh 0.055 gm butyrate (Acros, #263190050) into a 1.7 ml eppy tube 
3. Add 1 ml media and mix well by pipetting up and down  
4. Filter sterilize the butyrate solution using a tuffryn filter (Acrodisc, #4192), into a sterile 
eppy tube and wrap tube in foil to protect from light 
5. Final concentration of the butyrate stock is 500 mM 
6. Prepare fresh fatty acid-media (DHA or LA) solution for fatty acid only control 
treatments 
7. Add butyrate stock (final concentration of 5 mM) for fatty acid and butyrate 
combination treatment 
8. Use media only, butyrate in media, fatty acid and fatty acid and butyrate combination 
into the respective treatment slides 
9. Add fatty acid and/ or butyrate into the tube with media and mix well by gently pipetting 
and tilting the tube 
10. Start butyrate treatment during the designated time point of the final co-treatment either 
final 6, 12, 24 or 48 h of fatty acid treatment 
 
Imaging Day (Analysis is done in the Imaging Analysis lab in vet school) 
Things to carry to vet school: 
Lebovitz media, cell culture media. 
Dyes, inhibitors, PBS aliquots, butyrate weighted. 
Gloves, timers, pipettes, sterile tubes, syringes, sterile filters. 
Cells on slides wrapped in foil. 
Preparation: 
Warm Leibovitz media & cell culture media to room temperature (<2 h) before start. 
Check CO2, water and temperature in the incubator. 
Warm the dyes and make up stock solutions. 
Make up the inhibitors and necessary solutions as per the protocols below.  
   
Preparation of stock solutions and final concentration for treatment/ loading 
[Media refers to complete RPMI 1640 for YAMC cells and complete McCoy’s A media for the 
p53 isogenic cells] 
 
1) Preparation of 25% FBS-in serum free media solution for slide pre-coating 
Calculation:  
Ci = initial stock concentration, Cf = final required concentration, Vf = final required volume, 
Vi = initial volume of stock to start with 
  
Ci = 100%, Cf = 25%, Vf = 10 ml, Vi = ? 
Vi=    25% * 10 ml  =  2.5 ml (2.5 ml filtered FBS + 7.5 ml of serum free media, for 10 ml) 
100%  
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2.5 ml FBS + 7.5 ml Media ---> 10 ml Media/FBS 
 
 
2) Preparation of 50 µM final concentration of fatty acids in media for treatment 
Calculation:  
Ci = initial stock concentration, Cf = final required concentration, Vf = final required volume, 
Vi = initial volume of stock to start with 
 
Ci = 2.5 *1000 µM, Cf = 50 µM, Vf = 10 ml, Vi = ? 
Vi=    50 µM * 1 ml  =  0.2 ml (200 µl fatty acid + 9.8 ml of media, 10 ml fatty acid- media) 
2500 µM  
 
0.2 ml stock + 9.8 ml Media     ----> 10 ml FA/media 
 
 
3) Preparation of 5 mM final concentration of butyrate in media for treatment 
Calculation:  
Ci = initial stock concentration, Cf = final required concentration, Vf = final required volume, 
Vi = initial volume of stock to start with 
 
Ci = 500 mM, Cf = 5 mM, Vf = 10 ml, Vi = ? 
Vi=    5 mM * 10 ml  =  0.1 ml (100 µl butyrate + 900 µl of media- 10 ml butyrate- media) 
500 mM  
 
0.1 ml butyrate stock + 9.0 ml Media     ----> 10 ml butyrate/media 
 
 
4) Preparation of 2 mM stock solution and 3 µM final concentration of Fluo-4 (Molecular 
Probes # F14201)  
Prepare on the day of experiment 
Stock preparation of 2 mM Fluo-4 
Molecular weight of Fluo-4 is 1096.95 and the vial contains 50 µg 
1096.95 µg in 1ml is 1 mM 
50 µg (vial) …. should be dissloved in ? ml to make 1 mM 
50 µg  *1000 µl     = 45.58 µl = ~ 50 µl 
1096.95 µg 
 
Dissolve 50 µg Fluo-4 (vial) in 25 µl DMSO to make up 2 mM Fluo-4 stock solution 
Mix well by pipetting up and down 
 
Final concentration of 3 µM Fluo-4 
Calculation:  
Ci = 1 mM, Cf = 3 µM, Vf = 1 ml (900 µl of Leibovitz) Vi = ? 
Vi  =  3 µM * 1 * 1000 µl  =   1.5 µl  per ml of media 
2 * 1000 µM  
1.5 µl of Fluo-4 stock needs to be added to 1 ml Leibovitz to make a final concentration of 3 µM. 
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5) Preparation of 4 mM stock and 2.5 µM final concentration of Rhod-2  (Molecular Probes # 
R1245)  
Stock preparation of 4 mM Rhod-2 
Molecular weight of Rhod-2 is 1123.96 and the vial contains 50 µg 
1123.96 µg in 1ml  is 1 mM 
50 µg (vial) …. should be dissloved in ? ml to make 1 mM 
50 µg  *1000 µl     = 44.49 µl = ~ 45 µl 
1123.96 µg 
 
45/ 5 = 9 
Therefore dissolving 50 µg vial in 10 µl of DMSO will give a stock concentration of 5 
mM 
Dissolve 50 µg Rhod-2 (vial) in 10 µl DMSO to make up 5 mM Rhod-2 
Mix well by pipetting up and down. 
 
Final concentration of 2.5 µM Rhod-2 
Calculation:  
Ci = 5 mM, Cf = 2.5 µM, Vf = 1 ml (900 µl of Leibovitz) Vi = ? 
Vi  =  2.5 µM * 1 * 1000 µl  =   0.5 µl  per ml media 
5 * 1000 µM  
0.5 µl of Rhod-2 stock needs to be added to 1 ml Leibovitz to make a final concentration of 2.5 
µM 
 
 
6) Preparation of 1 mM stock Mitotracker Green FM and 200 nm final concentration (Molecular 
Probes # M 7514) 
Stock preparation of 1 mM Mitotracker Green FM 
Molecular weight of Mitotracker is 671.88 and the vial contains 50 µg. 
 
671.88 µg in 1ml  is 1 mM 
50 µg (vial) …. should be dissloved in ? ml to make 1 mM 
50 µg  *1000 µl     = 74.42 µl  
671.88 µg 
 
Therefore dissolving 50 µg vial in 74.42 µl of DMSO will give a stock concentration of 
1 mM 
 
Dissolve 50 µg Mitotracker (vial) in 74.42 µl DMSO to make up 1 mM Mitotracker 
Mix well by pipetting up and down. 
 
Calculation:  
Ci = 1 mM, Cf = 200 nM, Vf = 1 ml (900 µl of Leibowitz) Vi = ? 
Vi  =  200 nM * 1 * 1000 µl  =   0.2 µl  per ml  
1*1000*1000 nM      
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Therefore, 0.2 µl of Mitotracker green stock needs to be added to 900 µl Leibowitz for 
incubation to make a final concentration of 200 nM 
 
 
 
 
7) Preparation of 5 mM stock and 5 µM final concentration of Thapsigargin (Sigma, # T9033) 
Stock preparation of 5 mM Thapsigargin 
Molecular weight is 650.75 and TG is available as a 0.5 m/ vial 
3253.75 µg in 1 ml is 5 mM 
0.50 mg (vial) …. should be dissolved in ? ml to make 5 Mm 
0.5  * 1000 µg  *1000 µl     = ~154 µl   
3253.75 µg 
 
Dissolve the 0.5 mg Thapsigargin (vial) in 154 µl of DMSO to make 5 mM stock. 
Mix well by pipetting up and down 
 
5 µM final concentration of Thapsigargin  
Calculation:  
Ci = 5 mM, Cf = 5 µM, Vi  = ?,  Vf = 1000 µl (900 µl of Leibovitz+ 100 µl + ? µl of TG - 
imaging) 
 
Vi    =  1000 µl * 5 µM  = 1 µl 
  5 * 1000 µM      
1 µl of TG stock needs to be added to 1 ml (900 µl Leibovitz and 100 µl PBS at imaging to make 
a final concentration of 5 µM 
 
 
8) Preparation of 1 mM stock and 10 µM final concentration of RU-360  
Started experiments using 10 mM stock and then changed to 1 mM stock due to small volumes  
Make up RU-360 1 mM stock with degassed nanopure water and use 10 µM final concentration.  
- Take ~ 5 ml nanopure water in a 15 ml falcon and blow nitrogen from the nitrogen tank using a 
clean new glass pipette for 10 min. 
- Flush the lid with Nitrogen and tightly close the falcon tube and rush to the hood of cell culture 
and add the water into the vial of RU-360 and mix well 
 
Calculation for making up 10 mM RU stock 
Molecular weight of RU-360 is 550.8 
RU vial has 100 ug – should be dissolved in how many ml to make 1 mM stock 
 100 ug *1000 ul = 181.6 ul 
 550.8 ug 
 
Ci= 1 mM, Cf= 10 uM, Vf= 10 ml or 12 ml, Vi=? 
 
Vi = 10 *1000 µl * 10 uM = 100 ul RU stock into 10 ml media to make 10 µM final conc. 
  1*1000 µM 
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9) Preparation of 10 mM stock and 10 µM final concentration of SKF- 96365 (Calbiochem # 
567310) 
Stock preparation of 10 mM SKF 96365  
Molecular weight of SKF is 402.9 and the vial contains 5 mg. 
402.9 g in 1000 ml is 1000 mM 
402.9 mg in 1000 ml is 1 mM 
5000 µg (vial) …. should be dissloved in ? ml to make 1 mM 
5000 µg      = 0.01241 ml (12.4 ul of water) 
402.5 µg 
 
Add 5 mg in 1.241 of sterile water to make the final stock concentration of 10 mM.  
 
Calculation:  
Ci = 10 mM, Cf = 10 µM, Vf = 1 ml (900 µl of Leibovitz) Vi = ? 
 
Vi  =  10 µM * 1 * 1000 µl  =   1 µl  per ml  
10 * 1000 µM      
Therefore, 1 µl of SKF stock  needs to be added to the 1ml Leibovitz for incubation to make a 
final concentration of 10 µM 
 
 
10) Preparation of stock solution of EGTA (10 mM) and 1 M CaCl2 made up with Leibovitz 
(Sigma, # E3889) 
Stock preparation of 10 mM EGTA  
Molecular weight of EGTA is 380.4  
38.04 mg (.038 gm) in 10 ml is 10 mM  
-To make 10 mM stock - dissolve the 0.038 gm of EGTA in 10 ml Leibovitz 
-Put the tube in warm water bath to ensure complete dissolution of EGTA (difficult to dissolve) 
-Use 100 µl of EGTA stock in 1ml media to obtain 1 mM final concentration 
 
Stock of CaCl2 is 1 M made up in water. 
Final concentration of calcium chloride used is 5 mM (Vi = 5 µl) 
 
 
11) Preparation of 50 mM MitoQ stock and 5 µM final concentration (gift from Dr. Micheal 
Murphy)  
Stock preparation of 50 mM MitoQ 
Molecular weight of MitoQ is 678.81 and the vial contains 10.7 mg. 
 
678.81 µg in 1ml is 1 mM 
67881 µg in 1ml is 100 mM 
33940.5 µg in 1ml is 50 mM 
 
10700 µg (vial) …. should be dissloved in ? ml to make 1 mM 
10.7 *1000 µg *1000 µl     = 315.26 µl  
33940.5 µg 
  
120
 
Assume water density as 1 
315-10.7 = 304.3 µl 
Dissolve 10.7 mg in 304.3 µl of water   
Mix well by pipetting up and down. 
Aliquot and store in -20°C until further use. 
First make a 500 µM solution and then dilute to 5 µM 
Calculation: 
Ci = 50 mM, Cf = 500 µM, Vf = 500 µl,  Vi = ? 
Vi  =  500 µM * 500 µl  =   5 µl  for 0.5 ml  media 
50 * 1000 µM 
Take 5 µl of 50 mM stock MitoQ and add 495µl of media and mix well by pipetting up and 
down. This is 500 µM stock. 
Use 10 µl per 1 ml solution to make a final concentration of 5 µM for cell treatment.     
 
 
12) Stock preparation of 10 mM Decyl TPP bromide and use 5 µM final concetration  
Molecular weight of DTPP bromide is 483.46 and the vial contains 9.3 mg 
(9300 µg). 
 
483.46 µg in 1ml is 1 mM 
9300 µg (vial) …. should be dissloved in ? ml to make 1 mM 
9300 µg *1000 µl     = 19236.34 µl = 19.24 ml of ethanol 
483.46 µg 
 
To make up 10 mM = 19.24/ 10 = 1.92 ml 
Therefore dissolving 9.3 mg vial in 1.92 ml of ethanol or methanol will give a stock 
concentration of 10 mM 
Mix well by pipetting up and down. 
 
Calculation:  
Ci = 10 mM, Cf = 5 µM, Vf = 20 ml,  Vi = ? 
Vi  =  5 µM * 20 * 1000 µl  =   10 µl  for 20 ml media   
10 * 1000 µM 
0.5 µl of stock DTTP bromide per ml of media.   
 
 
Protocol #A-9 Measurement of Basal Cytosolic Ca2+ using Fluo-4 
 
Purpose: To study the effect of butyrate and fatty acid combination on basal intracellular Ca2+ 
level using fluo-4, a fluorescent cytosolic Ca2+ indicator 
 
Cell culture: YAMC cells, refer to Protocol # A-8 for seeding and treatment 
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Preparation of 2 mM stock solution and 3 µM final concentration of Fluo-4 (Molecular Probes # 
F 14201)  
Stock preparation of 2 mM Fluo-4 
Molecular weight of Fluo-4 is 1096.95 and the vial contains 50 µg 
1096.95 µg in 1ml is 1 mM 
50 µg (vial) …. should be dissloved in ? ml to make 1 mM 
50 µg  *1000 µl     = 45.58 µl = ~ 50 µl 
1096.95 µg 
 
Dissolve 50 µg Fluo-4 (vial) in 25 µl DMSO to make up 2 mM Fluo-4 stock solution 
Mix well by pipetting up and down 
Final concentration of 3 µM Fluo-4 
Calculation:  
Ci = 1 mM, Cf = 3 µM, Vf = 1 ml (900 µl of Leibovitz) Vi = ? 
Vi  =  3 µM * 1 * 1000 µl  =   1.5 µl  per ml of media 
2 * 1000 µM  
1.5 µl of Fluo-4 stock needs to be added to 1 ml Leibovitz to make a final concentration of 3 µM. 
Procedure 
1. Make 50 ml aliquots of Leibovitz media and bring it to 33°C by placing it in the 
incubator 
2. Make up your stock solution of Fluo-4 and bring to room temperature. 
3. Aspirate old media from each well of the slide 
4. Add 900 µl of warm Leibovitz media into each of the wells gently.  
5. Add 3 µl of Flou-4 at the corner of each well and rotate slide gently or use the pipette to 
mix. Place in 33°C, 5% CO2 incubator for 1 h. 
6. After 1 hour take the slide wash with Leibovitz three times. 
7. Add 900 µl of Leibovitz and take it t the microscopy room for imaging. 
8. Imaging each slide takes 10- 12 mins, so load the slides at a frequency of 15 min. 
 
 
Protocol #A-10 Measurement of Thapsigargin induced Ca2+ Kinetics 
 
Purpose: To demonstrate a time-dependent effect of butyrate and fatty acid combination on IP-
3/ ER calcium pool by Thapsigargin induction using fluo-4, a fluorescent cytosolic Ca2+ 
indicator. 
 
Cell culture: YAMC cells, refer to Protocol # A-8 for seeding and treatment. 
 
Preparation 
-Prepare stock solutions of Fluo-4 and Thapsigargin on the day of the experiment (refer to 
protocol #5 for reagent preparation). 
-Keep 100 µl of Thapsigargin aliquots ready for dilution of TG and Cacl2 
 
Procedure 
1. Make 50 ml aliquots of Leibovitz media and bring it to 33°C by placing it in the 
incubator. 
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2. Make up your stock solution of Fluo-4 and aliquot the required volume of reconstituted 
TG and bring them to room temperature. 
3. Aspirate old media from each well of the slide. 
4. Add 900 µl of warm Leibovitz media into each of the wells gently. 
5. Add 3 µl of Flou-4 at the corner of each well and rotate slide gently or use the pipette to 
mix. Place in 33°C, 5% CO2 incubator for 1 h. 
6. After 1 hour take the slide wash with Leibovitz three times. 
7. Add 900 µl of Leibovitz and take it t the microscopy room for imaging. 
8. Image 3 different fields per well with approximately 8-20 cells per field. 
9. Add TG (1 µl into 100 µl PBS) at the 3rd scan. 
10. Imaging each slide takes 5- 8 mins, so load the slides at a frequency of 7 min. 
 
 
Protocol #A-11 Measurement of IP3 and SOC Ca2+ (EGTA and Ca2+ add-back) 
 
Purpose: To demonstrate the effect of butyrate (6 and 24 h co-treatment) and fatty acid 
combination on Ip3 and SOC Ca2+ pools (Zeiss microscope). 
-To demonstrate the effect of fatty acid and butyrate combination on SOC by using EGTA to 
chelate the extracellular Ca2+and then to study the reversal of the effect by adding back CaCl2 
 
Cell culture: YAMC cells, refer to Protocol # A-8 for seeding and treatment. 
 
Preparation 
-Prepare stock solutions EGTA and Cacl2 ahead of time (previous day). Refer to reagent 
preparation protocol # A-8. 
-Prepare stock solutions of Fluo-4 and Thapsigargin on the day of the experiment. 
-Keep 100 µl of Thapsigargin aliquots ready for dilution of TG and CaCl2 
 
Procedure 
1. Make 50 ml aliquots of Leibowitz media and bring it to 33°C by placing it in the 
incubator. 
2. Make up your stock solution of Fluo-4 and bring to room temperature. 
3. Aspirate old media from each well of the slide. 
4. Add 900 µl of warm Leibovitz media into each of the wells gently. 
5. Add 3 µl of Flou-4 at the corner of each well and rotate slide gently or use the pipette to 
mix. Place in 33°C, 5% CO2 incubator for 1 h. 
6. After 1 hour take the slide wash with Leibovitz three times. 
7. Add 900 µl of Leibovitz and take it t the microscopy room for imaging. 
8. 3 different fields per well with approximately 8-20 cells per field will be imaged (only 
one well per slide can be recorded, because the cells in the other well were sitting out for 
too long).  
9. Add EGTA (100 µl) and at the 5th scan will add TG (1 µl TG in 100 µl PBS) and then at 
the 30th scan calcium chloride (5 µl in 100 µl PBS aliquots) will be added and a total of 
60 scans will be recorded. 
10. Imaging each slide takes 15- 18 mins, so load the slides at a frequency of 18 min 
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Protocol #A-12 Measurement of IP3 and SOC Ca2+ (using a SOC inhibitor, SKF-96365) 
 
Purpose: To demonstrate the effect of inhibiting store operated channels using SKF-96365 on 
butyrate and fatty acid combination at 12 and 24 h co-treatment using Fluo-4, a fluorescent Ca2+ 
indicator. 
  
Cell culture: YAMC cells, refer to Protocol # A-8 for seeding and treatment. 
 
Preparation 
- Prepare stock solutions of Fluo-4, SKF-96365 and Thapsigargin on the day of the experiment 
-Keep 100 µl of Thapsigargin aliquots ready for dilution of TG. 
 
Procedure 
1. Make 50 ml aliquots of Leibovitz media and bring it to 33°C by placing it in the 
incubator. 
2. Make up your stock solution of Fluo-4 and bring to room temperature, aliquot 7 µl TG 
stock into 693 µl of PBS, aliquot SKF (1 µl /well) for 1 set of slides. 
3. Aspirate old media from each well of the slide. 
4. Add 900 µl of warm Leibovitz media into each of the wells gently.  
5. Add 3 µl of Flou-4 at the corner of each well and rotate slide gently or use the pipette to 
mix. Place in 33°C, 5% CO2 incubator for 55 m. 
6. After 55 min take the slide and add 1µl SKF and incubate for 4 min. 
7. Following 5 min remove the Leibovitz with the dye and SKF and wash with 900 µl 
media. 
8. Add 1 µl of SKF and take it for imaging. 
9. choose 3 areas and take 5 scans, after the 5th scan add 100 µl TG in PBS and take a total 
of 90 scans.  
10. The process takes 20 minutes per well, so image only one well per treatment 
slide as the other well would be sitting out at room temp for too long and so cells 
would be compromised. 
 
 
Protocol #A-13 Measurement of mitochondrial-to-cytosolic Ca2+ ratio  
 
Purpose: To demonstrate the effect of butyrate (6,12 and 24 h co-treatment)and fatty acid 
combination on mitochondrial Ca2+ by co-loading cells with Rhod-2, mitochondrial and Fluo-4, 
cytosolic Ca2+ indicators. 
  
Cell culture: YAMC cells, p53 wild type and knock cell lines refer to Protocol # A-8 for 
seeding and treatment. 
 
Preparation 
- Prepare stock solutions of Fluo-4, and Rhod-2 (refer to protocol #A-8 for reagent preparation) 
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Procedure 
1. Make 50 ml aliquots of Leibovitz media and bring it to 33°C by placing it in the 
incubator. 
2. Make up your stock solution of Fluo-4 and Rhod-2 and bring to room temperature 
for 1 set of slides at a time. 
3. Aspirate old media from each well of the slide. 
4. Add 900 µl of warm Leibovitz media into each of the wells gently. 
5. Add 3 µl of Flou-4 and 0.5 of Rhod-2 µl at the corner of each well and rotate slide 
gently or use the pipette to mix. Place in 33°C, 5% CO2 incubator for 1 h. 
6. After 1 h wash three time with 900 µl Leibovitz media.  
Image 10 different fields per well with approximately 8-20 cells per field.  
 
 
Protocol #A-14 Measurement of mitochondrial-to-cytosolic Ca2+ ratio using Mito-
Tracker FM and Rhod-2  
 
Purpose: To demonstrate that Rhod-2 specifically loads in the mitochondria of the cell 
by co-loading with Mitotracker Green (Molecular Probes # M 7514). 
- Mitotracker is a mitochondrion specific dye and Rhod-2 is a dye which is specific for 
mitochondrial Ca2+.  Therefore co-loading cells with both the dyes specifically indicates that 
Rhod-2 loads into the mitochondria and not in other peri-nuclear organelles.  
 
Cell culture: YAMC or p53 cells, refer to Protocol # A-8 for seeding and treatment. 
Dye information:  
1. MitoTracker Green FM is used to confirm the mitochondrial Ca2+ accumulation seen 
with Rhod-2 fluorescence (Boitier, 1999).   
2. MitoTracker Green is a green-fluorescent mitochondrial stain which localizes in the 
mitochondria regardless of mitochondrial membrane potential.  
3. This dye has an added advantage in that it is essentially non-fluorescent in aqueous 
solution, only becoming fluorescent once it accumulates in the lipid environment of 
the mitochondria. 
 
Preparation 
- Prepare stock solutions of Fluo-4, Rhod-2 and MitoTracker Green FM (refer to protocol 
#A-8 for reagent preparation of Fluo-4 and Rhod-2) 
-  
Stock preparation of 1 mM Mitotracker Green FM 
Molecular weight of Mitotracker is 671.88 and the vial contains 50 µg. 
 
671.88 µg in 1ml  is 1 mM 
50 µg (vial) …. should be dissloved in ? ml to make 1 mM 
50 µg  *1000 µl     = 74.42 µl  
671.88 µg 
 
Therefore dissolving 50 µg vial in 74.42 µl of DMSO will give a stock concentration of 
1 mM 
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Dissolve 50 µg Rhod-2 (vial) in 74.42 µl DMSO to make up 1 mM Mitotracker 
Mix well by pipetting up and down. 
 
Calculation:  
Ci = 1 mM, Cf = 200 nM, Vf = 1 ml (900 µl of Leibovitz) Vi = ? 
Vi  =  200 nM * 1 * 1000 µl  =   0.2 µl  per ml  
1*1000*1000 nM      
 
Therefore, 0.2 µl of Mitotracker green stock needs to be added to the Leibovitz for incubation to 
make a final concentration of 200 Nm 
 
Procedure 
1. Make 50 ml aliquots of Leibovitz media and bring it to 33°C by placing it in the 
incubator 
2. Make up your stock solution of Fluo-4, Rhod-2 and Mitotracker after thawing the 
vials. Prepare dyes for 1 set of slides at a time 
3. Aspirate old media from each well of the slide 
4. Add 900 µl of warm Leibovitz media into each of the wells gently  
5. Add 3 µl of Flou-4 and 0.5 of Rhod-2 µl at the corner of each well and rotate slide 
gently or use the pipette to mix. Place in 33°C, 5% CO2 incubator for 1 h 
6. After 55 min add 0.2 µl of Mito-tracker green to the corner of each well.  
7. Gently rotate the slide and incubate at 33°C, 5% CO2  
8. After 5 min wash the cells (three times with 900 µl Leibovitz media) and take the 
slide with 900 µl of Leibovitz and start imaging.  
9. Dr. Rola will image 10 different fields per well with approximately 8-20 cells per 
field 
10. If magnification is set at 63X then high magnification images (for publication) can 
be obtained. 
 
Protocol #A-15 Measurement of mitochondrial-to-cytosolic Ca2+ ratio by blocking 
mitochondrial uniporter 
 
Purpose: To demonstrate the effect of butyrate (6, 12 and 24 h co-treatment)and fatty acid 
combination on mitochondrial Ca2+ by blocking the uniporter using RU-360 (blocked for 30 min 
and 1 h) by co-loading cells with Rhod-2, mitochondrial and Fluo-4, cytosolic Ca2+ indicators 
  
Cell culture: YAMC cells, p53 wild type and knock cell lines refer to Protocol # A-8 for 
seeding and treatment until day 3. 
 
Day 0  Day 1         Day 2        Day 3                              Day 4 
               
 
 
SEED  FA            FA            FA             (RU for 30 min)           B+FA          Image
                                                           (12 hrs B)    
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Treatment protocol for day-3  
1. Treat cells with 10 µM RU-360 for 30 min or 1 h (2 different sets of slides). 
2. After 30 mins remove the media with RU in the 30 min set. Wash gently and 
add fresh media only, media with DHA, media with LA, media with butyrate and DB 
and LB media into the respective slides and incubate. 
3. After 1 h of RU treatment. Repeat treatment changes for the 1 h + RU group.  
4. Use 1 set without RU as the control – RU set. 
 
Preparation 
- Prepare stock solutions of Fluo-4, and Rhod-2 (refer to Protocol #A-8 for reagent preparation) 
 
Procedure 
1. Make 50 ml aliquots of Leibovitz media and bring it to 33°C by placing it in the 
incubator. 
2. Make up your stock solution of Fluo-4 and Rhod-2 and bring to room temperature for 1 
set of slides at a time. 
3. Aspirate old media from each well of the slide. 
4. Add 900 µl of warm Leibovitz media into each of the wells gently. 
5. Add 3 µl of Flou-4 and 0.5 of Rhod-2 µl at the corner of each well and rotate slide gently 
or use the pipette to mix. Place in 33°C, 5% CO2 incubator for 1 h. 
6. After  1 h wash three time with 900 µl Leibovitz media.  
7. Image 10 different fields per well with approximately 8-20 cells per field.  
 
 
Protocol #A-16 Cell Death Detection ELISA, Plus 
Ref: Fan et al. Am J Physiol (1999), Ng et al. (2005) 
 
Purpose: To measure apoptosis by using a nucleosomal assay by quantifying histone-
complexed-DNA  fragments of floating cell population and to count the cells using the coulter 
counter so as to normalize the data to the number of adherent cells in the dish. 
 
Cell culture and treatment: YAMC or p53 cells were used.  
Seed cells per protocol A-8, 35 mm-cell-culture dish/ 1.5 ml 
Refer to Protocol # A-8 for fatty acid, butyrate and other treatments 
 
Preparation  
ELISA kit: Cell death detection ELISA Plus from Roche- (BM# 1774425) 
1. Reconstitute working solutions (refer to manual, pg 7) 
2. Bottle 1: anti-histone-biotin: each bottle, reconstitute in 450 µl double distilled H2O for 
10 min and mix well (store at 2-8°C upto 2 months) 
3. Bottle 2: anti-DNA-POD- reconstitute with 450 µl double distilled H2O for 10 min and 
mix well (store at 2-8°C upto 2 months) 
4. Bottle 3: Positive control - reconstitute with 450 µl double distilled H2O for 10 min and 
mix well (store at 2-8°C upto 2 months) 
  
127
5. Bottle 7: ABTS Tablets- dissolve 1 tablet in 5 ml of substrate buffer (vial 6). (100 µl / 
sample). This is light sensitive and hence store container in a foil wrap (store for 1 
month protected form light) 
6. Complete RPMI media (without γ- INF) and McCoy’s media 
7. Label 3 sets of 2 ml or 1.7 ml eppys (depending on the volume in the plate): floaters 
collection (step 1), supernatant collection (step 11) and counting.  
8. Warm complete RPMI 1640/ McCoy’s media and trypsin-EDTA to room temperature 
9. Work under sterile hood so turn the hood on and prepare 50 ml tubes of PBS for cell 
counting, cool the centrifuge to 4°C 
10. If using the coulter counter prepare the solutions in the vials the day ahead  
 
Procedure 
Preparation of supernatant 
1. Under sterile conditions in the hood: swirl the 35 mm dish and collect the media and 
floating cells into the 1st set of 2 ml eppy-tubes 
2. Add 1ml of sterile PBS into the plates and put them in the incubator for counting later 
3. Centrifuge at 5,000 rpm (Eppendorf centrifuge) for 5 min at RT. (pellets all the floaters 
which are usually apoptotic cells for the assay)  
4. Discard supernatant using 1ml pipette manually without disturbing the pellet (pellet is 
imaginary most of the time) 
5. Resuspend pellet in 1ml media without γ-IFN. Finger flick the tubes 
6. Wash: centrifuge again at 5,000 rpm (Eppendorf centrifuge) for 5 min at RT 
7. Get out as much of the supernatant (without disturbing the pellet) and discard it 
8. Resuspend cell pellet with 125 µl lysis buffer (bottle 5 of Cell death detection ELISA 
kit) 
9. Lysis: Mix thoroughly and incubate sample for 30 min at 4°C (cell culture fridge) (*prep 
immunoreagent) (manual: pg 9) 
 
For 10 tests- 40 µl of reconstituent from bottle 1 +  40 µl of reconstituent from bottle 2 + 
720 µl of incubation buffer (bottle 4). Mix well 
 
For 70 tests – 280 µl of reconstituent from bottle 1 + 280 µl of reconstituent from bottle 2 + 
5040 µl of incubation buffer (bottle 4). Mix well 
 
10. Centrifuge lysate at max speed (13,600 x g, eppendorf centrifuge) for 10 min, at 4°C. 
(Pellets out the intact cells and nuclei etc leaving the cytosolic fraction in the 
supernatant for the assay)  
11. Transfer 100 µl of the supernatant carefully into another eppy-tube without shaking the 
pellet. Keep tubes on ice. 
 
Continue in the main lab 
ELISA procedure 
12. Transfer 20 µl of all samples- cytoplasmic fraction (include Histone-DNA complex, 
bottle 3 into MP. Pipette into the middle of the MP well. 
13. Use 20 µL of 
Well (A –1) – Background (Bottle 4 of kit) 
Well (B-1) – Blank (ABTS solution - Tablet dissolved in substrate- reconstituted tablet) 
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Well (C-1) – Positive control (Bottle 3 of kit) 
14. Add to each well 80 µl of the immunoreagent using multiple channel pipette/ regular (no 
immuno-reagent into the blank) 
15. Cover the MP with an adhesive cover and foil. Incubate on a MP shaker under gently 
shaking (300 rpm) for 2 hr at 15-25°C. 
16. Remove the solution thoroughly by tapping (tape both sides of the modules to secure 
them). This step removes the unbound components (antibodies) 
 
17. Rinse each well 3x with 250 µl of incubation buffer (bottle 4). Remove solution 
carefully by tapping. 
18. Turn off lights. Pipette to each well 100 µl ABTS solution. 
19. Incubate on a plate shaker at 250 rpm in the cold room until the color development is 
sufficient for a photometric analysis (approx 2-5min). Check every minute. 
20. Measure at 405 nm against ABTS solution as a blank (reference wavelength approx 
490nm). 
 
Cell Counting (Hemocytometer) 
a. Swirl the plates with the PBS and aspirate the PBS from the plates. 
b. Add 0.5 ml Trypsin and put them in the incubator for 3 mints @ 330C. 
c. Add 1ml media into each of the plates with the trypsin. 
d. Swirl the plate and collect all the cell/ trypsin and media into the eppys’. 
e. Count the cells using hemocytometer.  
f. Calculate the cell density and total number of apoptotic cells. 
g. Use this count to calculate the apoptotic index. 
 
Cell counting using Coulter Counter (Ref: Evelyn Callaway) 
Prepare the vials with solution for counting the pervious day and check the functioning of 
the counter 
1. Turn power on, open door, lower stage. 
2. Remove vial of Coulter Clenz, replace with Isotone/Isoflow, raise stage 
3. Readout:   Setup #1 (S1).   Scroll down to last line and set cell size.  This measurement 
is to be set for the smallest cell of acceptable range.  Our lab usually sets 10.00 um. 
4. Select: FUNCTIONS on keypad.   Scroll to Flush aperture.   Hit: START/STOP to flush.  
Repeat flush, then replace Isotone.   Flush twice more. 
5. Select: OUTPUT on keypad.  Scroll to Count / Concentration and select one.  If 
“concentration” is selected, readout will be in #cells/ml.  Scroll to Dilution and enter 
dilution factor.   Leave units on um. 
6. Prepare sample cups 24-48 hours ahead:   De-gas Isotone by turning red lever to the left.   
Lift dispensing pump twice.   Turn red lever so it is parallel to the arm.  Fill Coulter vials 
with 20 ml per vial (two pumps of Isotone). 
7. Add 40 µl sample to Coulter vial (for 1:500 dil).  Place vial on stage, raise, and press 
START/STOP on keypad to count.   Count each sample 2-3 times and average. 
8. To shut down machine, replace vial of blue Coulter Clenz and flush aperture (under 
FUNCTIONS) 2-3 times.   When flush is complete, turn off power. 
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Cell Preparation 
1. Remove PBS from 35 mm dish or 6 well plate 
2. Add 0.75 ml Trypsin and incubate at 37°C for 3.5 min.  Swirl dish then incubate 1.5 min 
more. 
3. Add 1 ml media into each plate and collect cells/media into eppendorf tube 
4. Set Coulter Counter for “concentration” and count cells. 
 
Calculations 
1. Number on readout for Coulter counter set on “concentration” is in #cells/ml of original 
sample. 
2. Multiply #cells/ml by total volume of sample (usually 1.75 ml). 
3. Record results as total cells. 
 
 
Protocol #A-17 Caspase-3 Activity Assay 
 
Purpose: To measure apoptosis in adherent and floating cells and quantify apoptosis using 
caspase-3 activity kit 
 
Cell Culture and treatment: YAMC cells refer to protocol # A-8 for cell plating and treatment 
 
Procedure:  Both floaters and adherent cells were collected and Caspase-3 activity was 
measured 
 
Preparation: EnzChek Caspase-3 Assay kit #2 (Molecular Probes, #E-13184) 
*Reagent preparation 
Warm up water bath to ~50°C. 
Precool microcentrifuge at 4°C 
 
Bring the vials of Z-DEVD-R110 (component A), DMSO (component B), Ac-DEVD-CHO 
(component F), R110 reference standard (component G), 20X cell lysis buffer (component C), 
5X reaction buffer (component D) to RT. 
 
5 mM stock of Z-DEVD-R110 substrate  
Add 264 µl of DMSO directly into the vial of Z-DEVD-R110.  (The substrate may need gentle 
heating (~50°C) to completely dissolve.  
(Aliquot the remained substrate, protect from light, store at –20°C, desiccated). 
 
1 M DTT stock solution 
Add 650 µl of dd-H2O directly into the vial of DTT solid (component E). 
(Aliquot the remained stock, store at –20°C) 
 
1 mM stock solution of Ac-DEVD-CHO inhibitor 
Add 400 µl of DMSO directly into the vial of Ac-DEVD-CHO. 
(Aliquot the remained inhibitor, store at –20°C, desiccated). 
 
5 mM stock solution of the R110 reference standard 
Add 273 µl of DMSO directly into the vial of R110. 
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(Aliquot the remained substrate, protect from light, store at –20°C). 
 
**1X cell lysis buffer** (Mix right before use) 
Add 100 µl of the 20X cell lysis buffer to 1900 µl of dd-H2O.  (Keep on ice) 
 
2X reaction buffer 
Add 800 µl of the 5X reaction buffer and 20 µl of 1 M DTT to 1180 µl of dd-H2O. 
(*The 5X and 2X reaction buffer may contain micelles in suspension, it is normal and won’t 
affect the assay, but, just try to mix the reaction very well immediately before use) 
**2X substrate working solution**(mix right before use) 
Mix 20 µl of 5 mM Z-DEVD-R110 substrate with 1980 µl of the 2X reaction buffer. 
 
Procedure to harvest cells: 
1. Scrape adherent cells with robber policeman or plastic cell scraper (in the presence 
of medium) and tilt the plate and get out as much of the cells (both floaters and 
adherent cells) into labeled 15-ml falcons. 
2. Add 2 ml HBSS with phenol red (w/o Ca2+ and Mg2+) and transfer into falcon tube. 
3. Centrifuge at 200 x g at RT for 5 min. 
4. Aspirate supernatant carefully and resuspend pellets in 1.5 ml PBS, and transfer to 2 
mL epi-tube. 
5. Centrifuge at 1000 x g at 4°C for 10 min. 
6. Aspirate supernatant gently and resuspend cell pellets in 60 µl of the 1X cell lysis 
buffer. 
7. Incubate the lysate on ice for at least 30 min. 
 
Caspase-3 activity assay: 
1. After lysate were incubated on ice for 30 min, centrifuge the lysate at 5000 rpm for 5 
min at 4°C. 
2. Transfer the 65 µL of supernatant to a set of 0.6 µl eppy tubes and mix well.  
individual wells. (use 50 µl of the supernatant out of the 60 µl into individual 
microplate wells for caspase assay and save the remaining 15 µl for (10 µl) BCA 
protein assay). 
3. For the samples with inhibitor (one of no-treatment control and one DB 
combination) add 1 µl of 1 mM Ac-DEVD-CHO inhibitor to 50 µl of sample, as a 
competitive control.   
4. Cover the tube and incubate at RT for 10 min.  Then add the sample to wells (keep 
rest of the samples on ice). 
5. Add 50 µl of supernatant into individual wells and save 10 µl for protein estimation. 
6. Add 50 µl of 1X cell lysis buffer in one well as background. 
7. Add 50 µl of the 2X substrate working solution to each well. 
8. Cover the wells and incubate at RT for ~30 min. 
9. During the 30 min incubation, prepare the R110 standards 
a. Make 400 µl of 1X reaction buffer by diluting 80 µl of 5X reaction buffer with 
320 µl dd-H2O. 
  
131
b. Make [25 µM] R110 std by diluting 1 µl of 5 M R110 std with 199 µl of 1X 
reaction buffer. 
c. Make [12.5 µM] R110 std by diluting 90 µl of 25 µM R110 with 90 µl of 1X 
reaction buffer. 
d. Make [6.25 µM] R110 std by diluting 60 µl of 12.5 µM R110 with 60 µl of 1X 
reaction buffer. 
10. Add 100 µl of 25, 12.5, 6.25 µM R110 standards to separate wells right before 
measuring the fluorescence. 
11. Measure the fluorescence at Excitation 496/Emission 520 nm continuously (30 min, 
1 hr, 2 hr, or overnight) 
 
 
 
Protocol #A-18 BCA Protein Micro Assay 
 
Purpose: To estimate protein level in cell lysate using BCA protein assay. 
 
Principle of reaction: Bicinchoninic acid (BCA) is specific for cuprous ion.  The BCA assay 
combines the biuret reaction with properties of the BCA molecule.  Protein reacts with Cu2+ in 
an alkaline medium to produce Cu1+.  Two molecules of BCA react with one Cu1+ to form a 
purple reaction product that is visible at 562 nm. 
 
Preparation:  Pierce BCA Protein Assay- Reagent A, Reagent B  
Albumin Std 
 
-Prepare working reagent by mixing 50 parts A with 1 part B 
-Standards:  2 mg/ml as is and 1 mg/ml diluted in sample buffer 
 
Assay:  Load standards and samples directly into microtitre plate as follows: 
  
Albumin std conc Std vol (in µl) Sample Buffer  Working solution 
0 0 10 200 µl 
0.5 0.5 µl  (1 mg/ml) 9.5 200 µl 
1 1 9 200 µl 
2 2 8 200 µl 
4 4 6 200 µl 
7 7 3 200 µl 
10 5 (2 mg/ml) 5 200 µl 
15 7.5 (2 mg/ml) 2.5 200 µl 
 
 
1. Load 10 µl of sample and the volume of standard as provided in the table above. 
2. Mix thoroughly by pipetting up and down. 
3. Cover plate and incubate 37oC for 30 min to 1 h. 
4. Read at 562 nm. 
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Protocol #A-19 Coomassie Plus Protein Assay (Pierce) 
 
12*75 mm culture tubes: VWR International, Cat # 60818-408 
96 well flat bottom microtiter plate 
Coomassie Plus Reagent 
Homogenization buffer: Triton containing buffer with 6 β-Mercaptoethanol, Protease inhibitor 
cocktail, 10 mM sodium vanadate. 
BSA standards:  
 
1. Perform assay in triplicate – standards and samples 
2. Mix samples and standards in 12*75 mm culture tubes. 
3. Add the required volumes of water, BSA and homogenization buffer and 
samples into the respective tubes. 
4. Add 500 µl Coomassie plus reagent (repeater pipette) and mix by vortexing. 
5. Transfer 300 µl to microtiter plate and read at A595 immediately. 
 
 
 
Standard Curve 
µg/ml 
Protein 
0.25 
µg/µl 
BSA 
1 µg/µl 
BSA 
2 µg/µl 
BSA 
Water µl Homog. 
Buffer µl 
Reagent 
µl 
Position 
0 0 - - 497.5 µl 2.5 µl 500 µl A1-3 
0.5 2 µl - - 495.5 2.5 500 C1-3 
1 4 µl - - 493.5 2.5 500 A1-3 
2 - 2 µl - 495.5 2.5 500 D1-3 
4 - 4 µl - 493.5 2.5 500 E1-3 
10 - 10 µl - 487.5 2.5 500 F1-3 
20 - - 10 µl 487.5 2.5 500 G1-3 
 
 
 
Samples Amt 
Sample 
Water Reagent Position 
 2.5 µl 497.5 µl 500 µl  
 
Change the volume of water based on sample volume to make a total volume 1000 µl. 
 
 
 
Protocol #A-20 Total cell lysate preparation for Western Blot  
 
Purpose: To quantify Bcl2 protein expression in n-3 PUFA and butyrate treated YAMC cells 
versus n-6 PUFA and butyrate treated cells using immunoblotting. 
 
Cell culture and treatment: YAMC cells were grown, expanded in 8- T-175 flasks.  
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Cells were treated with 50 DHA or LA for 72 h and 5 mM butyrate for the final 24 h and Bcl2 
was measured using immunoblotting 
1. No treatment (negative control) 
2. DHA+B 
3. LA+B 
4. Butyrate only (positive control) 
 
Following the treatments cells are harvested and a total cell lysate prepared and total protein is 
quantified by coomasie plus protein assay following which Bcl2 was immunoblotted. 
 
 Reagent Volume 
Needed for 10 
ml of Total 
Cell Buffer 
Final 
Conc. 
Total Volume 
Needed for 
100 mL 
A 500 mM Tris-HCl (pH 7.2) Sigma, T1503, 
(6.1 g/100 ml) 
1 50 
mM 
10 ml 
A 
 
1.0 M Sucrose (17.2g/100ml) Sigma, S9278 2.5 ml 250 
nM 
25 ml 
A 200 mM EDTA (pH 7.6) Sigma, ED4SS 
(0.76 g/10ml) 
100 µL 2 mM 1 ml 
A 100 mM EGTA (pH 7.5) Aldrich, 23453-2 
(0.38 g/10 ml) add NaOH to get it to 
dissolve and bring pH up to 7.5 
100 µL 1 
mMq 
1 ml 
A 0.4 M NaF (0.168 g/10ml) Sigma S6521 1.25 µL 50 
µM 
12.5 µL 
A Water 4.79175  4.792 ml 
A 10% Triton X-100 Sigma, T6878, 2 ml in 20 
ml ddH2O 
1 ml 1 % 10 ml 
A 10 Mm activated sodium orthovanadate, 
Sigma, S6508 (1.839 mg/ml) 
100 µl 100 
µM 
1 ml 
     
B Sigma Protease Cocktail (P8340) 400 µl  4 ml 
B β-mercaptoethanol, Bio-Rad 161-0710 (14.2 
M) 
7 µl 10 
mM 
70 µL 
 
 Preparation of Total cell lysate 
Prepare 5 ml of membrane Homogenization Buffer (with 10% Triton X to solubilized 
membranes)  
500 mM Tris  - 500 µl  
1 M sucrose  - 1.25 ml   
200 mM EDTA -  50 µl   
100 mM EGTA  - 50 µl  
0.4 m NaF - 0.625 µl  
10% Triton - 500 µl  
10 mM orthovanadate - 50 µl     to be added on the day of use 
PI cocktail - 200 µl  
β-mercaptoethanol - 3.5 µl 
  
134
Water – 2395.875 µl  
 
For 4 T-175 flasks – resuspend in 500 µl Homogenization buffer. 
1. Trypsinize four (for each treatment and control group) 80-90% confluent T-175 flasks 
(wash each flask with 20 ml HBSS and 12 ml trypsin) for 7-9 min or till the cells lift off. 
2. Stop trypsinization with 25 ml complete media.  
3. Spin at 200*g for 5 min at room temperature. 
4. Resuspend the pellet in 25 ml PBS.  
5. Spin at 200*g for 5 min at room temperature and discard supernatant. 
6. Resuspend each pellet in 2 ml PBS and transfer all of the resuspended pellets into one 15 
ml falcon. 
7. Spin at 200*g for 5 min at room temperature and discard supernatant. 
8. Repeat steps 6 and 7 for a total of 3 PBS washes. 
9. Following the final wash, carefully remove as much of the supernatant. 
10. Resuspend the pellet in 500 µl Homogenization buffer for each treatment and transfer to 
labeled glass Teflon homogenization tubes. 
11. Homogenize with motor and white pestle –6 strokes (pestle motion up and down is 
considered as one stroke). 
12. Pass homogenate through a 27-gauge needle into a 1.5 ml eppy tubes. 
13. Set the tubes on ice for 20 min. 
14. Spin 20 min 14,000 * g, 4oC in eppendroff centrifuge. 
15. Aliquot supernatant and save at -80°C for further protein estimation and immunoblotting 
 
 
Protocol #A-21 Bcl2 quantitation for YAMC cells treated with DHA and butyrate 
 
Refer to appendix A-8 for cell treatment, appendix A-20 for cell lysate preparation and appendix 
A-18 and A-19 for protein estimation. 
 
Protein concentration and Antibodies for Bcl2 Western blot 
1. 30 µg of the protein from each of the treatments are run on a 4-20% polyacriliamide gel 
and blotted onto a PVDF membrane. 
2. Rabbit anti-mouse Bcl2 antibody (dilution 1:3000) from Pharmingen (#554279) is used 
as a primary antibody 
3. Goat anti rabbit IgG from Kirkegaard and Perry Laboratories (# 0741506) is used as a 
secondary antibody (1:10000 dilution). 
4. M1 cell lysate was used as a positive control (Pharmingen # 16296Y, lot #M039093) 
 
Preparation 
   -Thaw samples on ice 
  -Label 0.6 ml eppy tubes 
  -Turn water bath on and set temperature to 98°C 
  -Prepare the western template sheet  
  - Cut Immobilon membrane and filter papers ready 
  
 Sample Preparation 
1. Thaw the samples on ice while you turn on the water bath and set the temperature to 
98°C (takes about 15 min).  
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2. Dye used for the sample dilution is 5X Pyronine. Use 1X of the dye based on the 
total volume of sample required (usually 25 µl total).  
3. With the aid of western template sheet make the necessary dilution (if required) and 
add the calculated amount of dye and water to the samples and standard. 
4. Quick spin. 
5. Boil the samples for 5-10 min depending on the volume of the samples (25 µl 
volume boil for 10 min). Do not boil the marker. 
6. Quick- spin of the samples on the tabletop. 
 
 Gel unit set up  
7. Take the pre-made gel (4-20%) and carefully rip off and discard the white tape and 
the comb.  Mark the lanes on the plate. 
8. Attach the gel to the gel rack align 3rd with the lower gasket and clamp the unit. 
(Note that the red clip should have the broad end facing you, broad ends face outside on 
all 4 clips). 
9. Pour running buffer to fill the stand and the trough up to the top mark. 
10.  Use gel-loading tips (or 10 µl art tips) and load the complete sample volume. 
11. Close the unit with the lid and check the leads and make sure black-to-black and red-
to-red. 
12.  In the cold room run the gel at 45-70 amps for 1 hour. 
13.  After about 40 min check every 10 min to see if the gel is running. 
14.   Stop the gel just above the lower most mark on the plate. 
 
 Gel transfer 
15.  Take the gel transfer unit in a staining tray and pour transfer buffer into it and the 
trough. 
16.  Take the cassette and lay it open. 
17.  Put a sponge on the black side of the cassette and place a filter paper on top of it. 
18.  Pour transfer buffer to keep it wet. 
19. Take the gel plate out of the running trough and transfer the running buffer into the 
bottle for reuse. 
20.  Crack open the plate with a scalpel between the markings on the plate all around by 
keeping the large side of the gel down. 
21.  Cut the gel just above the bottom bit by bit with a scalpel and push through the slit 
in the gel plate to separate the gel. 
22. Carefully separate the gel from the plate and cut the gel at lane one to identify the 
side (left end). 
23. Place the gel on the filter paper with lane one on the right (protein side facing the 
membrane. 
24.  Take the membrane out of the sandwich (Immobilon—p, Invitrogen, LC 2005-2) 
and wet it by squirting methanol (better to put it in a dish with methanol). 
25. Cut the right hand top corner of the membrane to identify the side. 
26. Place the membrane on the gel and place the other filter paper on the membrane. 
Now, roll a glass tube on the filter paper to eliminate any air bubbles inb/w. 
27. Place the sponge and close the white side of the cassette and clip it.  
28. Place the cassette in the transfer unit with the hinges facing the top and black side 
facing back. 
29. Put a stir bar into the transfer trough. 
  
136
30. Fill the trough with transfer buffer just enough to cover the hinges of the cassette. 
Check the terminals black to black correspond. 
31. Place it on the cold room stir plate. 
32. Connect black-to-black and red-to-red and set current to 400 m amps and let it 
transfer for 90 min. 
 
Blocking 
33.  At the end of 90 min- make 4% nonfat dry milk/ PBS/ Tween in a 50 ml tube (to 30 
ml of PBS –Tween and add 1.2 gms of pre-weighted milk powder). Mix gently by 
inverting. 
34. Pour the milk into a dish and keep ready to transfer the membrane into it. 
35. After the transfer is complete- open the gel unit and transfer the transfer buffer into 
the bottle. 
36. Use a pair of forceps to take the membrane and place the membrane into the milk 
dish (with the side facing gel-protein side now facing top) 
37.  Place it on the shaker for 1 hr at room temperature. 
 
 Primary antibody 
38. Take a dish with 1.2 gm dry milk powder and 30 ml PBS- Tween. Mix and pour into 
a new dish. 
39. Transfer the membrane from the blocking buffer into the dish with fresh milk.  
40. Now, add the appropriate volume of the primary antibody (based on the dilution and 
add it into the dish). 
41. Close the lid of the dish and shake it gently on the cold room shaker overnight. 
   
 Washing 
42. The next day take the membrane and give a quick wash with PBS –Tween. 
43. Then replace the membrane in fresh PBS- Tween in the dish and keep on the shaker 
at room temp for 10 min. Let it shake vigorously. 
44. Repeat the wash 2 times at 10-min interval. 
 
 Secondary antibody 
45.  Make 30 ml milk/ PBS/ Tween and pour into the dish after the second wash. 
46. Add the required volume of secondary antibody based on the dilution. 
47. Set on shaker for 1 hr at room temperature. 
48. Repeat washing with PBS –Tween 3 times. 
49. While the 1 wash of 2°dary antibody is going on turn on the imager and set focus. 
  
 Developing 
50. After the 2nd wash is complete 
51. Cut an acetate sheet into 2 halves and remove the black sheet inb/w 
52. Mix 0.5 ml of chemiluminescent super signal reagent A with 0.5 ml of reagent B in 
an ependroff tube. 
53. Mix gently by inversion. 
54. Now transfer the membrane b/w the layers of the acetate sheet and squirt the 
developing solution on the top.  
55. Slowly close the top layer so that the solution gets evenly distributed on the 
membrane. 
  
137
56. Expose for 5 minutes and then transfer the membrane on to the clean acetate sheet  
57. Transfer it into the quality one imager for imaging immediately. 
 
 Imaging 
58. Turn on switch and make sure the lever on the hood is at chemiluminescence. 
59. Select Quality on program on desktop. 
60. Select scanner – click on chemidoc.xrs. 
61. Step 1- option is chemiluminescences.  
62. Step 2 – live focus. Focus with a printed sheet and set the iris as you need for 
brightness. Zoom and focus, as you need for clarification. 
63. Freeze. Put the gel in the imager and zoom and freeze again. Close the door. 
64. Click on live acquire. 
65. Starting exposure time – for Bcl2 imaging - used 30 sec. 
Total exposure time – 150 sec 
Number of exposures – 5 
66. Imager takes 5 pictures in 150 sec. 
67. Below is the image obtained obtained from one of the representative experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. YAMC cell extract immonoblot analysis for Bcl2 protein expression.  YAMC cell extracts 
were harvested for various treatements (in duplicate) and total cell lysates containing 30 µg of protein 
were probed for Bcl2 expression.  Cell lysates - untreated cells (lanes C1, C2), butyrate- (5 mM for 24 h) 
(B1, B2); LA (50 µM for 72 h) and butyrate (5 mM for 24 h) treated (LB1, LB2); and DHA  (50 µM for 
72 h) +butyrate (5 mM for 24 h) (DB1, DB2) treated cells were blotted on a 4-30% SDS-PAGE gel to 
quantitate Bcl2 expression. 
 
 
 
 
 
 
C1 LB1C2 B1 B2 LB2 DB1 DB2
Molecular 
marker
26 kD 
Positive 
control
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Quantitation of Bcl2 protein expression  
 
Treatment Adjusted Intensity*mm2 Standard Deviation 
C1 5709.15 262.55 
C2 4702.31 200.67 
B1 3962.77 196.59 
B2 5275.71 217.02 
LB1 9131.85 315.76 
LB2 12645.35 421.77 
DB1 7948.84 373.85 
DB2 5781.76 286.11 
 
Quantitation of Bcl2 protein expression.  Table represents the adjusted volume intensity for Bcl2 protein 
expression (bands quantitated following western blot) in YAMC cell extracts.  Refer to appendix A-21 and 
figure 21 for additional details.   
 
Conclusion:  Preliminary data from the representative experiment demonstrates that DHA and butyrate 
combination downregulated Bcl2 expression in YAMC cell lysates. 
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Protocol #A-22 Preparation of a Modified AIN-76A Diet (15% fat, 6% fiber) 
 
 
Ingredient  Bioserve # Corn Oil Fish Oil 25 kg CO 25 kg FO 
Sucrose #3900 32.00% 32.00% 8.0  8.0  
Casein #1100 20.00% 20.00% 5 5 
Corn Starch #3200 22.00%  22.00%  5.5 5.5 
DL- Methionine #1340 0.30% 0.30% 0.075 0.075 
AIN-76 Salt Mix #F8505 3.50% 3.50% 0.875 0.875 
AIN-76 Vitamin Mix #F8000 1.00% 1.00% 0.25 0.25 
Choline Chloride #6105 0.20% 0.20% 0.05 0.05 
Cellulose #3425 6.00% 6.00% 1.5 1.5 
Corn Oil  15.00% 3.50% 3.75 0.875 
Fish Oil  0.00% 11.50% 0.0 2.875 
Total  100% 100% 25.00 kg 25.00 kg 
 
Materials 
1. The following ingredients are stored at room temperature 
Dextrose  
Casein 
Cellulose   
Mineral Mix 
DL-methionine 
Choline Bitartrate (with desiccant) 
 
2. The following ingredients are stored in the cold room: 
Vitamin Mix 
 
3. The following ingredients are stored in the -20°C walk-in cooler in Dr. Chapkin’s lab: 
Fish and corn oil (under N2) 
 
Preparation 
- Check all ingredients quantity about 3 weeks prior to mixing diet (ingredients take 
about 2-3 weeks to arrive). 
- Thaw the oils by setting them at 4°C the previous day of mixing. 
- Take the 2 mixing bowls and mixers for the Hobart mixer from Dr. Lupton’s lab and 
label them (corn oil- yellow tape and fish oil- blue tape). Transfer the bowls to the 
mixing room (basement). 
- Label color coded (yellow for corn oil and blue for fish oil) cage cars with the name of 
the diet, date of preparation and initials. 
- Make sure that the measuring bowls, spatulas etc are clean before use. 
- Bring 3 extra large beakers (5000 ml), 2 medium beakers (1000 ml). 
- Don’t forget your protocol sheet. 
 
Supplies to be carried to the basement 
• Weighing scale, 5000 ml beakers (2) and 2000 ml beakers (2). 
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• Cart loaded with all the ingredients to be used for the diet preparation. 
• 1-2 gallon size Ziploc bags (50) to store the diet. 
• 4-5 spatulas and 2 large metal spoons, weight spatula one for each ingredient to be 
added, few scoops, scrub and soap to wash. 
• Pen, paper towels, scissors, gloves and sharpies. 
• Weigh the fish and corn oils in the lab into the 5000 ml plastic beakers and take them 
to the basement and the rest of the ingredients will be weighed downstairs. 
 
Weighing Ingredients 
Weigh out the ingredients to prepare each diet (30 kg/diet). 
  
1. Weigh out the amount of oil needed into 5000 ml beakers- 2 for corn oil and 1 for 
fish oil diet.  
2. After weighing, add the small amount of corn oil needed for the fish oil diets to the 
fish oil.   
3. Cover the oil beakers with aluminum foil and set it on the cart to be transferred into 
the basement. 
4. Flush the original stock oil containers with N2 before closing the lid and storing 
away in -20°C. 
 
To the Basement 
o Take all the equipment and ingredients listed in the preparation paragraph to the 
basement. 
o Don’t forget to take the pre-weighted oil beakers. 
 
1. Place one of the large plastic containers on the large scale and tare.  Using the plastic 
scoop, add dextrose until the required weight is reached. 
2. Now add the dextrose into the large mixing bowl. Take caution to add the required 
amounts into either the fish or the corn oil bowls. 
3. Using the same procedure as above, weigh out casein and fiber (cellulose) for each 
diet. 
4. Place a small plastic container on the top loading scale and tare.  Using a weigh 
spatula, add mineral mix to the container until the appropriate weight is reached.  
Remove from the scale, set aside and keep covered.   
5. Weigh out vitamin mix, DL-methionine, and choline bitartrate as described in step 4. 
 
Mixing the Ingredients 
**IMPORTANT—Prepare corn oil diet first before fish oil to prevent cross 
contamination of equipment and diets. 
 
1. Now to the large container of casein add the pre-weighted ingredients one by one 
and stir briefly between the additions of each ingredient. 
Add in order: DL-methionine, Choline bitatarate, Vitamin mix and Mineral mix. Use 
the metal scoop and mix well as the mineral ix tends to clump. 
2. Now add pre-weighted amount of cellulose into the bowl for the Hobart mixer with 
dextrose.  Stir well with a fresh pair of gloves and metal scoop until mixed well. 
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3. On top of the dextrose/fiber mixture, slowly pour in the container of casein with all 
the other smaller ingredients (mixed).  Mix well with metal scoop until fairly well 
blended. 
 
4. Place the mixing bowl on the stand of the mixer and latch it down on both sides.  
Attach the color-coded mixing beater, and raise the mixing stand until it is at its 
highest point.  
 
5. Cover the bowl with the plastic lid. 
 
6. Set the mixer speed to (1), the slowest speed.  Set the timer for 2 minutes and press 
the start button.  The machine will begin mixing. 
 
7. After 2 minutes, use a fresh pair of gloves and check to make sure that the 
ingredients at the bottom of the bowl are mixed well.  Close the lid and turn on the 
mixer again for 1 minute or until the ingredients are well mixed. 
 
8. Once the mixer stops get the appropriate oil for the diet and pour ½ of it slowly 
between the beater and the bowl into the dry ingredients.  Run it at slow speed (1) 
for 2 minutes. 
 
9. Once the oil initially poured appears to be well blended, add another ½ of the oil 
mixture and allow it to mix.  Repeat this step until all of the oil mixture is well 
blended into the rest of the ingredients.   
 
10. Close the bowl, set the timer for 5 minutes and allow the mixer to blend on low 
speed (1). 
 
11. After five minutes, use clean gloves clean the beater bar and the sides of the bowl. 
 
12. Now, close the bowl and with the mixer speed on 2, blend for another 8-10 minutes 
to ensure thorough mixing. 
 
 
Storage of Diets 
 
1. Once the mixing is complete remove the bowl from the mixer and use a clean pair of 
gloves and scoop and scrap off all the diet sticking on the beater and sides of bowl. 
 
2. Take out a small amount of diet into a clean Ziploc bag and keep in 4°C to be used 
for diet analysis.   
 
3. Take 2 ziploc bags and put one into the other (double bag). Place the appropriately  
labeled card between the 2 bags.  
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4. Use a pair of clean gloves and scoop and take the diet into the inside bag. Fill the 
bag to 2/3rd and remove all the air from the bag and seal it tightly and store in -20°C 
in the basement.  
 
 
Clean-up after mixing the diet 
 
1. Clean the large bowl and beater using soap and the scrub in the large sink. Make 
sure they are thoroughly clean.  Spray with ethanol and dry with paper towels.  After 
the clean bowl and beater are put away on the cart, prepare the next diet. 
 
2. Sweep the floor and leave it clean before you leave. 
 
3. Make sure all the left over ingredients are closed in their respective boxes and 
sealed.  Label the boxes with the date that it was opened and used first.  Put the 
boxes in their respective places.   
 
4. Wash all the small equipment in the lab and dry them thoroughly. Put all the 
equipment back in their appropriate place. 
 
 
 
 
 
Protocol # A-23 Crypt Isolation Protocol 
 
Preparation-Several days before 
1. Prepare and aliquot stock solutions of BSA (10%), Glutamine (200X), EDTA (50X).   
 
Preparation 
BSA: 100 X=10 g BSA / 100 ml HBSS-CaMg 
Gln: purchased from GibcoBRL at 200 mM (200 X) 
Butyrate: 200 X=2.2 g Butyrate / 100 ml HBSS-CaMg 
EDTA: 50 X=56 g EDTA / 100 ml HBSS-CaMg 
 
Prepare 1X PBS  
Mix 1 vial of Dulbecco’s Phosphate Buffered Saline (w/o CaMg) into 990 ml 
RNase-free H2O until dissolved.  Store at room temperature. 
This will make 10X PBS. 
Dissolve 100 ml of 10X PBS into 900 ml of RNase-free H2O to make 1X PBS. 
 
Store EDTA at 4°C.   
Store BSA and Glutamine at -80°C. 
 
Materials  
BSA: Boehringer Manheimer, Cat# 100 018- Mol. Wt- 68,000 
Butyrate: Acros #263190050 
DTT: Sigma, Cat # D 0632 
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0.75 M, EDTA (tetrasodium)- Sigma, Cat# ED 45S 
200 mM, Glutamine: Gibco, Cat# 35050 
HBSS without Calcium and Magnesium- Sigma, Cat# H-6648 
HBSS with Calcium and Magnesium- Sigma, Cat# H-8264 
Live-Dead Viability cytotoxicity kit- Molecular probes, Cat# L3224 
 
Solutions: 
1X PBS :  500 mL warm (37oC), 500 mL cold (4oC) 
 
HBSS (w/Gln+BSA),EDTA,DTT               Final Concentration 
 -1 mL – 200 mM Gln       1 mM  
 -2 mL - 10% BSA       0.1% 
 -8 mL - 0.75 M Na4EDTA    30 mM 
 -o.77 gm - DTT        25 mM 
 -Combine Gln, BSA, EDTA, DTT in 150 mL HBSS (Sigma H-6648) 
 -pH to 7.4 - 7.5 with HCl 
 -Bring final volume up to 200mL.  Warm to 37oC 
 
HBSS (w/Gln+BSA) : 
 -1mL - 200mM Gln 
 -2mL - 10% BSA 
 -Combine Gln, BSA in 200mL final volume HBSS (Sigma H-6648) 
 -Cool on ice (4oC) 
 
Solutions prepared on day of experiment 
Turn on the water bath to 37°C and the Juan centrifuge to cool to 4°C 
 
Amount to add (in ml) Amt to add (in 
gm) 
 
EDTA  
50X 
Glutamine 
200X 
BSA 
10% 
(100X) 
DTT 
(as powder) 
Temperature 
HBSS+CaMg 
(300 ml) 
---- 1.5 3 ---- 4°C  
HBSS-CaMg 
(300 ml) 
12 1.5 3 1.15  37°C  
(pH-7.4-7.5) 
Final Conc. 30 mM 1 mM 0.1% 25 mM  
 
Preparation for the kill 
- Surgical equipment (blunt and sharp scissors, forceps) 
- Ice bucket with Petri dish and rubber policeman on it to cool 
- 50ml centrifuge tubes 
- Cups (2) with warm PBS  
- Sterile transfer pipettes 
- Leibovitz media 
- Large and small weigh boats  
- Biohazard bags to dispose the rat 
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Crypt Isolation Procedure 
**This procedure describes the isolation of the rat colonocytes. 
 
1. Euthanize rat by CO2 asphyxiation (3 minutes) and cervical dislocation.  Open 
abdomen with a ventral midline incision and perforate the diaphragm. 
 
2. Cut the large intestine at the rectum.  Continue to remove the large intestine up to 
the cecum.  Rinse the colon in the cups with warm PBS by shaking it gently to 
remove all the feces. 
 
3. Place tissue segment in weigh boats of warm PBS.  
 
4. Cut open the colon to expose lumen and rinse with warm PBS.  Place colon in a 
flask with ~30 ml of HBSS (Gln+BSA) w/ EDTA+DTT buffer (~5ml/cm of tissue).   
 
5. Incubate in the shaking water bath for 15 minutes @ 37°C.  Set shaker to level #6. 
 
6. Pour contents of the flask into a Petri dish (on ice). Gently scrape the mucosal side 
of the tissue with a rubber policeman.  
 
7. Using a sterile pipette, pipette up the scraped cells and transfer the contents of the 
petri dish into a 50ml centrifuge tube and place in centrifuge. 
 
8. Centrifuge at 100xg (960-1000 rpm) for 3 minutes at 4°C.   
 
9. Remove supernatant and resuspend in 30ml HBSS (w/ Gln +BSA) to wash cells and 
repeat wash 3 times with centrifugation at 100xg for 3 mins. 
 
10. Discard supernatant and resuspend pellet in 10 ml of Leibovitz buffer. 
 
11. Keep all cell suspensions on ice and take to Image Lab. 
 
On the day of the experiment 
 
Time Crypt 
Out 
Crypt 
scrapped 
Image 
lab 
Loading 
time 
Imaging 
time 
Total 
time 
taken 
Parameter 
measured 
Rat 
#1 
8:52 am 9:07 am 9:27 am 9:35 am 10:06 am 1 h, 14 m Control 
vs C+RU 
Rat 
#2  
  10:50 am 
(given by 
Ev) 
10:54 am 11:14 am  Ratio 
over time 
Rat 
#3  
  1:15 pm 
(given by 
Ev) 
1:20 pm 1:50 pm  Control 
vs 
butyrate 
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At the Image Lab 
Don’t forget to take  
  - Warm cell suspensions 
  - Chamber slides pre-coated with FBS overnight   
- 1.7 ml microcentrifuge tubes (labeled)  
- 18x18 cover slips 
  - Pipette tips and pipettes 
- Leibovitz media, Fluo-4, Rhod-2, Viability kit  
  - Centrifuge and microcentrifuge tube racks for incubator 
  - Protocol and time sheet 
  - Extra timers if necessary  
  
Testing for Calcium 
1. Hold all crypts on ice in cell culture room until needed. 
 
2. Add 25 µL of DMSO into 50 ug vial of Fluo-4 (2 mM stock) and 10 ul DMSO into 
50 ug vial of Rhod-2 (5 mM stock) and pipette up and down slowly to mix. 
 
3. Aliquot necessary amount of viability dye, Ethidium Homodimer, (1 µL / tube) into 
microcentrifuge tube covered with foil. 
 
4. Take 1.7 ml eppy tubes and label them as 0 m, 15 m and + butyrate (2 tubes for each 
sample). Take 900 µl of Leibovitz in each of the tubes. 
 
5. Add 25 µl of the appropriate crypt pellet to the ‘0’ labeled microcentrifuge tubes.  
(We had duplicate tubes for each treatment).  
 
6. Load the 2 tubes with 0.5 µl of Rhod-2 and 3 µl of Fluo-4 for 30 min 
 
7. After 15 minutes take 25 µl of crypt pellet and load the duplicate tubes of 15 
minutes time sample with Rhod-2 and Fluo-4.  
 
8. Following 5 minutes take crypt pellet in the + butyrate sample (add 5 µM final 
concentration). Co-load with Rhod-2 and Fluo-4 for 30 minutes. 
 
9. Rotate the sample with and without butyrate (do 0 and 15 minutes with butyrate 
followed by no butyrate in one rat and 0 and 15 mintues without butyrate followed 
by + butyrate sample at 20 minutes in the other). This randomizes the imaging.  
 
5 µM final concentration (0.5 µl of stock) of Rhod-2  
 
3 µM final conc. of Fluo-4 (1.5 µl stock)  
 
30 min 
incubation 
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10. Invert microcentrifuge tubes to mix cells and incubate the suspensions for the 
appropriate time at Cells will settle to the bottom of the tube. 
 
11. Load appropriate amount of Rhod-2 and Fluo-4 to each eppy tube of cells for 30 
minutes.  Invert tube to mix cells and incubate at 37°C. Leave the tubes open to 
allow CO2 
 
12. After 30 minutes take the 1 set of tubes and remove the media and add 600 µl of 
Leibovitz gently along the sides of the tube.  
 
13. Take 6 µl of the washed crypt pellet into the center of the well and hand it over to 
Dr. Rola. 
 
14. Gently cover with an 18x18 cover slip (try to avoid smashing cells).  Give to Dr. 
Rola for analysis. 
 
15. Image 4 wells per sample. As we are analyzing the last sample. Load 25 µL of crypt 
pellet with 1 µL of ethidium homodimer and of 1 µL calcein. Incubate at   37°C for 
5 minutes. 
 
16. After incubation with the viability dye is completed, transfer 6 µL of the cell pellet 
to a glass microscope slide.  Cover with and 18x18 cover slip.  Images for viability 
will be captured like the rest of the samples. We estimate the percentage that is 
green (viable) to red cells which are not viable. This gives us an idea of the viability 
of the crypts. 
 
 
Protocol #A-24 Crypt Cell Viability Assay 
Ref: Sanders, (2004); Hong MY, (2003); Source: Molecular Probes 
 
Purpose: To measure crypt cell (colonocyte) viability by using a The LIVE/DEAD 
Viability/Cytotoxicity Kit.  
The LIVE/DEAD Viability/Cytotoxicity Kit used was from Molecular Probes (L3224).  
 
Information about the kit: The live/ dead kit is a two-color assay to determine viability of cells 
in a population. The kit identifies live versus dead cells on the basis of membrane integrity 
(Ethidium homodimer-1) and esterase activity (Calcein AM).  
 
Basis: Live cells have ubiquitous intracellular esterase activity. This is determined by the 
conversion of cell permeant, non-fluorescent calcein AM to a highly fluorescent calcein which is 
retained inside the cell to emit a uniform green signal.  Ethidium homodimer-1 enters a cell with 
damaged plasma membrane and is excluded by the intact plasma membrane of live cells.  
Therefore, Ethidium homodimer enters dead cells with a compromised plasma membrane and 
undergoes a 40 fold enhancement in fluorescence to produce a bright red fluorescence 
differentiating it from a viable green cell.   
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Procedure 
1. An aliquot of crypt pellet (at 37°C) is co-loaded with 1 µl of ethidium homodimer-1 
and 1 µl of calcein AM. 
2. The eppendroff tubes in incubated in the 37°C incubator (keep lid open for free flow 
of CO2) for 5 min.  
3. Take 6 µl of the viability dye loaded crypt pellet onto 2 wells of the chambered 
cover-glass. 
4. Place a cover slip gently taking care not to crush the crypts. 
5. Mount on the Zeiss microscope stage and image the crypts. 
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APPENDIX B 
 
DATA TABLES 
 
APOPTOSIS- Nucleosomal assay (YAMC) 
 
Apoptosis in YAMC cells following 6, 12, 24 and 48 h butyrate co-treatment  
 
Table B1: 24 h apoptosis data 
 
Treatment Mean Std Error p-value Count 
Control 0.394 0.203 0.05 16 
Butyrate 0.904 0.613  12 
LA 0.372 0.187  12 
DHA 0.242 0.237  12 
LB 0.741 0.351  14 
DB 1.345 0.189  14 
 
 
 
Table B2- 12 h apoptosis data 
 
Treatment Mean Std Error p-value Count 
Control 0.382 0.037 0.05 8 
Butyrate 0.5.09 0.089  6 
LA 0.423 0.067  6 
DHA 0.330 0.121  6 
LB 0.758 0.120  7 
DB 1.322 0.238  7 
 
 
 
Table B3-12 h apoptosis data 
 
Treatment Mean Std Error p-value Count 
Control 0.299 0.047 0.05 14 
Butyrate 0.900 0.182  13 
LA 0.423 0.067  6 
DHA 0.330 0.121  6 
LB 0.827 0.089  14 
DB 1.263 0.170  11 
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Table B4- 6 h apoptosis data 
 
Treatment Mean Std Error p-value Count 
Control 0.293 0.084 0.05 6 
Butyrate 0.365 0.089  4 
LA 0.321 0.086  6 
DHA 0.155 0.055  6 
LB 0.260 0..044  6 
DB 0.414 0.116  6 
 
 
 
Table B5- 48 h apoptosis data 
 
Treatment Mean Std Error p-value Count 
Control 0.294 0.025 0.05 6 
Butyrate 1.152 0.089  4 
LA 0.135 0.055  4 
DHA 0.216 0.036  4 
LB 1.240 0.202  4 
DB 1.011 0.230  4 
 
 
 
 
Caspase-3 assay as an indicator of apoptosis in YAMC cells  
 
Table B6- 24 h apoptosis data 
 
Treatment Mean Std Error p-value Count 
Control 44.716 0.924 0.05 5 
Butyrate 83.242 8.440  5 
LB 72.765 5.392  6 
DB 104.492 7.384  5 
 
 
 
 
  
150
Apoptosis in YAMC using RU-360, a blocker of mitochondrial uniporter 
 
Table B7- 24 h Butyrate induced apoptosis in YAMC cells ±RU-360  
 
Treatment Mean Std Error p-value Count 
Control 1.859 0.129 0.0039 3 
Control+RU 1.264 0.140  3 
Butyrate 1.904 0.094  4 
Butyrate+RU 1.781 0.231  4 
LB 1.717 0.306  4 
LB+RU 2.305 0.224  4 
DB 3.335 0.592  4 
DB+RU 2.252 0.350  4 
 
 
 
Table B8- 12 h Butyrate induced apoptosis in YAMC cells ±RU-360 
 
Treatment Mean Std Error p-value Count 
Control 0.933 0.131 0.0002 5 
Control+RU 0.708 0.079  5 
Butyrate 0.941 0.112  5 
Butyrate+RU 1.019 0.126  5 
LB 0.741 0.194  5 
LB+RU 0.919 0.095  5 
DB 2.153 0.367  5 
DB+RU 1.356 0.261  5 
 
 
 
Table B9- 12 h Butyrate induced apoptosis in YAMC cells ±RU-360  
 
Treatment Mean Std Error p-value Count 
Control 0.450 0.035 0.0001 6 
Control+RU 0.826 0.166  6 
Butyrate 1.556 0.170  2 
Butyrate+RU 1.657 0.155  3 
LB 0.801 0.277  4 
LB+RU 1.370 0.084  7 
DB 1.940 0.197  4 
DB+RU 1.227 0.409  3 
STS 6.365 0.320  5 
STS+RU 5.508 0.367  3 
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CYTOSOLIC CALCIUM 
 
Cytosolic Ca2+ in YAMC cells with 6, 12, 24, 48 and 72 h Butyrate Co-Treatment  
 
Table B10- 24 h data 
  
Treatment Mean Std Error p-value Count 
Control 1.847 0.043 0.0001 113 
Butyrate 1.691 0.094  63 
LA 2.381 0.079  103 
DHA 2.006 0.107  84 
LB 2.228 0.088  53 
DB 1.966 0.038  57 
 
 
 
Table B11- 24 h data with 10 mM butyrate 
 
Treatment Mean Std Error p-value Count 
Control 0.294 0.240 0.0001 56 
Butyrate 1.152 0.226  50 
LA 0.135 0.225  81 
DHA 0.216 0.161  58 
LB 1.240 0.149  65 
DB 1.011 0.136  56 
 
 
 
Table B12- 12 h data 
   
Treatment Mean Std Error p-value Count 
Control 1.913 0.058 0.0001 91 
Butyrate 1.829 0.067  67 
LA 2.519 0.094  79 
DHA 2.338 0.059  93 
LB 2.553 0.094  69 
DB 2.139 0.049  76 
 
 
 
Table B13- 6 h data  
 
Treatment Mean Std Error p-value Count 
Control 1.466 0.046 0.0001 46 
Butyrate 1.629 0.045  58 
LB 1.772 0.066  66 
DB 1.949 0.068  78 
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Table B14- 48 h data  
 
Treatment Mean Std Error p-value Count 
Control 2.647 0.240 0.0001 56 
Butyrate 3.263 0.361  11 
LA 2.580 0.225  58 
DHA 3.343 0.161  81 
LB 3.246 0.226  12 
DB 3.091 0.245  29 
 
 
 
Table B15- 72 h data (Dec.’05) 
 
Treatment Mean Std Error p-value Count 
Control 2.647 0.240 0.0001 56 
Butyrate 2.907 0.220  18 
LA 2.425 0.166  57 
DHA 3.343 0.161  81 
LB 2.262 0.239  7 
DB 2.784 0.140  17 
 
   
 
Table B16- EGTA and Ca2+ add-back (Feb.18.’05) 
 
Treatment Mean Std Error p-value Count 
Control 1.865 0.053 0.0001 41 
Butyrate 1.964 0.120  17 
LA 1.751 0.079  47 
DHA 1.535 0.897  46 
LB 1.790 0.073  29 
DB 1.601 0.071  34 
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Cytosolic calcium following inhibition of SOC with SKF-96365 
 
Table B17- Cytosolic calcium following 24 h butyrate co-treatment with SKF, an inhibitor 
of SOC  
 
Treatment Mean Std Error p-value Count 
Control 1.847 0.043 0.0001 6 
Control+SKF 1.090 0.060  6 
Butyrate 1.691 0.094  6 
Butyrate+SKF 1.029 0.026  6 
LB 2.381 0.088  6 
LB+SKF 0.728 0.029  6 
DB 1.966 0.038  6 
DB+SKF 1.009 0.079  6 
 
 
 
Table B18- 12 h butyrate induced cytosolic calcium change with SKF-96365 (Mar.05.’05) 
 
Treatment Mean Std Error p-value Count 
Control 1.913 0.058 0.0001 6 
Control+SKF 1.090 0.060  6 
Butyrate 1.829 0.067  6 
Butyrate+SKF 1.032 0.085  6 
LB 2.553 0.094  6 
LB+SKF 0.925 0.064  6 
DB 2.139 0.049  6 
DB+SKF 0.872 0.053  6 
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MITOCHONDRIAL CALCIUM 
 
Mitochondrial :Cytosolic Ca2+ Ratio in YAMC cells with 6, 12 and 24 h butyrate treatment  
 
Table B19 -24 h data 
 
Treatment Mean Std Error p-value Count 
Control 2.855 0.048 0.0001 46 
Butyrate 2.716 0.055  50 
LA 2.575 0.070  40 
DHA 3.152 0.048  47 
LB 2.842 0.055  36 
DB 3.826 0.072  36 
 
   
 
Table B20- 12 h data  
  
Treatment Mean Std Error p-value Count 
Control 2.801 0.137 0.0001 43 
Butyrate 2.704 0.047  39 
LA 2.001 0.078  44 
DHA 2.425 0.058  44 
LB 2.650 0.042  44 
DB 3.167 0.069  45 
  
 
 
Table B21- 6 h data 
   
Treatment Mean Std Error p-value Count 
Control 3.014 0.095 0.0001 44 
Butyrate 3.054 0.050  44 
LA 2.980 0.053  44 
DHA 4.841 0.125  44 
LB 3.148 0.065  42 
DB 5.189 0.111  40 
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Mitochondrial :Cytosolic Ca2+ Ratio in YAMC cells with RU-360 (6, 12 and24 h) and 
Butyrate Co-treatment 
 
Table B22- 24 h Mitochondrial calcium with RU-360- 1 h RU-360 data 
 
Treatment Mean Std Error p-value Count 
Control 3.747 0.080 0.0001 18 
Control+RU-360 3.379 0.035  21 
DB 5.963 0.199  20 
DB+RU-360 4.762 0.267  32 
 
 
Table B23- 12 h Mitochondrial calcium with RU-360- 1 h RU 
 
Treatment Mean Std Error p-value Count 
Control 1.971 0.065 0.0001 24 
Control+RU-360 2.010 0.051  23 
Butyrate 2.280 0.084  22 
Butyrate+RU-360 2.792 0.099  22 
LB 2.067 0.040  23 
LB+RU-360 2.054 0.061  21 
DB 3.468 0.147  22 
DB+RU-360 3.039 0.130  23 
 
 
Table B24- 6 h Mitochondrial calcium with RU-360- 1 h RU 
 
Treatment Mean Std Error p-value Count 
Control 1.743 0.045 0.0001 20 
Control+RU-360 1.957 0.069  22 
Butyrate 1.667 0.052  24 
Butyrate+RU-360 1.965 0.081  22 
LB 1.698 0.023  25 
LB+RU-360 1.834 0.054  22 
DB 3.439 0.159  21 
DB+RU-360 2.559 0.090  22 
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p53 CELL LINE DATA 
 
Apoptosis in p53 wild type (WT) and Knock out (KO) cells  
 
Table B25- 12 h Butyrate induced apoptosis in p53 wild type (WT) cells  
 
Treatment Mean Std Error p-value Count 
WT-Control 0.199 0.022 0.0001 6 
WT-LB 1.253 0.132  6 
WT-DB 1.807 0.211  5 
KO-Control 0.187 0.020  5 
KO-LB 0.940 0.086  5 
KO-DB 1.458 0.106  5 
 
 
Apoptosis in p53 cells using RU-360, a blocker of mitochondrial uniporter 
 
Table B26- 12 h Butyrate induced apoptosis in p53 wild type (WT) cells ±RU-360 
 
Treatment Mean Std Error p-value Count 
WT-Control 0.199 0.022 0.0001 6 
WT-Control+RU 0.133 0.017  6 
WT-LB 1.253 0.132  6 
WT-LB+RU 0.976 0.024  6 
WT-DB 1.807 0.211  5 
WT-DB+RU 0.961 0.059  6 
 
 
 
Table B27- 12 h Butyrate induced apoptosis in p53 knock out (KO) cells ± RU-360  
 
Treatment Mean Std Error p-value Count 
KO-Control 0.187 0.020 0.0001 5 
KO-Control+RU 0.213 0.038  6 
KO-LB 0.903 0.100  4 
KO-LB+RU 0.778 0.033  5 
KO-DB 1.400 0.103  6 
KO-DB+RU 0.801 0.035  6 
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Apoptosis in p53 cells using Mito-Q, a mitochondrially targeted antioxidant  
 
Table B28- 12 h Butyrate induced apoptosis in p53 wild type (WT) cells ± Mito-Q  
 
Treatment Mean Std Error p-value Count 
WT-Control 0.261 0.068 0.0001 6 
WT-Control+MQ 0.310 0.021  6 
WT-LB 1.221 0.057  6 
WT-LB+MQ 0.834 0.076  6 
WT-DB 1.594 0.153  6 
WT-DB+MQ 0.963 0.130  5 
 
 
 
Table B29- 12 h Butyrate induced apoptosis in p53 knock out (KO) cells ± MitoQ  
 
Treatment Mean Std Error p-value Count 
KO-Control 0.302 0.042 0.0001 6 
KO-Control+MQ 0.201 0.091  6 
KO-LB 1.475 0.204  6 
KO-LB+MQ 0.905 0.207  6 
KO-DB 1.996 0.149  6 
KO-DB+MQ 1.477 0.226  6 
 
 
Mitochondrial :Cytosolic Ca2+ Ratio in p53 cells with 6, 12 and 24 h Butyrate Co-treatment  
 
Table B30 - 24 h Mitochondrial calcium in p53 wild type (WT) and knock out (KO) cells 
 
Treatment Mean Std Error p-value Count 
WT-Control 0.547 0.030 0.0001 28 
WT-LB 0.441 0.021  23 
WT-DB 0.689 0.057  17 
KO-Control 0.490 0.023  20 
KO-LB 0.410 0.027  18 
KO-DB 0.797 0.086  9 
 
 
Table B31- 6 h Mitochondrial calcium in p53 wild type (WT) and knock out (KO) cells 
 
Treatment Mean Std Error p-value Count 
WT-Control 0.492 0.018 0.0001 27 
WT-LB 0.448 0.024  24 
WT-DB 0.703 0.048  27 
KO-Control 0.533 0.017  24 
KO-LB 0.446 0.018  22 
KO-DB 0.645 0.061  24 
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Table B32- 24 h Mitochondrial calcium in p53 wild type (WT) and knock out (KO) cells  
 
Treatment Mean Std Error p-value Count 
WT-Control 0.581 0.021 0.0001 38 
WT-LB 0.539 0.031  30 
WT-DB 0.698 0.032  41 
KO-Control 0.497 0.074  7 
KO-LB 0.479 0.094  30 
KO-DB 0.857 0.230  25 
 
 
Table B33- 6 h Mitochondrial calcium in p53 wild type (WT) and knock out (KO) cells 
 
Treatment Mean Std Error p-value Count 
WT-Control 0.583 0.028 0.0001 30 
WT-LB 0.584 0.035  41 
WT-DB 0.877 0.021  38 
KO-Control 0.721 0.038  33 
KO-LB 0.532 0.011  47 
KO-DB 0.960 0.044  32 
 
 
 
Table B34- 12 h Mitochondrial calcium in p53 wild type (WT) and knock out (KO) cells 
 
Treatment Mean Std Error p-value Count 
WT-Control 1.921 0.095 0.0001 27 
WT-LB 2.101 0.084  30 
WT-DB 2.416 0.052  32 
KO-Control 2.237 0.044  37 
KO-LB 2.132 0.084  29 
KO-DB 2.506 0.052  31 
 
 
Mitochondrial :Cytosolic Ca2+ Ratio in p53 cells with RU-360 and 12 h Butyrate Co-
treatment  
 
Table B35- 12 h Mitochondrial calcium in p53 wild type (WT) cells ± RU-360 
 
Treatment Mean Std Error p-value Count 
WT-Control 0.872 0.035 0.0001 29 
WT-Control+RU 0.843 0.039  35 
WT-LB 0.982 0.027  35 
WT-LB+RU 0.975 0.028  33 
WT-DB 1.136 0.050  34 
WT-DB+RU 0.946 0.020  34 
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Table B36- 12 h Mitochondrial calcium in p53 knock out (KO) cells ± RU-360 
 
Treatment Mean Std Error p-value Count 
KO-Control 0.832 0.028 0.0001 26 
KO-Control+RU 0.866 0.023  27 
KO-LB 0.897 0.017  35 
KO-LB+RU 0.729 0.018  39 
KO-DB 1.184 0.056  27 
KO-DB+RU 0.977 0.035  32 
 
 
 
  
  
160
VITA 
Satya Sree N. Kolar 
 
Address  
 Kleberg Center, Room 321   Phone: 832-671-3831 
 Texas A&M University 
 College Station, Texas 77843-2471  email: kolar5@yahoo.com 
 
Education 
  M.S., Nutrition, May 2003 
 University of Kentucky, Lexington, KY 
 B.M.S., Bachelor of Medicine and Bachelor of Surgery, October 1991 
 Bangalore University, Bangalore, India 
 
Honors and Awards 
 Scholarship- Board of Regent’s Fellowship (August, 2003) 
 Travel awards- IFN travel grant (August, 2006; November, 2006) 
ASNS diet and cancer RIS graduate student poster competition   
  First Prize (April, 2006) 
College of Agriculture and Life Sciences Student poster competition 
  Second Prize (Spring, 2007) 
  
Publications (abstracts excluded) 
Ng Y, Barhoumi R, Tjalkens RB, Fan YY, Kolar S, Wang N, Lupton JR, 
Chapkin RS.  The role of docosahexaenoic acid in mediating mitochondrial 
membrane lipid oxidation and apoptosis in colonocytes.  Carcinogenesis. 
2005;26(11):1914-21. 
 
Kolar S, Barhoumi R, Lupton J, Chapkin RS.  Docosahexaenoic acid and 
butyrate synergistically induce colonocyte apoptosis by enhancing 
mitochondrial Ca2+ accumulation.  Cancer Research 2007 (In press). 
 
Kolar S, Barhoumi R, Callaway E, Fan YY, Wang N, Lupton J, Chapkin 
RS.  Synergy between Docosahexaenoic acid and butyrate elicits p53 
independent apoptosis via mitochondrial Ca2+ accumulation in human colon 
cancer cells and rat primary colonic culture. Manuscript submitted. 
 
 
 
 
 
